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Chapter 1 
Introduction 

Chapter 1 
Background 
One of the main functions of the human kidney is the clarification of blood from human 
waste products, such as ureum and creatinine. Failure of functioning of the kidneys may 
ultimately lead to death. When the stage of very limited kidney functioning (5 to 10% of 
norm-al) is reached, renal replacement therapy becomes essential to survive. Chronic renal 
replacement therapy has been available since the 1960s. At present, three major types of 
renal :replacement therapy are available: haemodialysis, peritoneal dialysis and kidney trans-
plantation. 
W"ith haemodialysis, the body is connected to an extracorporeal filter or dialyser, consist-
ing of a semipermeable membrane to which blood is taken and returned. This requires a 
permanent artificial access to the body (a shunt, fistula or synthetic graft), that usually is cre-
ated in the forearm. Dialysis fluid, resembling blood plasma, is passed in the opposite direc-
tion across the outside of the membrane. Waste products and excess water from the blood 
diffuse into this dialysis fluid. Several forms of haemodialysis are available in the 
Netherlands. Most patients receive full care centre haemodialysis which requires the patient 
to travel to a dialysis centre, usually 3 times a week. The patient is attached to a dialysis 
machine for 3-4 hours. Limited care or active centre haemodialysis is similar to full care cen-
tre haemodialysis, but the patient takes active responsibility for the treatment, implying that 
the majority of the (nursing) tasks involved are performed by the patient him/herself. 
Another modality is home haemodialysis whereby the patient has all the necessary equip-
ment at home and takes active responsibility for the treatment; some help from a partner, 
family member or nursing assistant is usually necessary. 
The second major form of renal replacement therapy is peritoneal dialysis, which was 
developed in the 1970s. With this modality, the peritoneum (abdominal membrane) is used 
for the removal of waste products. A sterile dialysis fluid is introduced into the peritoneal 
cavity through a built-in catheter and remains in place for several hours. Continuous ambu-
latory peritoneal dialysis is a home-based technique, requiring the patient to exchange the 
used dialysis fluid for fresh dialysis fluid 4 to 5 times daily. \"X-'ith automated peritoneal dial-
ysis, the patient is connected each night to an automated cycler which conducts the 
exchange of dialysis fluids. This nightly peritoneal dialysis can be combined -with one or two 
manual exchanges of dialysis fluid during the day (continuous cycling peritoneal dialysis). 
The third major form of renal replacement therapy is renal transplantation, also available 
since the 1960s. Transplantation is the treatment of choice for most patients with end-stage 
renal disease, because -with this modality more kidney functions are restored than only the 
removal of waste products and excess fluids from the blood. Transplantation can either be 
performed with a donor kidney from a relative or with a cadaver donor kidney: immuno-
suppressive drugs are necessary to prevent rejection of the graft. Graft survival ranges from 
70 to 90% at 3-5 years. The ongoing shortage of donor organs means that there is a long 
waiting list for the transplantation procedure. In 2000, about 1,400 persons in tl1e 
Netherlands were awaiting kidney transplantation. 1 
In the Netherlands on January 1 2001, 9,850 patients were being treated with renal 
replacement therapy, almost equally divided bet\Veen dialysis (n=4,818) and renal trans-
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plantation (n=5,032)2 This implies a prevalence of about 600 persons per million of the 
population, when prevalence is defined as renal failure being treated with either dialysis or 
transplantation. The absolute number of patients has been growing 4-6% annually over the 
last 10 years. The increase in new patients with end-stage renal disease is particularly marked 
in the older age groups.2 Age is a determinant of kidney failure: the prevalence of chronic 
kidney failure increases from 54 per million in those aged 0 to 15 years to 1,486 per million 
in those aged 65 to 74 years.2 The average age at start of renal replacement therapy is cur-
rently 59 years, compared with 48 years in 1980.2 Each year in the Netherlands 1,400 to 
1,500 patients begin renal replacement therapy in one of the 53 dialysis and transplantation 
centres (including paediatric centres). Table 1 lists the main treatment modalities and the 
number of Dutch patients treated per modality as at January 1 2001. 
Table 1: Number of patients per treatment modality as at 1.1.2001 
Treatment modality Sub-type (see text) Number of patients % 
Haemodialysis (HD) Full Care Centre HD (FCHD) 2852 29.0 
limited Care HD (LCHD) 406 4.1 
Home HD (HHD) 84 0.9 
Peritoneal Dialysis (PD) Continuous Ambulatory PD (CAPO) 1073 10.9 
Automated PD (APD) 403 4.1 
Transplantation (TX) Post-mortem donor 4069 41.3 
Uvin -related donor 963 9.8 
Total 9850 100.0 
Source: Renal Replacement Registry of the Netherlands 2 
The incidence of renal replacement therapy is not a function of the true incidence of renal 
failure alone, but also of a country's healthcare budget and treatment capacity for renal fail-
ure) 4 Because renal replacement therapies are lifelong, complex and costly, there is con-
tinuous interest in the evaluation of costs and effects of such treatment. 5-8 This interest 
even precedes the period in which Health Technology Assessment (HTA) emerged. HTA 
can be described as a multi-disciplinary research field, investigating the societal conse-
quences of medical technology such as drugs, medical devices and surgical procedures. 9 Its 
aim is to support rational medical decision making and rational healthcare policy, by pro-
viding a systematic evaluation of all relevant medical, epidemiological, economic, social and 
ethical issues that surround new or existing medical technologies. W'ithin HTA research, the 
field of economic evaluation received increasing interest in recent years.10 The aim of eco-
nomic evaluation is to inform decision makers about the relative efficiency of alternative 
courses of action for a specified medical problem.11 Limited healthcare budgets, the ageing 
population with concomitant pressure on healthcare provision, and advances in medical 
technology have stimulated further interest in this research discipline. However, efficacy or 
effectiveness is no longer the only criterium for a decision to reimburse a new medical tech-
nology. Information on the relation between input (costs) and output (e.g. in terms of sur-
vival and quality of life of patients) is also needed for such a decision. The work presented 
in this thesis has emerged against this background of health technology assessment and 
economic evaluation. 
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Outline and research questions 
The main objective of the research presented here is to evaluate the costs and outcomes of 
end-stage renal disease treatments in the Netherlands. The study was started in 1995 as a 
sub-study of the Netherlands Cooperative Study on Adequacy of Dialysis (NECOSAD-I), 
a prospective cohort study aiming at the identification of factors that determine outcome 
of dialysis treatmentl2 !3 This sub-study, called the NECOSAD-Technology Assessment 
Study (NECOSAD-TAS), comprised additional data collection on costs of therapy and 
quality of life of patients. The results of NECOSAD-TAS are presented in this thesis. 
The thesis comprises nine chapters. This chapter (chapter 1) presents a general introduction 
and an outline of the research questions addressed in the subsequent chapters. 
Chapter 2 presents a systematic review of the literature on health-related quality of life of 
dialysis and transplant patients, focusing on four health profiles and two health preference 
methods frequently used in renal patients. The questions addressed are: 
• \Xlhat are the psychometric properties of health profiles and health preference 
methods as applied in renal patients? 
• How does health-related quality of life of end-stage renal disease patients com-
pare with that of a healthier population, such as a general population sample? 
• 'VV'hich medical, socio-demographic and disease-related factors determine 
health-related quality of life of end-stage renal disease pa-tients? 
• Do health-related quality of life outcomes differ between patients treated with 
different therapeutic modalities? 
Chapter 3 reports on health-related quality of life of haemodialysis patients and peritoneal 
dialysis patients. Quality of life was assessed with health profiles/health status measures 
(Short-Form 36 and EQ-5DpwfilJ and with health preference methods (Standard Gamble 
and Time Trade Off). The research questions are: 
• Is the quality of life of both patient groups similar? 
• Does the quality of life of dialysis patients differ from a general population 
sample of similar age? 
• Wbat is the relationship between socio-demographic, patient-related and treat-
ment-related background variables and quality of life outcomes? 
• What is the relationship between health profiles and health preference meth-
ods? 
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Chapter 4 presents a cross-sectional study on quality of life outcomes of two groups of 
peritoneal dialysis patients. This study is similar to that presented in chapter 3, but covers 
different patient groups. The research questions are: 
"' Does the quality of life of automated peritoneal dialysis patients differ from 
that of continuous ambulatory peritoneal dialysis patients? 
• Does the quality of life of peritoneal dialysis patients differ from that of a gen-
eral population sample of similar age? 
• \Xlhat is the relationship between quality of life outcomes and socio-demo-
graphic, patient-related and treatment-related background variables? 
Chapter 5 addresses economic aspects of renal replacement therapy. An overview of eco-
nomic evaluations of renal replacement therapies, published bet\veen 1985 and 2000, is pre-
sented. The main research questions are: 
• \Vhat is the current knowledge on the costs and effects of renal replacement 
therapies? 
" \\lhat is the quality of economic evaluation studies performed in the field of 
renal replacement therapies? 
Chapter 6 reports on the cost of illness and the public health burden of end-stage renal dis-
ease in the Netherlands. Four research questions are addressed: 
• \Xlhat are the costs of the different renal replacement therapies? 
• \'{/hat are the societal costs of end-stage renal disease in 1994? 
• \Xlhat are the expected societal costs in the period 1999-2003, taking into 
account demographic and epidemiological developments? 
• How many Disability Adjusted Life Years are associated with end-stage renal 
disease in the Dutch population? 
Chapter 7 combines the quality of life information and economic data presented in the pre-
vious chapters in an economic evaluation of six renal replacement therapies (five dialysis 
modalities and renal transplantation). The main questions are: 
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'" What is the cost-effectiveness and cost-utility of the six renal replacement 
therapies? 
• \\?hat is the overall cost-effectiveness and cost-utility of the Dutch end-stage 
renal disease treatment program? 
• \Xlhat is the expected influence of policies to transfer patients from more 
expensive to less expensive treatment modalities on the overall cost-effective-
ness of the Dutch end-stage renal disease treatment program? 
Chapter 1 
Chapter 8 offers a reflection on the use of health preferences in economic evaluation stud-
ies. This chapter is rooted in an observation made while performing the quality of life stud-
ies in dialysis patients. Although no differences in health preferences "\Vere found between 
the patient groups, the general population samples seemed to have different health prefer-
ences for health states of different patient groups. This triggered interest in the influence 
of experience \vith disease on the valuation of health status. Thus, the following questions 
are addressed: 
• Is there any evidence that experience with illness influences the valuation of 
health' 
• Is there any difference between valuations of students and dialysis patients 
regarding hypothetical health states? 
• Do the valuations of the actual health status of dialysis patients differ from val-
uations of the general population for similar health states? 
Finally, chapter 9 presents the main conclusions of this work, together with some method-
ological and theoretical reflections. Furthermore, implications for future research are dis-
cussed. A summary in English and Dutch concludes the thesis. Because chapters 2 to 8 of 
this thesis were written as independent papers, there is some overlap concerning study 
design and methodology; however, this means that each chapter can be read as an inde-
pendent study. 
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Chapter 2 
De Wit GA, de Charro FTh. The use of health profiles and health preference 
methods in end-stage renal disease patients: a systematic review of the liter-
ature. Submitted. 
Abstract 
This paper reports on a systematic review of the literature on Health Related Quality of 
Life (HRQOL) of end-stage renal disease patients, as measured with four well-known 
health profiles (Short-Form-36, Nottingham Health Profile, Sickness Impact Profile and 
Quality of Life Index) and two health preference methods (Time Trade Off and Standard 
Gamble). In a J\tfedLine search, 815 articles regarding HRQOL of end-stage renal disease 
patients were found. Of these, 109 had applied one of the six HRQOL questionnaires list-
ed above. Five more of such papers were identified with an additional search in ENIBASE 
and PsyciNFO databases. Of the 114 publications initially selected, 57 remained after fur-
ther selection based on study quality criteria. Findings are discussed along the four main 
research questions that were covered in the selected papers: 
1 \XThat are the psychometric properties of health proflles and health preference 
methods as applied in renal patients? 
2 How does HRQOL of end-stage renal disease patients compare with that of a 
healthier population, such as a general population sample? 
3 \"'Vbich medical, socio-demographic and disease-related factors determine 
HRQOL of end-stage renal disease patients? 
4 Do HRQOL outcomes differ between patients treated with different therapeu-
tic modalities? 
The main conclusions are: 
1 the methodological soundness of Short Form 36 and Sickness Impact Profile is 
best documented, 
2 HRQOL of end-stage renal disease patients is worse than HRQOL of the gen-
eral population, 
3 a higher age and the presence of comorbid diseases are strong determinants of 
lower HRQOL, 
4 HRQOL of transplanted patients is better than HRQOL of dialysis patients, 
but no major HRQOL differences exist bet\veen patients treated with different 
dialysis modalities. 
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Introduction 
Dialysis and transplantation, treatment options for patients with end-stage renal disease 
(ESRD), have been among the first fields of medicine where the "quality of life concept" 
was introduced.1 Dialysis became available in the 1960s and was the first treatment for 
patients who would otherwise have died. It soon became clear that the quality of this exten-
sion of life was considerably affected. Patients were hampered in many domains of every-
day life and dialysis was not providing the return to normal health that was initially hoped 
for. New therapeutic possibilities such as renal transplantation, the rising prevalence of 
renal failure, the high cost of therapy, and improvements in existing therapies have inspired 
sustained interest in quality of life aspects of renal replacement therapies. Historical reviews 
on quality of life research in ESRD patients were performed by Gokal,2-3 Parsons and 
Harris,4 and Kaplan De-Nour and Brickmann.s Over the last 30 years, the definition of 
quality of life and thus the character of quality of life research has changed dramatically, 
reflecting the maturation of the scientific discipline itself 6 In the early years of dialysis, 
research was mainly directed at vocational rehabilitation and the presence of stress and psy-
chiatric disturbances in patients7 -8 Tbe 1980s constituted a research period with large stud-
ies comparing different treatments, using batteries of questionnaires, each directed at sepa-
rate dimensions of quality of life (uni-dimensional questionnaires).9 The availability of 
more sophisticated, multi-dimensional questionnaires to describe and value quality of life 
in the 1990s is reflected in increasing use of such questionnaires in ESRD patients.10-11 
Also, disease specific questionnaires, 12 and health preference methods or utility instruments 
have been applied more often in recent years.13 
Despite the maturation of the discipline of quality of life measurement, consistency in 
the definition and measurement of quality of life is stilllacking.14 Psychologists, economists 
and clinicians all seem to have their own ideas on quality of life. Different "schools" do 
agree on the fact that quality of life is a multi-dimensional and subjective phenomenon. 
Besides, the limitation of (measurement of) quality of life to health-related quality of life is 
increasingly common. One workable definition of health-related quality of life (HRQOL) 
is: "those health-related aspects of life which are capable of being modified by the provi-
sion of healthcare".1.5 A modern taxonomy of approaches to the measurement of HRQOL 
is described by Guyatt et aJ.l6 They distinguish bettveen generic and disease-specific instru-
ments to assess HRQOL. Generic instruments may be used in any population, regardless 
of the underlying condition, while disease-specific instruments are only applicable in spe-
cific patient-groups. Two types of generic instruments exist: (1) health profiles and (2) 
health preference methods or utility measures. Health profiles cover a range of dimensions 
of HRQOL, including physical, psychological and social functioning. Depending on the 
specific health profile, scores on indi·vidual dimensions may be combined into summary 
scores for physical, mental or psychosocial functioning, or into one overall score. Health 
preference methods or utility measures are rooted in economic and medical decision mak-
ing theory. These measures are aimed at eliciting the value a person attaches to a health 
state, relative to perfect health and death. HRQOL is summarised as a single number, usu-
ally bettveen 0 and 1. Health preference scores elicited from patients reflect both the health 
status of the patient and the value of that health status to the patient. In recent years, the 
emphasis in HRQOL research in ESRD patients has been on the use of these health pro-
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flies and health preference methods. Uni-dimensional questionnaires, -widely used in the 
1980s, seem to be used less often nowadays. The aim of this article is to present a review 
of the literature on the application of health proflies and health preference methods in 
ESRD patients. Besides a part of the literature that is entirely descriptive in nature, the lit-
erature in this field aims generally at answering one or more of the following questions: 
1 W'hat are the psychometric properties of health profiles and health preference 
methods as applied in renal patients? 
2 How does HRQOL of ESRD patients compare v.ith that of a healthier popu-
lation, such as a general population sample? 
3 \Xi'hich medical, socio-demographic and disease-related factors determine 
HRQOL of ESRD patients? 
4 Do HRQOL outcomes differ betv.reen patients treated with different therapeu-
tic modalities? 
\~'e will discuss our findings along these four questions. 
Methods 
Several sources were used to identify published papers on HRQOL of ESRD patients 
(including pre-dialysis patients entering ESRD treatment). Firstly, a MEDLINE search 
(1966 through 1999) was performed. The search strategy is outlined in Appendix I. Other 
sources of information were two general quality of life bibliographies 1 17 and other pub-
lished reviews 2-518. Further, we carefully tracked all the references of selected publications. 
Finally, we searched the El\ffiASE and PsyciNFO databases for additional references not 
found using the strategy described above. 
\X7e have used the following selection criteria for our search, to ensure that only the rela-
tively well designed and well-reported studies were incorporated in our rev-iew: 
• studies must report self-assessed HRQOL data of ESRD patients, 
• no interim reports were selected if a final report was available, 
• double publications of the same study data were only included if different 
research questions were addressed, 
• data must be reported in a -way that allows for verification (for instance, conclu-
sions drawn should be supported by reported data), 
• in cross-sectional studies aiming at the comparison of HRQOL of patients 
treated with different modalities, multivariate control for case-mix differences 
must have been applied, 
13 
The use of health profiles and health preference methods in end stage renal disease patients 
• studies aiming at the comparison of ESRD patients' HRQOL and HRQOL of 
the general population must have used age-matched control samples from the 
general population, or control for age in a multivariate analysis. 
Furthermore, the following types of studies were excluded from the revie\v: 
" studies with a main focus on HRQOL of diabetes mellitus patients or com-
bined kidney-pancreas transplant, 
" studies that report only staff-assessment of HRQOL of ESRD patiem:s, 
• studies that applied generic instruments only to test construct validity of dis-
ease-specific or uni-dimensional HRQOL instruments, 
" studies describing samples of less than 20 patients, and 
" cross-sectional studies that describe HRQOL outcomes without any further 
analysis. 
Results 
HRQOL instruments used in ESRD patients 
Because our current review was aimed only at the use of health profiles and health prefer-
ence methods in ESRD patients, we a pri01i limited the list of instruments relevant to our 
review. However, some further limitations in the list of viable instruments were made on 
the basis of the following reflections. Some authors regard rating scales (Visual Analog 
Scales) also as health preference methods. 19 However, many different operationalisations of 
rating scales were found in the literature, with different anchor points, instructions and scal-
ing. These differences in operationalisation hamper unambiguous interpretation of scores. 
\"X/e therefore choose not to include the rating scale approach in our revie\\~ Another cate-
gory of HRQOL instruments combines patient-derived information on health status with 
community-derived valuations for these health states. These instruments are primarily suit-
able for use in economic evaluation studies since they allow for the calculation of Quality 
Ad;usted Life Years (QALYs). Examples of such instruments are the EuroQol (EQ-5D) 
Instrument,20 the Rosser and Kind Scale,21 and the Quality of \\lell Being Scale.22 Such 
instruments have scarcely found application in ESRD patients and have therefore not been 
included in our revie\\~ Also, not all available health profiles have been applied in ESRD 
patients. As a consequence, well-known profiles, such as the COOP charts and the Duke 
Health Profile, could not be selected for our review. Ultimately, the following six HRQOL 
instruments were selected for the review: 1fedical Outcomes Study Short-Form Health 
Survey, Sickness Impact Profile, Nottingham Health Profile and the Quality of Life Index 
(representing the health profiles), and Time Trade Off and Standard Gamble (representing 
the health preference methods). In the following, the six selected instruments are described 
briefly. 
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The Afedical Ott/comes Stucfy ShoJt-Form Health StmJf!)l is available in different lengths, the 36-
item short-form health survey (SF-36) being by far the most frequently used. The SF-36 · 
generates a profile of scores on 8 multi-item scales, reflecting 8 dimensions of HRQOL.23 
These dimensions are (1) physical functioning, (2) role limitations due to physical problems, 
(3) bodily pain, (4) general health perceptions, (5) vitality, (6) social functioning, (7) role lim-
itations caused by emotional problems and (8) mental health. Raw scores are transformed 
to scale scores bet\veen 0 and 100, where a higher score indicates better health. Two sum-
mary scores may be computed from the scores of the 8 sub-scales of the SF-36, the 
Physical Component Summary (PCS) and the ,Y!ental Component Summary (MCS)24 
Norm-scores for (sub-groups of) the general population are available. 
The Sickness Impact Projile (SIP) is a behaviourally based measure to assess the impact of 
disease and treatment on functional status.25 The instrument contains 136 statements, cov-
ering 12 clifferent domains: (1) sleep and rest, (2) eating, (3) work, (4) home management, 
(5) recreation and pastime, (6) ambulation, (7) mobility, (8) body care and movement, (9) 
social interaction, (10) alertness behaviour, (11) emotional behaviour, and (12) communica-
tion. Respondents either agree or disagree with the statement. Results may be presented as 
a 12-dimensional profile score, or by means of sub-scores: a "physical" score based on 3 
scales, a "psychosocial" score based on 4 scales, and a total score. Scores represent a per-
centage of the total possible score and range from 0 to 100, v.rhere 0 represents optimal 
health. 
The j'\,Tottingham Health Prrfile (:.":"HP-1) contains 38 dichotomous questions about health 
status, which may be summarised in 6 sub-scales: (1) physical mobility, (2) energy, (3) pain, 
(4) sleep, (5) social isolation, and (6) emotional reaction.2G Scales range from 0 to 100, with 
higher scores indicating more limitations. The NHP docs not summarise individual scale 
scores in an overall score. 
The Qnality of Life Index (or Spitzer:r Quality of Life Index- QLI) was originally designed to 
measure the general well-being of terminally ill cancer patients, but has been used broadly 
for chronically ill patients populations.27 The QLI consists of five domains of HRQOL ((1) 
activity level (including occupation), (2) activities of daily living, (3) feelings of healthiness, 
(4) quality of social support and (5) psychological outlook), each with three levels of func-
tioning. Scores of 0, 1 and 2 for each level reflect increasing well-being and may be summed 
to a total score ranging from 0 to 10. 
The Time Trade Off (TTO) is an interview technique that is aimed at eliciting the value a 
person attaches to his current health state.28 It is based on the principle that the less prefer-
able the current health state is, the higher the proportion of remaining life-time a person is 
willing to trade off to gain normal health will be. The respondent is asked whether he is 
prepared to give up some remaining time of life, in order to improve the current health 
state to normal health. The quotient of the chosen number of years in a normal health state 
over statistical life expectancy yields the TTO score, a score between 0 and 1, where a high-
er score represents a better health state. 
Finally, the Standard Gamble (SG) is an interview technique, that is based on the principle 
that a respondent will be more willing to accept a risk in order to gain normal health, if the 
current health state is regarded as less desirable. 19 The respondent is presented with two 
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hypothetical alternatives and asked to choose the one preferred most. The first alternative 
offers the certainty of staying in the current health state for the remainder of the respon-
dent's life. The second alternative is a gamble with specified probabilities for both the pos-
itive outcome of the gamble (a normal health state for the remainder of the time) and the 
negative outcome (death). As with ITO, a score between 0 and 1 is derived, where higher 
scores represent better health states. 
Results of the literature search 
The MEDLINE search generated 815 references that were all checked for the tyorpe of 
HRQOL instrument that was used. Out of these 815 papers, a total number of 109 papers 
was initially selected because one of more of the six selected HRQOL instruments was 
applied. Five more papers were identified with a control search in ElviBASE and 
PsyciNFO. After reading those 114 papers, a further selection was made on the basis of cri-
teria discussed in the methods section. Finally, 57 papers were selected for this review. Most 
studies that were not selected were (older) descriptive cross-sectional studies that suffered 
from a lack of adjustment for differences in case-mix between different treatment groups. 
Appendix 2 shows a comprehensive overview of all selected studies with the following key 
features: first author, year of publication, study design, aim of study, number and treatment 
modality of patients, HRQOL instrument used and main outcomes. In addition, appendix 
3 provides six tables that show published scores for each of the six selected HRQOL 
instruments. These tables may be used as a quick reference for clinicians and researchers 
who apply those instruments in ESRD populations. In the remainder of the results section, 
we will discuss the findings of selected studies, centred around the four research questions 
that were formulated in the introduction section. 
Research question 1: What are the psychometric properties of health profiles 
and health preference methods as applied in renal patients? 
Because the six selected HRQOL instruments are well tested and validated generic instru-
ments, they should be useful for application in both healthy and diseased populations. 
Therefore, psychometric testing for specific patient groups, i.e. dialysis patients, is in gen-
eral not considered as a necessity. Indeed, many authors refer to the fact that these generic 
instruments have been tested for psychometric properties in other populations and in gen-
eral were found to have adequate test properties.1 1 29-37 However, extensive methodologi-
cal work on feasibility, reliability, validity and responsiveness of these HRQOL instruments 
in ESRD populations was found in our review. Also, because all instruments aim to meas-
ure HRQOL, some authors have studied the relationship of health profiles scores to health 
preference scores. 
Feasibility. The administration of ITO and SG requires an interview situation. The SIP is 
often presented in an interview situation as well, although self-assessment is also possible. 
Both NHP and SF-36 are generally self-administered. The ITO and SG require a certain 
level of cognitive functioning from the respondent.38 Several publications mention that 
some respondents were unable to answer SG and ITO because of cognitive failures, or 
stipulate that patients refused to answer because of other reasons, e.g. religion. 38-41 
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Percentages of non-response to these instruments as high as 19 % have been reported. 38 
Other authors did not encounter specific problems when administering SG and/ or TTO. 42 
The SF-36, SIP and NHP are generally well accepted by patients and can be self-adminis-
tered43-47 In a study comparing the feasibility of NHP and SIP, Essink-Bot eta!. found the 
NHP to be more feasible than the SIP, i.e. shorter and less difficult.44 No information on 
feasibility of QLI was found. 
Validity. Evidence for discriminant validity, in a sense that the instrument is able to dis-
criminate benveen HRQOL of patients on different treatment modalities or with different 
underlying diseases in a way that is predicted a priori, is presented for the TT0,40 48 and for 
th_e SF-36.43 49 In one study, evidence for construct validity of TTO (the level of agreement 
with other measures that aim to measure the same underlying construct) was obtained 
through a comparison of the independent rating of the quality of life of a patient by his 
nephrologist and the patient himself. 39 The rank correlation between the mean scores of 
nephrologists and patients was 0.51. Another study also provided with evidence for con-
struct validity by means of a comparison of patient ITO scores and nephrologists', nurs-
es' and relatives' assessment of patients HRQOL.40 The correlations between patients' 
TTO scores and external raters' scores were positive and statistically significant, but rela-
tively low (r from 0.27 to 0.40). Essink-Bot eta!. studied the construct validity of NHP and 
SIP in dialysis patients, comparing the pattern of Intra Class Correlation (ICC) coefficients 
between conceptually similar scales of NHP and SIP, and between scales of NHP /SIP and 
related domain-specific HRQOL measures with proven validity.44 The association patterns 
observed between the NHP and the SIP, and other instruments were largely as expected, 
supporting the construct validity of these two instruments. No information on validity of 
SG and QLI was found. 
Rtliabili!)' (reproducibility or test-retest reliability) refers to the degree to which results 
obtained by a measurement can be reproduced. The study of reliability of HRQOL scores 
in ESRD patients might be troubled by the occurrence of real changes in health status 
between t\vo moments of measurement, for instance when assessed before and after a dial-
ysis session. One study reported test-retest reliability of the TTO to be 0.85, when the tests 
were administered 6 weeks apart. 48 One large study reassessed the TTO in 171 ESRD 
patients 4 weeks after the first interview and found the intra-class correlation coefficients 
(ICC) to be 0.81.40 A pilot study from the same research group reported a test-retest cor-
relation coefficient of 0.628, 6 weeks after the initial interview.39 One study on the reliabil-
ity of the NHP found Spearman correlation coefficients of 0.69 to 0.85 between first and 
second administration of this questionnaire. SO Another study used ICC's for the test-retest 
reliability of the NHP, and found these to be between 0.55 and 0.8044 Because the NHP 
was administered just before and one day after dialysis in that study, the authors preclude 
that the relatively low ICC's might be attributed to real differences in patients' health status 
before and after dialysis.44 Laupacis et al found ICC's exceeding 0.80 when the repro-
ducibility of the SIP was studied two months after the initial interview in 40 patients who 
received a placebo to erythropoietin, a drug used for anaemia. 51 Test-retest reliability of SG 
and QLI has not been studied in ESRD populations. 
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Reliability (homogeneity or internal consistency) estimates the extent to which different sub~ 
parts of an instrument measure the critical attribute. Evaluating the internal consistency of 
SF~36, adequate Cronbach's alphas for group comparisons(> 0.7) were reported by sever~ 
al authors.43-4? 49 The internal consistency of NHP, as studied by Badia et aL,50 was very 
good for the entire instrument (Cronbach's alpha 0.91), and somewhat less for individual 
sub-scales (ranging from 0.58 (social isolation) to 0.86 (pain). One other study compared 
internal consistency of l':HP and SIP, and found that the NHP (Cronbach's alphas 0.39~ 
0.80) yielded somewhat higher internal consistency estimates than the SIP (0.14 to 0.95).44 
Responsiveness to change. Another important feature of a HRQOL instrument should be sen-
sitivity, or responsiveness to clinically meaningful changes. This is especially relevant in 
studies evaluating the effectiveness of interventions. One study evaluated the responsive~ 
ness to change of ITO in a prospective study that attempted to reach an adequate dialysis 
dose (defined as total weekly clearance of waste products Kt/Vurea > 1.0) in underdialysed 
patients (Kt/Vurea < 0.8, n=26).52 The ITO was found not to be responsive: no significant 
correlation between change in Kt/V urea values from initial to second evaluation and the 
change in ITO values could be demonstrated (r = 0.07). The authors' explanation for this 
finding is that, because the ITO allows patients to apply internal weights to the effect of 
ESRD and its treatment on HRQOL, the patient does not weight such improvements in 
therapy heavily. Several other studies reported on ITO's responsiveness to change in 
prospective studies evaluating the effect of the drug erythropoietin.13 53-54 Two studies 
found that TTO scores remained stable over time, although health profiles showed increas-
es in some domains of HRQOL, such as fatigue and physical functioning_13 53 One small-
er study (n=28) by Harris showed higher ITO scores after introduction of erythropoi-
etin.54 Larger improvements in HRQOL, such as found when prospectively comparing pre-
and post~transplant HRQOL, were reflected (P<O.OOS) in higher TTO scores in several 
studies.SS-5? Responsiveness may in general be hampered by floor- or ceiling effects, indi-
cating that the majority of the patients show scores around the upper or lower bound of 
the range of possible scores. One study found such effects using the NHP..58 In a group of 
limited care haemodialysis patients, the median score in 2 out of 6 scales was 0 (best pos~ 
sible score), while median scores in the other 4 scales also did not allow for further differ-
entiation between sub-groups of patients. A comparative study between NHP and SIP 
found the distribution of scores of the SIP to be even more skewed in the direction of 
good functioning than those of NHP.44 Appropriate use of the whole range of possible 
scores was reported for the SF-36 sub-scales, 12 45-47 except for the nvo role functioning 
scales.45-4? No information was found on responsiveness of SG and QLI instruments. 
Relationship if health prrjiles and health priference scores. Although all instruments selected aim to 
measure HRQOL, reported correlations between the respective outcome measures were 
low to moderate. A correlation of 0.43 was found between QLI and IT0.40 Correlations 
between the global, physical and psycho~social SIP scores and TTO were ~0.23, ~0.15 and~ 
0.17, respectively, as reported in the Canadian Erythropoietin Study. 51 Similar correlations 
between SIP and TTO (r = 0.19) and SIP and SG (r = 0.31) were found in a study by 
Hornberger et aL42 The two health preference instruments that were used in that study (SG 
and TTO), showed only a moderate correlation (r = 0.31), despite the conceptual similari~ 
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ty of both instruments. Hornberger et al. found that agreements bet\veen measures were 
especially poor at the individual level, with patients reporting low HRQOL according to one 
method and a high HRQOL according to the other. Most patients had discrepancies of 
greater than 50 percent bet\veen the highest and lowest scores on the different instruments 
used. This study showed that the method chosen to evaluate HRQOL may produce sub-
stantiallv different impressions of HRQOL of patients. Revicki used (sub-scales of) SIP, 
SF-36 and SG in a group of 73 pre-dialysis patients and found correlations between SIP 
and SG and SF-36 and SG not to be higher than 0.19, with one exception of 0.30, for the 
correlation benveen the SIP sub-scale home management and SG.38 Although the selected 
instruments all aim at measuring HRQOL, different instruments may lead to different con-
clusions on HRQOL of a patient population. Health profiles and health preference meth-
ods are at best moderately correlated. 
Research question 2: How does HRQOL of ESRD patients compare with 
that of a healthier population, such as a general population sample? 
Because it is known that HRQOL scores are negatively related with age, only those studies 
that compared HRQOL of ESRD patients with age-matched samples of the general pop-
ulation are reviewed here. Thirteen studies provide with such information.11 29 46-47 .59-67 
Except three studies that were performed in transplanted paticnts,61 64 66 all studies report-
ed that ESRD patients rated their HRQOL on average lower than the normal population, 
irrespective of the type of HRQOL instrument that was used. However, differences 
between ESRD patients and the general population -,.vere more obvious in the physical 
domains of HRQOL than in the mental domains.l 1 60-63 6.5 Five studies that focused on 
HRQOL differences between transplanted patients and the general population draw differ-
ent conclusions.61 63-64 66-67 The studies by Benedetti ct aL61 and Rebollo et aJ.64 found lit-
tle differences in SF-36 scores and a study by Niechzial et al.66 found equal or better NHP 
scores for transplant recipients, compared -,.vith the general population. The study by Shield 
et al. 67 found that transplanted patients were not significantly different from the general 
population in SF-36 dimensions of bodily pain, vitality and mental health. Finally, a study 
by {\..'fatas et aL63 described that up to 40% of non-diabetic and up to 65(% of diabetic trans-
plant recipients had SF-36 scores below the 95% confidence interval for age-matched con-
trols of the general population. This was especially true in the physical domains of the SF-
36. Three studies stratified the ESRD populations into age-groups and found that differ-
ences bet\veen ESRD patients and general population samples are smaller in d1e higher age-
group(s)60-62 One of the two studies that found little HRQOL differences between ESRD 
patients and the general population was also performed in a group of patients older than 
65 years.64 
Research question 3: Which medical, soda-demographic and disease-related 
factors determine HRQOL of ESRD patients? 
HRQOL of dialysis patients may be determined by socio-demographic, treatment related 
and disease related variables, as well as psychological and social factors. J\1any studies have 
linked HRQOL outcomes to such variables, but only those studies that report these analy-
ses in a multivariate way are reviewed here. Of the selected studies, sixteen reported on 
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important determinants of HRQOL.10-11 29 32 34-36 47 49 65 68-73 All studies that analyzed the 
influence of the presence of co-morbid conditions on HRQOL outcomes reported similar 
findings: concurrent diseases have a negative influence on HRQOL)O 29 34-36 47 49 68 70-71 
73 Especially diabetes mellitus 10 35-36 68 71 73 and cardiovascular disease 10 34-35 73 were iden-
tified as diseases that influence the physical domains of HRQOL A higher age was found 
to be negatively associated with NHP scales of pain and mobility,65 SF-36 scales physical 
functioning,29 47 49 68 vitality 47 49 and role limitations due to physical functioning,29 49 phys-
ical SIP score,lO 35-36 69 psychological SIP score,lO 69 total SIP score, tO 35 69 QLI score 71 
and positively with SF-36 scale social functioning.681Iore years of education was found to 
be positively associated with overall HRQOL outcomes,10 35 69 71 physical 10 35 and psy-
chological/mental HRQOL outcomes. tO 35 65 69 Some socio-demographic factors that were 
found to be negatively associated with HRQOL were female sex 10 47 black race 36 and 
Hispanic race,49 while being married,72 a higher socio-economic status, 10 and being 
employed 29 69 71 were positively associated with HRQOL. No agreement was found on the 
relationship between time on dialysis / total time with end-stage renal disease and HRQOL 
outcomes. A large study by Niechzial et al. 65 found that patients who were on dialysis for a 
longer time had more severe problems with NHP scales pain, emotional reactions, sleep 
and mobility. \Xlight et al. described a similar negative influence of treatment duration on 
physical functioning. 47 In contrast, Morton and colleagues 73 described that length of time 
on dialysis was positively associated with good outcomes on physical and social function-
ing. Others 71 found no influence of length of time on dialysis on HRQOL scores. Higher 
haemoglobin levels were described to have a positive influence on total SIP score,10 physi-
cal SIP score, 10 SF-36 domains of social functioning, role limitations caused by emotional 
problems and vitality,29 and physical functioning and vitalit:y.47 Some studies have analysed 
the associations bertveen HRQOL outcomes and renal function parameters. Higher hema-
tocrit levels were found to positively affect total SIP score 10 and changes in hematocrit lev-
els were associated with positive changes in overall health.11 Serum albumin was found to 
be positively related to 7 out of 8 SF-36 scales,68 QLI score 71 and total SIP score34 One 
study that linked HRQOL outcomes to residual renal function found that this was positively 
associated with SF-36 scales social functioning, role limitations due to physical problems, 
role limitations caused by emotional problems, mental health and vitality.29 A later report 
on the same study population showed that physical HRQOL in haemodialysis and peri-
toneal dialysis and mental HRQOL in haemodialysis patients was to a larger extent 
explained by a greater physical symptom burden (occurrence and frequency of itching, 
cramps, fatigue etc.) than by any other determinant.70 Morbidity, defined as the number of 
hospital admissions in the past six months, was negatively related with total SIP score and 
physical and psychosocial SIP scores,69 with some SF-36 scales 49 and with the ITO 
score_72 One striking finding is that five studies that aimed to explain HRQOL outcomes 
from dialysis adequacy data, all found that adequate dialysis was not an important factor_10 
29 47 68 73 
Ten studies focused on the effects that erythropoietin treatment of ESRD-related 
anaemia had on HRQOL. 11 13 .53-54 74-79 Of these studies, only two were designed as ran-
demised controlled trials.13 74 The study by the Canadian Erythropoietin Study Group 
showed that the global and physical scores on the SIP improved in patients treated 'N"ith ery-
thropoietin compared with those given placebo.13 Significant improvements were noted in 
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the response of patients to questions on body care and movement, home maintenance, 
ambulation, communication and work among those treated with eq.rthropoietin. Despite 
these improvements, patients' TTO scores remained stable.13 The second randomised con-
trolled trial was performed in predialysis patients.74 This study showed that there were sig-
nificant differences between patients using erythropoietin and the placebo group on 
changes in SF~36 sub~scales of energy (vitality) and physical functioning. Other published 
studies were all observational studies, with patients serving as their own controls in a pre-
and post-erythropoietin use situation. The largest of these observational studies involved 
1004 patients, divided over patients who were not using erythropoietin before (new-to-ery-
thropoietin) and patients who were already using erythropoietin (old-to-erythropoietin). 11 
Significant improvements in SF-36 sub-scales of physical functioning, vitality, social func-
tioning and mental health, and in the 1.-Tental Component Summary Score were described 
for new-to-erythropoietin patients. Patients already using erythropoietin did not experience 
changes in HRQOL during the study period. At follow-up, a comparison of the old-to-ery-
thropoietin patients with the new-to-erythropoietin patients revealed that SF~36 scores for 
the latter group achieved the same levels as the former group. Three studies used the SIP 
to evaluate changes in HRQOL after start of erythropoietin use. 53 77 79 These studies all 
described improvements in the psychosocial dimension of SIP and the global SIP scores, 
and t\vo studies also described improvements in the physical dimension of SIP. 53 79 Three 
studies evaluated HRQOL changes after start of erythropoietin use with the NHP instru-
ment.75-76 78 A large study by Evans et al. found significant improvements in the energy, 
emotional wellbeing and social isolation domains of the NHP. 78 The positive effect of ery-
thropoietin on energy and emotional wellbeing was confirmed in t\vo smaller studies.75-76 
Only two studies have attempted to identify factors that were independently related to 
HRQOL improvement after erythropoietin treatment.11 79 It was found that most substan-
tial improvements in HRQOL were experienced by patients with poor baseline HRQOLJ9 
Furthermore, erythropoietin induced changes in haematocrit level were positively associat-
ed with HRQOL outcomes in SF-36 scales of general health, vitality and social function-
ing,ll and with the global score of SIP7 9 
Research question 4: Do HRQOL outcomes differ between patients treated 
witb different therapeutic modalities? 
Many studies comparing the HRQOL of different treatment modalities have been pub-
lished. A major drawback of all studies is the lack of randomisation of patients over dif-
ferent modalities. As a consequence, selected patients are being treated with selected modal-
ities. To overcome this objection at least partially, cross-sectional studies were only selected 
for this review if differences in case-mix had been corrected with multivariate analyses 
techniques. The NHP was used in one study in 1027 haemodialysis and peritoneal dialysis 
patients. 6S For each of the 6 sub-scales of NHP, it was concluded that peritoneal dialysis 
patients did not differ significantly from haemodialysis patients. From this cohort of dialy-
sis patients, 138 patients were transplanted,66 which markedly affected their functioning in 
the energy, sleep and emotional reactions domains of HRQOL. The ITO was used in six 
studies comparing modalities.40 55-57 72 80 One small study compared HRQOL effects of 
high-flux and conventional haemodialysis techniques in a cross-over trial. 80 The 22 patients 
who completed both phases of the trial did not experience differences with respect to 
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HRQOL. Five studies concluded that transplanted patients had a better HRQOL as meas-
ured with ITO than dialysis patients.40 55-57 72 Three of those studies were prospective 
studies that followed unselected samples of patients from dialysis through transplanta-
tion.SS-57 Six to thirty months after transplantation, patients valued their HRQOL on aver~ 
age with a ITO score that was 0.17-0.33 (P<0.001) higher than their pre-transplantation 
score. Two of these prospective studies also included the SIP instrument.55-56 Both the 
physical (P<O.OOJ) and psychosocial sub-scores (P<O.Ol), and the total SIP score improved 
significantly (P<O.OOJ) after transplantation. l\. study by Julius et al. using the SIP found that 
CAPD patients had the highest scores on the physical functioning scale (indicating more 
physical dysfunctioning), followed by centre haemodialysis patients, cadaver transplant and 
related transplant patients. 36 Differences were not statistically significant, except ben.:veen 
CAPD and related transplant patients. The SIP instrument was also used in a Spanish study 
involving 1013 dialysis patients, who received either conventional haemodialysis, haemo-
diafiltration or peritoneal dialysis. 10 After adjusting the HRQOL outcomes for case-mix dif-
ferences, no significant differences were found in relation to dialysis modality. Of this sam-
ple of 1013 Spanish dialysis patients, 88 patients were successfully transplanted. Their 
changes in HRQOL were described by Jofre et al.81 Improvements were reported in the 
physical, psychosocial and global domains of SIP, but "\vere most marked in the psychoso-
cial domain. For unclear reasons, women benefited less from a transplant than men. Also, 
older age and greater prior co-morbidity diminished the beneficial effects of transplanta-
tion.Bl The widely cited study by Hart and Evans used the SIP in a study comparing 
HRQOL of home-haemodialysis, centre haemodialysis, CAPD and transplanted patients.35 
This study clearly demonstrated for the first time that many of the intermodality differences 
observed in other studies may have resulted from variations in case-mix. After such adjust-
ments, only transplanted patients showed significantly better SIP scores. The three dialysis 
modalities were comparable with regard to adjusted SIP scores. Finally, four studies used 
the SF-36 and one study the SF-20 for comparison of ESRD treatment modalities.20 31 43 
47 73 A study by Khan et al showed that CAPD and haemodialysis patients showed signifi-
cantlyworse (P<0.01) scores than transplanted patients on 6 out of 8 sub-scales of SF-36.43 
The differences bet\veen dialysis and transplant patients were most pronounced in the phys-
ically oriented scales of the SF~36. Only emotional role functioning and mental health of 
dialysis patients were similar to those of transplanted patients. A prospective study by 
1vfeers et al. compared a cohort of patients that was trained for self-care haemodialysis with 
an age- and co-morbidity-matched cohort of full-care haemodialysis patients.31 It was con-
cluded that self-care dialysis patients performed better than full-care dialysis patients on SF-
36 scales role limitations caused by emotional problems, social functioning, mental health 
and vitality. 1vferkus et al. reported on HRQOL of patients three months after the start of 
dialysis treatment.29 Peritoneal dialysis and haemodialysis patients in this study showed 
comparable levels of HRQOL, except for the mental health sub-scale, where haemodialy-
sis patients appeared more impaired than peritoneal dialysis patients. This patient sample 
was followed until18 months after start of dialysis.S2 It was shown that haemodialysis had 
a consistently favourable effect on physical HRQOL over time compared with peritoneal 
dialysis. iYiental HRQOL remained stable over time. The study by \Vight et al. showed a 
HRQOL advantage of transplanted patients and similar HRQOL of patients on all dialysis 
modalities, except for an independent negative effect of hospital haemodialysis on mental 
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health47 Finally, one study that compared HRQOL of CAPD and i\PD patients found no 
influence of treatment on HRQOL of patients./3 In conclusion, there is convincing evi-
dence that HRQOL of transplant patients is better than that of dialysis patients. J\1ost stud-
ies that have compared HRQOL of patients on different dialysis modalities have found no 
or few differences ben.veen the modalities. 
Discussion 
The use of one or more of the six selected HRQOL scales, four of them health profiles 
and t\VO of them health preference methods, has been described more than 100 times. 
Especially the health profiles SIP and SF-36 have found widespread application in ESRD 
populations. Of the health preference methods, ITO was used more often than SG. Out 
of all publications, we have selected 57 relatively well designed and conducted studies for 
the current review. Four main research questions could be distinguished in the selected 
papers. W'e will discuss our main findings along these research questions. 
\XTith respect to the methodological and psychometric aspects of the use of these gener-
ic instruments in ESRD patients, most studies found that test properties were acceptable to 
satisfying. However, some concerns about the ITO instrument remained. Application of 
the ITO was hampered by relatively high non-response. 38-40 Also, the ITO was found not 
to be responsive to clinical changes.13 52-53 Elsewhere, we have postulated that ITO might 
be less suitable for use in chronically ill patient populations, because patients adapt to their 
illness and tend to use only the upper parts of the scale.S3 The same remarks may be valid 
for a HRQOL instrument familiar to TTO, the SG, but less evidence on the use of SG in 
ESRD populations was available. The correlations between scores derived with the health 
preference methods and the health profiles scores \vere poor to moderate. This finding is 
in accordance with results of previous research in other seriously ill patient groups. 84-SS The 
low correlation coefficients found in the studies imply that the variance in SG and ITO 
scores can hardly be explained by the individual HRQOL dimensions covered in the health 
profiles. The implication is that both types of questionnaires truly reflect different and pos-
sibly complementary aspects of the HRQOL concept. The health status measures mainly 
assess patients' functioning on different domains of quality of life, whereas the health pref-
erence methods elicit individual judgements on the value of the current health status, rela-
tive to full health and death. The preference scores may be influenced by factors not cov-
ered by the health status questionnaires: beliefs about health, previous experiences and 
knowledge, a person's attitude towards risk and time and non-health related factors, such as 
financial status and the availability of social support. 86 
The second research question focused on comparisons with age-matched samples of the 
general population. It was shown convincingly that dialysis patients' HRQOL is worse than 
HRQOL of age-matched samples from the general population. However, differences were 
less marked for older patient groups and for transplanted patients. In general, differences 
were more profound in the physical than in the mental and social domains of HRQOL. 
Concerning the third research question, the determinants of HRQOL of ESRD patients, 
extensive research "\Vas found in our review. The number and type of co-morbid conditions 
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(especially diabetes mellitus), age and educational level were often found to be associated 
with HRQOL outcomes. The positive influence of use of erythropoietin on HRQOL of 
ESRD patients is undoubted. Positive changes after the introduction of erythropoietin use 
have been reported in the physical, mental and social domains of HRQOL. Furthermore, 
it was found that the physical and overall domains of HRQOL are far better explained than 
the psychosocial domains of HRQOL, both in terms of number of determinants known 
to be associated with HRQOL and total amount of variation explained. Limitations of 
most studies are that only a few of the many possible determinants were included in the 
analyses. Therefore, the total explained variation of HRQOL by the selected background 
characteristics was low to moderate, in general. This implies that factors so far not known 
or not analysed contribute to HRQOL levels of ESRD patients. Even studies that attempt-
ed to include demographic, treatment related, biomedical as well as renal disease related fac-
tors found R 2 to be only 10 to 37 %.10 29 34-36 47 73 Efforts to identify additional factors that 
influence HRQOL of ESRD patients have not been particularly successful so far. Besides, 
not all determinants known can be modified by healthcare interventions. One interesting 
study found that large HRQOL differences existed bertveen patients treated in different 
dialysis centres, even after adjustment for differences in case-rnix./1 This study draws the 
attention to a less well studied area: the relationship berv:.reen the process of care and 
HRQOL outcomes. \Xlhy do patients in one dialysis centre show better HRQOL than in 
another centre? Can differences in the process of care be identified and quantified? These 
questions remain to be answered by future research. 
The fourth research question, the comparison of HRQOL of patients treated with dif-
ferent modalities resulted in the conclusion that there is convincing evidence that HRQOL 
of transplanted patients is better than HRQOL of dialysis patients. However, results of this 
rev1.ew of the literature do not justify the choice of one dialysis modality over the other 
because of perceived HRQOL benefits. 1Iost studies concluded, when differences in case-
mix between patient groups were statistically controlled for, that treaunent modality is not 
a determinant of HRQOL. The quality of life of patients who are being treated with two 
more recently developed dialysis techniques, namely APD and daily horne haernodialysis, is 
less well studied so far. Two of the selected studies included APD patients,32 73 but only 
one small study explicitly compared HRQOL of APD patients with CAPD patients.73 No 
differences were found. Larger studies should certify this finding. 
Summarising, 57 well-designed and well-performed HRQOL measurements using health 
proflles or health preference methods were found in the literature. Especially the Short-
Form-36 and Sickness Impact Profile have found widespread application in ESRD patients. 
In some dialysis centres, SF-36 is even used for regular monitoring of patients, to identify 
(changes in) problem areas and to modify these problems where possible.46 Also, for SF-36 
and SIP, most evidence on the psychometric soundness of application in ESRD patients is 
available. The health preference methods Time Trade Off and Standard Gamble have been 
used less often, and more doubts about their application remain after studying the litera-
ture. One striking finding is that TIO and SG scores do not correlate with health profiles 
scores. When using TTO and SG, it would be advisable to also apply one of the health pro-
files. Convincing evidence is available on the fact that HRQOL of dialysis patients is worse, 
especially in the more physically oriented domains of HRQOL, than HRQOL of the gen-
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era! population, and on the fact that HRQOL of transplanted patients is better than 
HRQOL of dialysis patients. No major differences in HRQOL of patients on different 
dialysis modalities were found. Regarding the four research questions identified, the ques-
tion on determinants of HRQOL in ESRD patients seems to leave most room for further 
research. 
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Appendix I 
The following search strategy was used for the MEDLINE literature search (period covered 
1966 through 1999). The MESH terms "Quality-of-life", "Quality-Adjusted-Life-Years", 
"Health Surveys'' and "Health Status Indicators" were each combined with all of the fol-
lowing ESRD specific NIESH terms: "Haemodialysis", "Peritoneal Dialysis", "Kidney 
Transplantation", ''Dialysis", "Kidney Failure", "Kidney Failure, Chronic" and "Renal 
Failure". All subheadings were included with each MESH term. The selection was a priori 
limited to publications in the English, French, German and Dutch languages and to adult 
populations. A similar search strategy was used for an additional search in ENIBASE (197 4 
through 1999) and PsyciNFO (1967 through 1999) databases, supplemented with the 
requirement that one of the six selected HRQOL instruments (either full name or abbre-
viated name) was found in either title, abstract or control (= MESH) terms. 
25 
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Appendix II: Systematic overview of all selected studies 
Study, year Design Aim a N patients I 
Treatment a 
HRQOL Main Outcomes 
instrument 
Research question I: What are the psychometric properties of health profiles and health preference methods as applied in renal 
patients? 
Churchill et al., 1984 
.)9 
Churchill et al., 1987 
40 
Churchi!l et al., 1991 
52 
Laupacis et al., 1991 
51 
Schrama et al., 1991 
58 
Hornberger et al., 
1992 42 
Kurtin et al., 1992 
45 
Revicki, 1992 38 
Prospective, 
observational 
Prospective, 
observational 
Prospective, 
observational 
Prospective, 
intervention 
(ret) 
Cross-sectional, 
observational 
Prospective, 
observational 
Prospective, 
observational 
Cross-sectional, 
observational 
TestingTTO 
instrument 
- Psychometric testing 
ofTIO instrument 
-To study the 
relationship between 
LCHD OLI ond TTO 
Testing responsiveness 
ofTIO 
-Testing reliability and 
responsiveness ofTTO 
-To study the 
relationship between 
SIPandTIO 
Testing feasibility of 
NHP 
Relationship between 
TIO, SG and SIP 
Testing feasibility and 
reliability of SF-36 
- Relationship between 
SG and SIP 
-Testing feasibility of 
SG 
n=73: 42 FCHD, 17 
CAPD, 14TX 
N-194: 28 HHD, 
42 FCHD, 79 TX, 
31 CAPD,I4 
n-47: 47 FCHD + 
LCHD (n.s.) 
n-118: 118 FCHD 
n=60: 60 LCHD 
n=SB: 58 FCHD 
ncJ7: 37 FCHD 
n"'73: 73 pre-
dialysis 
TTO 
TTO,QLI 
TTO 
TTO,SIP 
NHP 
TTO,SG, 
SIP 
SF-36 
SG,SIP 
SF-36 b 
Use of the TTO instrument was considered feasible in ESRD 
patients. Test-retest reliability was high (correlation 
coefficient 0.8). Construct validity ofTTO was supported by 
test-results (rank correlation between different raters _ __Qj__ll. 
- Evidence for discriminant validity was found. Test-retest 
reliability was high (Intra-Class-Correlation coefficient 0.81 ). 
- QLI and TTO were moderately correlated: the correlation 
coefficient was 0.43. 
TTO not responsive to changes in adequacy of dialysis. 
- TTO not responsive to changes in hemoglobin caused by 
use of erythropoietin. Test-retest reliability was good: Intra-
Class-Correlation coefficient > 0.80. 
-SIP andTTO were weakly correlated: Pearson's correlation 
coefficients between -0.15 and -0.23. 
Administration feasible. Ceiling effects were found: more than 
40 % of patients had hi£hest possible scores in NHP scales. 
Moderate correlation between SG and SIP (Spearman rank-
correlation coefficient 0.31 ). Weak correlation between TTO 
and SIP (correlation coefficient 0.18). SG and TTO were 
moderately correlated (0.31 ). 
Administration feasible. Floor- and ceiling-effects were found 
in two role functioning scales. Reliability estimates adequate 
for £roup comparisons (Cronbach's a from 0.62 to 0.90). 
- Correlations were weak to moderate: Pearson's 
correlations between SG and individual SIP scales between 
-0.07 and -0.30. Correlations between SG and individual SF-
36 scales between 0.09 and 0.12. 
- 19 % of patients were unable to complete the SG or 
provided inconsistent responses. 
N ~• 
(Appendix II continued) 
Study, year 
Badia et al., 1994 50 
Meyer et al., 1994 
46 
Design 
Prospective, 
observational 
Cross-sectional, 
observational 
Khan et al., 1995 'G Cross-sectional, 
observational 
Meers et al., 1995 Cross-sectional, 
33 observational 
Essink-Bot et al., 1996 Cross-sectional, 
44 observational 
Lenert, 1996 4T 
Molzahn et al., 1996 
48 
Molzahn et al., 1997 
72 
Ozminkowski, 1997 
49 
Wight et al., 1998 
47 
Prospective, 
observational 
Prospective, 
observational 
Prospective, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Aim a 
Testing test-retest 
reliability and internal 
consistency of NHP 
Testing feasibility .and 
reliability of SF-36 
N patients I 
Treatment a 
n=l70: 170 FCHO 
n= I I 2: I 12 dialysis 
(n.,.) 
HRQOL Main Outcomes 
instrument 
NHP Spearman-correlation coefficients > 0.6 for all NHP scales. 
NHP was considered sufficiently reliable. Overall NHP 
showed satisfactory internal consistency (Cronbach's o. 0.91 ), 
but not all sub-scales equally satisfactory. 
SF-36 Reliability (Cronbach's a) > 0.77 for all scales. SF-36 was 
considered sufficiently reliable. Administration to dialysis 
patients on a regular basis in a busy clinic was considered 
feasible. 
Testing feasibility and n= 185: I 02 TX, 43 SF-36 Administration of SF-36 was feasbile. Evidence for 
validity of SF-36 FCHD, 27 CAPD discriminant validitv of SF-36 was found. 
Inter-rater agreement n=30: 30 FCHD SF-36 Caregivers' (nurses and nephrolog'1sts) scores were lower 
on patients' HROOL than patients' scores. 
Psychometric testing of n=63: 63 FCHD SIP, NHP Weak correlations between NHP and SIP. NHP performed 
SIP and NHP better than SIP in terms of feasibility and internal 
Testing feasibility of SG 
andTTO with 
computer and 
interview based 
administration 
Psychometric testing of 
TTO 
Inter-rater agreement 
on patients' HRQOL 
Testing validity and 
reliability of SF-36 
Psychometric testing of 
SF-36 
N=25: 25 FCHO 
n=215: 52 FCHO, 
37 HHO, 30 CAPO, 
96TX 
n=215: 52 FCHO, 
37 HHO, 30 CAPO, 
96TX 
N=515:212TX, 
304 dialysis (n.s.) 
N=520: I 00 FCHO, 
42 HH0,41 
LCHO, 228 TX, 
109 CAPO 
SG,TTO 
TTO 
TTO 
SF-36 
SF-36 
consistency. 
Both interviews and computer based-administration were 
feasible. Computer-assisted administration derived higher 
scores. One patient did not understand the concept of 
probability with SG. 
Test-retest reliability was good (0.85). Evidence for 
discriminant validity was found. 
Significant differences in ratings among rater groups: nurses' 
ratings were lower than patients', physicians' ratings were 
higher than patients' ratings. Correlations among ratings 
ran_ged between 0.19 and 0.49. 
Evidence for discriminant and construct validity is presented. 
Internal consistency was good (Cronbach's u. > 0.85 for 
all scales). 
Self-administration is feasible. Internal consistency was 
satisfactory (Cronbach's o.: > 0.72 for all scales). Floor-
and ceiling effects were found for the role functioning scales. 
'v 00 
(Appendix II continued) 
Study, year Design Aim a N patients I 
Treatment a 
HRQOL Main Outcomes 
instrument 
Research question 2: How does HRQOL of ESRD patients compare with that of a healthier population, such as a general popula-
tion sample? 
~g:wvell et al., 1989 
Benedetti et al., 1994 
61 
Meyer et al., 1994 
46 
Beusterien et al., 1996 
11 
DeOreo, 1997 62 
Merkus et al., 1997 
29 
Niechzial et al., 1997 
(J5 
Shield eta!., 1997 67 
Matas et a!., 1998 63 
Mingardi et al., 1998 
60 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Prospective, 
intervention 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Prospective, 
intervention 
Cross-sectional, 
observational 
Comparison dialysis n=53: 53 FCHD SIP Dialysis patients showed more dysfunction than did age-
and _general population matched controls from the .l!eneral population. 
Comparison dialysis n= not mentioned SF-36 Authors claim that differences between transplanted patients 
and general population (all TX patients) > 60 years and the general population were not significant. 
Because the number of patients is not given in the paper, this 
mi_ght be caused by insufficient power of the study, 
Comparison dialysis n= 112: I 12 dialysis SF-36 Dialysis patients' HRQOL was worse than HRQOL of the 
and .l!eneral population (n.s.) 2:eneral population, in all ei_ght sub-scales of the SF-36. 
Comparison dialysis n=484: 411 FCHD, SF-36 ° Dialysis patients' HRQOL was worse than HRQOL of the 
and _general population 53 CAPO, 20 n.s. 2:eneral population. 
Comparison dialysis n= I 000: I 000 SF-36 Patients' physical functioning worse than general population 
and general population FCHD scores, except in the oldest age groups.ln mental functioning, 
less difference was observed. 
Comparison dialysis 
and general population 
Comparing dialysis and 
general population 
Comparing TX and 
general population 
Comparison ESRD 
patients and general 
population 
Comparison dialysis 
and general population 
n=226, 120 FCHD, 
106 CAPD 
n= I 027' I 027 
FCHD +CAPO 
n.s. 
n-303, 303 TX 
n=ll38: 1138TX 
n=240: 240 dialysis 
(n.s.) 
SF-36 
NHP 
SF-36 
SF-36 
SF-36 
Dialysis patients' HRQOL scores were lower than general 
population scores, with the exception of bodily pain in 
peritoneal dialysis oatients. 
Patients showed worse HRQOL than the general population 
in all NHP sub-scales, except pain. 
At hospital discharge after transplantation, patients' scores 
were lower than general population norms. One year later, 
patients were similar to general population in three scales 
(bodily pain, vitality and mental health) and worse in the 
other five scales of SF-36. 
Up to 65 % of transplanted patients showed HRQOL scores 
that were below the 95 % confidence inte1·val of general 
population norms, especially in the physical HRQOL 
domains. 
Dialysis patients showed worse HRQOL than the general 
population, except in the mental health field. Differences 
were less marked in older patients. 
N 
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Study, year 
Rebollo et al., 1998 
64 
Wight et al., 1998 
47 
Niechzial et al., 1999 
66 
Design 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Aim a N patients I 
Treatment a 
HRQOL Main Outcomes 
instrument 
Comparison ESRD n= 124: I 00 FCHD, SIP, SF-36 HRQOL of transplanted patients was similar to HRQOL of 
patients > 65 years and 24 TX the general population. Dialysis patients scored worse in the 
J!eneral population physical functionim: and general health domains. 
Comparison ESRD N=S20: I 00 FCHD, SF-36 HRQOL of all patients was worse than HRQOL of the 
patients and general 42 HHD, 41 general population. 
population LCHD, 228 TX, 
109 CAPO 
ComparingTX and 
general population 
n=I04: 104TX NHP Three months after transplantation, transplanted patients 
were similar to general population in five out of six NHP 
scales and showed fewer problems than the general 
population in the sleep dimension. 
Research question 3: Which medical, socio-demographic and disease-related factors determine HRQOL of E.SRD patients? 
Hart et al., 1987 "15 Cross-sectional, Identify determinants n=859: 347 FCHD, SIP Strongest independent associations with SIP scores had: 
Julius et al., 1989 j(j 
Auer et al., 1990 f7J 
Canadian EPO Study 
Group, 1990 13 
Deniston et al., 1990 
77 
Evans et al., 1990 78 
Harris et al., 1991 
54 
Auer et al., 1992 ?S 
observational of HRQOL 287 HHD, 81 diabetes mellitus, educational level, respiratory conditions, 
Cross-sectional, 
observational 
Prospective, 
intervention 
Prospective, 
intervention 
(ret) 
Cross-sectional, 
observational 
Prospective, 
intervention 
Prospective, 
intervention 
Prospective, 
intervention 
Identify determinants 
of HRQOL 
CAPO, J 44 TX neurological problems, cardiovascular problems, 
transplantation, musculoskeletal disorders, gastrointestinal 
problems. 
n=459: 171 FCHO, SIP 
125 CAPO, 16JTX 
Strongest independent associations with SIP scores had: age, 
diabetes mellitus, number of co-morbidities, black race, 
CAPO (as opposed to transplantation). 
Comparing HRQOL n=24: 24 FCHD NHP HRQOL improvements after start of EPO use in energy, 
pre-post start EPO use physical mobility and emotional wellbein.e sub-scales of NHP. 
Study influence of EPO n=ll8: 118 FCHD TTO,SIP Patients using EPO improved in the global and physical scales 
on HRQOL of SIP, but no changes in HRQOL as measured with TTO 
could be demonstrated. 
Compare patients with n=l87: 187 FCHD SIP Patients using EPO had better HRQOL as measured with 
and without EPO .2:lobal SIP and psychosocial SIP scales. 
Comparing HRQOL n=333: 333 FCHD NHP HRQOL improvements after start of EPO use in energy, 
pre-post start EPO use emotional reactions and social functionin.e sub-scales of NHP. 
Comparing HRQOL n=28: 28 FCHD TTO TTO scores improved after the introduction of EPO. 
pre-post start EPO use 
Comparing HRQOL n=22: 22 CAPO 
pre-post start EPO use 
NHP HRQOL improvements after start of EPO use in energy and 
emotional reactions sub-scales of NHP. 
v' (Appendix II continued) 0 
Study, year Design Aim a N patients I HRQOL Main Outcomes 
Treatment a instrument 
Harris et al., 1993 Cross-sectional, Identify determinants n-360: 360 pre- SIP Strongest independent associations with SIP scores were 
34 observational of HRQOL dialysis found for stroke, coronary artery disease, serum albumin 
level educational level income. 
Muirhead eta!., 1994 Prospective, Comparing HRQOL n=40: 40TX TTO,SIP HRQOL improvements after start of EPO use in global, 
53 intervention pre-post start EPO use physical and psychosocial domains of SIP, but no 
iml'!rovement ofTTO score. 
Hilbrands et al., 1995 Prospective, Compare two n=l20: 120TX SIP Patients who were treated with cydosporine showed better 
87 intervention immunosuppressive psychosocial functioning than patients treated with a 
"' 
thera ies combination of azathio rine and rednison. 
Revicki et al., 1995 Prospective, Study influence of EPO n-83: 83 pre- SIP Patients using EPO improved in the physical function and 
74 intervention on HRQOL dialysis patients SF-36 'b vitality sub-scales of SF-36. No changes were shown in three 
{ret} SIP sub-scales that were used. 
Beusterien et al., 1996 Prospective, - Identify determinants - n-484: 411 SF-36 b - Positive changes in HRQOL were associated with 
II intervention of HRQOL FCHO, 53 CAPO, erythropoietin use and changes in hematocrit level. 
20 n.s. 
-Comparing HRQOL - n= I 004' 884 - New EPO users reported improvements in physical 
of new-to-EPO and FCHO, 89 CAPO, functioning, vitality, social functioning, mental health and the 
old-to- EPO users 31 n.s. Mental Component Summary Score. No improvements were 
shown in old-to-EPO grou~. 
Moreno et aL, 1996 Cross-sectional, Identify determinants n=l013:891 SIP Strongest independent associations with SIP scores were 
10 observational of HRQOL FCHO, 7 HHO, 40 found for age, co-morbidity, diabetes mellitus, female sex, 
CAPO, 70 educational level, socio-economic level, hemoglobin and 
haemodiafiltration hematocrit. 
Moreno et al, 1996 Prospective, Compare patients with n~86, 86 FCHO SIP Patients using EPO improved in global, physical and 
79 intervention and without EPO use psychosocial domains of SIP. Patients with lower HRQOL at 
baseline experienced a more substantial improvement than 
12atients with higher baseline HRQOL scores. 
Morton et aL, I 996 Cross-sectional, Is adequate dialysis n= I IS: 55 FCHD, SF-36 Adequate dialysis was not a predictor of any of the HRQOL 
32 observational associated with 27 CAPO, 33 APO outcomes. 
HRQOL? 
Morton et a!., I 996 Cross-sectional, Identify determinants n=60, 44 CAPO, 16 SF-20 Strongest independent associations with HRQOL outcomes 
73 observational of HRQOL APO were found for time on dialysis, diabetes mellitus, peripheral 
vascular disease, heart disease, creatine-, protein-, calcium-, 
phosphate- and glucose levels. 
;:; 
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Study, year 
Molzahn et al., 1997 
72 
Merkus et al., 1997 
29 
Mazes et al., 1997 
7[ 
Niechzial et al., 1997 
65 
Ozminkowski, 1997 
49 
Shield et al., 1997 "61 
Hathaway et al., 1998 
69 
Johnson et al., 1998 
88 
Sloan et al., 1998 ()8" 
Wight et al., 1998 
47 
Design 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Prospective, 
observational 
Prospective, 
observational 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Aim a N patients I 
Treatment a 
Identify determinants o-215, 52 FCHO, 
of HRQOL 37 HHO, 30 CAPO, 
96TX 
Identify determinants n-226: 120 FCHD, 
of HRQOL 106 CAPO 
Identify determinants n-680: 525 FCHD, 
of HRQOL ISS CAPO 
Identify determinants n= I 027: I 027 all 
of HRQOL dialysis (n.s.) 
Identify determinants N-SIS,212TX, 
of HRQOL 304 dialysis (n.s.) 
Compare two o-303, JOJTX 
HRQOL 
instrument 
TTO 
SF-36 
Qll 
NHP 
SF-36 
SF-36 
Main Outcomes 
The TTO score was associated with transplantation, the 
number of hospitalizations, marital status and outlook (future 
expectations). 
Strongest independent associations with SF-36 outcomes 
were found for number of co-morbid conditions, residual 
renal function, hemoglobin level, age, employment, protein 
intake, CAPO, renal vascular disease. 
The following attributes were found to be independently 
associated with HRQOL: age, education, employment, 
diabetes, stroke. Furthermore, differences in adiusted 
HRQOL scores bet:WEl:El:_n dialysis centres were found. 
Strongest independent associations with NHP outcomes 
were found for time on dialysis, age, educational level, 
primary renal disease, Previous transplant. 
Strongest independent associations with SF-36 outcomes 
were found for age, risk group (type of co-morbid 
conditions), household income, race. 
Patients treated with tacrolimus had similar SF-36 outcomes 
immunosuppressive as patients treated with cyclosporine. 
therapies 
Identify determinants n=91: 91 TX SIP Strongest predictors of post-transplant HRQOL were 
of post-transplant employment, the number of hospital admissions in first six 
HROOL months, a.ee, social support and education. 
Are race and gender n=90: 90 TX SIP Although baseline HRQOL was not different between 
associated with post- Caucasian-Americans and African-Americans, African-
transplant HRQOL? Americans showed less positive changes in HRQOL after 
renal transplantation than Caucasian-Americans. 
Identify determinants oo9S, 95 FCHO 
of HRQOL 
Identify determinants N-520' 100 FCHO, 
of HRQOL 42 HHD,41 
LCHO, 228 TX, 
109 CAPO 
SF-36 
SF-36 
Strongest independent associations with SF-36 outcomes 
were found for serum albumin concentration, age and 
presence of diabetes mellitus. 
Strongest independent associations with SF-36 outcomes 
were described for age, presence of comorbidity, presence of 
social and emotional support and female sex. 
w 
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Study, year 
Merkus et al., 1999 
70 
Design 
Cross-sectional, 
observational 
Aim a 
Identify determinants 
ofHRQOL 
N patients I 
Treatment a 
n=226: 120 FCHD, 
106 CAPD 
HRQOL Main Outcomes 
instrument 
SF-36 Strongest independent associations with SF-36 outcomes 
were found for physical symptom burden, medium and high 
comorbidity-age index, lower residual renal function, lower 
hemoglobin and lower protein intake. 
Research question 4: Do HRQOL outcomes differ between patients treated with different therapeutic modalities? 
Churchill et al., 1987 Cross-sectional, Comparing treatment N= 194:28 HHD, TTO Transplantation patients showed better HRQOL than all 
40 observational modalities 42 FCHD, 79 TX, dialysis patients. No differences in HRQOL between dialysis 
Hart et al., 1987 35 
Julius et al., 1989 j() 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Churchill et al., 1992 Prospective, 
80 intervention 
_--.i!:f!l 
Russell et al., 1992 Prospective, 
57 intervention 
Laupads et al., I 993 Prospective, 
55 intervention 
Khan et al., I 995 43 Cross-sectional, 
observational 
Laupads et al., I 996 Prospective, 
56 intervention 
Meers et al., 1996 Prospective, 
31 observational 
Moreno et al., I 996 Cross-sectional, 
10 observational 
Comparing treatment 
modalities 
Comparing treatment 
modalities 
Comparing high-flux 
and conventional 
FCHD 
3 I CAPD, 14 modalities. 
LCHD 
n=859: 347 FCHD, 
287 HHD,BI 
CAPD, 144TX 
SIP Transplantation patients showed better HRQOL than all 
dialysis patients. No differences in HRQOL between dialysis 
modalities. 
n=459: 171 FCHD, SIP CAPD patients showed worse physical functioning than 
125 CAPD, TX 163 transplanted patients. 
n=22: 22 FCHD TTO, SIP HRQOL of patients on both treatments was similar. 
Comparing HRQOL n=27: 9 HHD, 10 TTO HRQOL improved after transplantation. 
ore- and oost TX FCHD. 8 CAPO 
Comparing HRQOL n=73: 73 FCHD TTO, SIP b HRQOL improved after transplantation, as measured with 
TTO and SIP. pre- and post TX 
Comparing treatment 
modalities 
Comparing HRQOL 
pre- and post TX 
Comparing treatment 
modalities 
Comparing treatment 
modalities 
n= 172: I 02 TX, 43 SF-36 Transplanted patients showed better HRQOL than all dialysis 
FCHD. 27 CAPD patients. 
n= 167: 167 FCHD TTO, SIP HRQOL improved after transplantation, as measured with 
TTO and SIP. 
n=34: 17 FCHD, 17 SF-36 
LCHD 
n=IOI3:891 SIP 
FCHD, I 0 HHD, 
41 CAPD,71 
haemodiafiltration 
Self-care haemodialysis patients showed better HRQOL in 
SF- 36 domains of social functioning, mental health, role 
functioninl! emotional and vitalitY. 
No differences were found in HRQOL between dialysis 
modalities. 
~ 
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Study, year 
Morton et al., 1996 
73 
Klang et al., 1997 "]"J 
Merkus et al., 1997 
29 
Molzahn et al., 1997 
72 
Niechzial et al., 1997 
65 
jofre et al., 1998 '81 
Wight et al., 1998 
47 
Merkus et al., 1999 
82 
Niechzial et al., 1999 
6(j 
Design 
Cross-sectional, 
observational 
Prospective, 
intervention 
Cross-sectional, 
observational 
Cross-sectional, 
observational 
Cro~s-sectional, 
ob~ervational 
Prospective, 
intervention 
Cross-sectional, 
observational 
Prospective, 
observational 
Prospective, 
intervention 
Aim a N patients I 
Treatment a 
HRQOL Main Outcomes 
instrument 
Comparing treatment n::::60: 44 CAPO, 16 SF-20 HRQOL of patients treated with APD and CAPO was found 
modalities APD to be similar. 
Comparing HRQOL n""28: 28 pre- SIP After start with dialysis, overall SIP scores and scores in the 
Rre-post start dialysis dialysis pati~ots physical and R~Y!;_hosocial domains did not change. 
Comparing treatment n""226: 120 FCHD, SF-36 FCHD patients showed !ower levels of mental health, in 
modalities I 06 CAPO comparison with CAPO patients. 
Comparing treatment n::::215: 52 FCHD, TTO HRQOL of transplanted patients was better than HRQOL of 
modalities 37 HHD, 30 CAPO, all dialysis patients. 
96TX 
Comparing treatment 
modalities 
n= I 027' I 027 
FCHD +CAPO 
(n.s.) 
NHP 
Comparing HRQOL n::::93: 93 dialysis SIP 
pre- and post TX (n.s.) 
Comparison treatment N::::520: I 00 FCHD, SF-36 
modalities 42 HHO, 41 
LCHD, 228 TX, 
109 CAPD 
Comparing HRQOL N:::: 139: 84 FCHD, SF-36 
over time in dialysis 55 CAPO 
patients 
HRQOL of patient~ treated with FCHD and CAPO wa~ 
found to be similar. 
HRQOL improved after transplantation. 
HRQOL of transplanted patients was better than HRQOL of 
at! dialysis patients. No HRQOL differences were described 
within the dialysis modalities, except a mental health 
disadvantage for FCHD patients. 
After adjustment for initial HRQOL and comorbidity, a 
consistently favorable effect of haemodialysis on physical 
HRQOL over time was found compared with peritoneal 
dialysis, whereas mental HROOL values remained similar. 
Comparing HRQOL n= 138: 138 FCHD NHP HRQOL improved in the energy, emotional reactions and 
pre- and post TX + CAPO (n.s.) sleep domains. 
a abbreviations: EPO ::::: crythropoielin, FCHD::::: full care centre haernoclialysis, J ,CHD :::::limited care centre haemodialysis, HHD ::::: home haemodialysis, 
CAPD ::::: continuous ambulatory peritoneal dialysis, APD ::::: :wtomntecl pcritonealcli'llysis, TX ::::: renal transplantation, n.s. :::::non-specified 
b only selected stJb-scales of the instruments \vere used 
The use of health profiles and health preference methods in end stage renal disease patients 
Appendix 3: Reference tables with reported values of six 
selected HRQOL instruments 
Table 3A: Reported values of Time Trade Off (TTO) instrument ', 
by treatment modality 
First author/year FCHD b HHD b LCHD b CAPO b TX b Non-specified 
dialysis 
Churchill, I 984 ' 0.57 0.57 0.80 
Churchill, 1987 40 0.43 0.49 0.49 0.56 0.84 
Canadian EPO Study, 1990 13 & 
Laupacis, 1991 51 0.42 - 0.58 
Churchill, 1991 52 0.44- 0.50 0.44- 0.50 
Harris, 1991 54 0.49 - 0.72 
Russell, 1992 57 0.74 0.41 
Hornberger, 1992 42 0.72 - 0.81 
Churchill, 1992 80 0.58 - 0.64 
Laupacls, 1993 55 0.79 0.58 
Muirhead, 1994 53 0.60 - 0.61 
Laupacis, I 996 SG 0.57 0.68 - 0.75 
Lenert, 1996 41 0.71 - 0.84 
Molzahn, 1996 48 & 
Molzahn, 1997 72 0.39 0.61 0.53 0.76 
a Yalues relative to 0 (death) and 1 (full health) 
b abbreviations of treatment modalities: FCHD = full care centre haemodialysis, LCHD = limited care 
centre haemodialysis, HHD = home haemodialysis, CAPD = continuous ambulatory peritoneal dialysis, 
APD = automated peritoneal dialysis, TX ::: renal transplantation, n.s. ::: non-specified 
Table 3B: Reported values of Standard Gamble (SG) instrument ', by treatment modality 
First author/year 
Hornberger, 1992 42 
Revicki, 1992 38 
Lenert, 1996 41 
FCHO b 
0.62- 0.72 
0.66- 0.72 
a values relative to 0 (death) and 1 (full health) 
b abbreviations of treatment modalities: see table 3A 
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Table 3C: Reported scores on Sickness Impact Profile (SIP), by treatment modality 
First author/year FCHD a HHD a LCHD a CAPD a Non~speci~ TX' Pre~ 
fied dialysis dialysis 
Global SIP score 
Hart, 1987 I 3.9 9.5 13.7 5.5 
Bj6rve!l, 1989 59 13.0 
Canadian EPO Study, 1990 13 & 
Laupacis, 1991 51 4.4-12.2 
Deniston, 1990 Ti 13.0- 18.0 
Churchill, 1992 80 18.3- 20.3 
Harris, 1993 34 24.5 
Muirhead, 1994 53 8.8-12.9 
Hilbrands, 1995 87 3.5-9.1 
Moreno, 1996 lO 15.0 
Moreno, 1996 79 13.5-19.8 
Essink, 1996 44 12.2 
Laupacis, 1996 56 13.1 5.3 
Klang, I 997 30 6.0 4.0 
Rebollo, 1998 64 20.0 9.3 
Hathaway, 1998 69 17.4 5.4- 6.3 
Jofre, 1998 81 9.7 5.9 
Johnson, 1998 88 16.4-19.1 3.6-9.0 
Physical SIP score 
Hart, 1987 5 I 0.3 6.1 11.7 3.3 
Bj6rvell, 1989 59 12.0 
Canadian EPO Study, I 990 13 & 
Laupacis, 1991 51 2.4- 6.4 
Deniston, 1990 77 11.0- 13.0 
Churchill, 1992 80 11.9-10.4 
Harris, 1993 34 21.3 
Laupacis, 1993 55 6.4 2.6 
Muirhead, I 994 53 6.4- 8.4 
Hilbrands, 1995 87 0.8- 5.7 
Moreno, 1996 10 12.0 
Moreno, I 996 79 15.4-19.6 
Essink, 1996 44 9.8 
Laupacis, 1996 56 6.4 3.3 
Klang, 1997 30 3.6 3.1 
Rebello, 1998 64 15.5 4.6 
Hathaway, 1998 69 11.0 2.5- 3.2 
Jofre, 1998 81 5.5 3.6 
Johnson, 1998 88 10.4- 12.0 1.7-6.3 
Psychosocial SIP score 
Hart, 1987 5 9.7 6.4 8.2 4.1 
Bj6rvell, 1989 59 9.5 
Canadian EPO Study, 1990 13 & 
Laupacis, 1991 Sl 3.0- 11.8 
Deniston, 1990 77 10.0- 16.0 
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(Table 3C continued) 
First author/year FCHD a HHD a LCHD a 
Psychosocial SIP score 
Churchill, 1992 80 15.8-18.8 
Harris, 1993 34 
Laupacis, 1993 55 
Muirhead, 1994 53 
Hilbrands, 1995 87 
Moreno, 1996 10 
Moreno, 1996 79 10.8- 19.0 
Essink, 1996 44 8.6 
Laupacis, 1996 56 12.4 
Klang, I 997 30 4.3 
Rebello, 1998 64 20.1 
Hathaway, 1998 69 
Jofre, 1998 81 10.1 
Johnson, 1998 88 
a abbreviations of treatment modalities: see table 3A 
b lower scores indicate a better quality of life 
CAPO a Non-speci- TX' Pre-
fied dialysis dialysis 
21.4 
12.0 4.3 
6.7- 11.0 
1.3-4.5 
14.0 
4.7 
2.3 
7.6 
17.2 5.4- 6.3 
5.6 
16.1- 18.8 3.8- 10.2 
Table 3D: Reported scores on Short-Form 36 (SF-36), by treatment modality 
First author/year FCHD a HHDa LCHD a CAPO a Non-speci- TX' Pre-
fied dialysis dialysis 
Physical Component Summary score (PCS) 
Beusterien, 1996 11 35-37 
De Oreo, I 997 62 35 
Merkus, 1999 82 41-43 38-41 
Mental Component Summary score (MCS) 
Beusterien, 1996 11 43-47 
De Oreo, 1997 62 48 
Merkus, 1999 82 44-45 43-46 
Physical functioning sub-scale (PF) 
Kurtin, 1992 45 48-60 
Revicki, 1992 38 45-54 
Benedetti, 1994 61 61 
Meyer, 1994 46 49 
Khan, 1995 43 46 39 68 
Meers, 1995 33 49 
Revicki, 1995 37 44-52 
Beusterien, 1996 11 44-48 
Meers, 1996 3l 37 61 
Morton, 1996 32 43 46 c 
De Oreo, 1997 62 44 
Merkus, 1997 29 51 61 
Shield, 1997 67 57-69 
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(Table 3D continued) 
First author/year FCHD a HHD a LCHD a CAPO a Non-sped- TX' Pre-
fied dialysis dialysis 
Physical functioning sub-scale (PF) 
Mingardi, 1998 60 52 
Matas, 1998 63 55-79 
Ozminkowski, 1998 49 53 70 
Rebol!o, 1998 64 48 75 
Sloan, 1998 68 43 
Wight, 1998 4 7 34 47 28 41 62 
Merkus, !999 70 82 53 -59 49-56 
Role limitations due to physical problems - sub-scale 
Kurtin, 1992 45 28-35 
Benedetti, 1994 61 58 
Meyer, 1994 46 33 
Khan, 1995 43 51 30 63 
Meers, 1995 33 41 
Meers, 1996 31 37 63 
Morton, 1996 32 34 20 c 
De Oreo, 1997 62 40 
Merkus, 1997 29 29 32 
Shield, 1997 67 29-38 
Mingardi, 1998 60 38 
Matas, 1998 63 46-78 
Ozminkowski, 1998 49 39 60 
Rebello, I 998 64 64 81 
Sloan, !998 68 62 
Wight, 1998 47 24 41 17 20 54 
Merkus, 1999 70 82 38-39 28-34 
Bodily pain sub-scale 
Kurtin, 1992 5 50-63 
Benedetti, 1994 61 68 
Meyer, !994 46 60 
Khan, 1995 43 71 59 78 
Meers, 1995 33 70 
Beusterien, I 996 11 62-64 
Meers. 1996 31 66 68 
Morton, 1996 32 67 61 c 
De Oreo, 1997 62 60 
Merkus, 1997 29 64 74 
Shield, 1997 67 60-75 
Mingardi, 1998 60 60 
Matas, 1998 63 64-79 
Ozminkowski, 1998 49 59 76 
Rebello, 1998 64 67 79 
Sloan, 1998 68 55 
Wight, 1998 4 7 49 55 55 59 70 
Merkus. 1999 70 82 70-72 59-66 
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(Table 3D continued) 
First author/year FCHD a HHD a LCHD a CAPO a Non·speci· TX' Pre· 
fied dialysis dialysis 
General health sub·scale 
Kurtin, 1992 45 38-41 
Benedetti, 1994 61 64 
Meyer, 1994 46 44 
Khan, 1995 43 42 40 64 
Meers, J 995 33 49 
Beusterien, 1996 11 43-45 
Meers, 1996 31 45 55 
Morton, 1996 32 37 43 c 
De Oreo, 1997 62 so 
Merkus, 1997 29 43 46 
Shield, 1997 67 37-65 
Mingardi, I 998 60 36 
Matas, 1998 63 45-69 
Ozminkowski, 1998 49 44 58 
Rebollo, 1998 64 36 69 
Sloan, 1998 68 39 
Wight, I 998 4 7 32 38 32 35 54 
Merkus, 1999 70 82 44-46 39-48 
Vitality sub·scale 
Kun:in, 1992 45 35-43 
Revicki, 1992 38 38 
Benedetti, 1994 61 58 
Meyer, 1994 46 45 
Khan, 1995 43 41 38 63 
Meers, 1995 33 48 
Revicki, 1995 37 37-43 
Beusterien, 1996 11 39-49 
Meers, 1996 31 39 64 
Morton, 1996 32 39 39 c 
De Oreo, 1997 62 47 
Merkus, 1997 29 49 52 
Shield, 1997 67 38-62 
Mingardi, 1998 60 44 
Matas, 1998 63 49-62 
Ozminkowski, 1998 49 42 58 
Rebollo, 1998 64 so 67 
Sloan, 1998 68 41 
Wight, r 998 47 35 42 32 36 53 
Merkus, 1999 70 82 49-52 45-50 
Social functioning sub·scale 
Kurtin, 1992 45 55-56 
Benedetti, 1994 61 80 
Meyer, 1994 46 65 
Khan, 1995 43 54 so 80 
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(Table 3D continued) 
First author/year FCHD a HHD a LCHD a CAPO a Non-sped- TX' Pre-
fied dialysis dialysis 
Social functioning sub-scale 
Meers, 1995 33 74 
Beusterien, 1996 11 53-61 
Meers, 1996 31 63 81 
Morton, I 996 32 60 61 c 
De Oreo, 1997 62 66 
Merkus, I 997 29 63 69 
Shield, 1997 61 53-79 
Mingardi, 1998 60 63 
Matas, 1998 63 73-87 
Ozminkowski, 1998 49 66 82 
Rebello, I 998 64 80 93 
Sloan, 1998 68 63 
Wight, 1998 4? 42 63 49 50 75 
Merkus, 1999 ?0 82 68-72 61-69 
Role limitations caused by emotional problems- sub-scale 
Kurtin, 1992 45 35-54 
Benedetti, 1994 61 73 
Meyer, 1994 46 55 
Khan, 1995 43 75 67 80 
Meers, 1995 33 69 
Meers, I 996 31 47 90 
Morton, 1996 32 61 45 c 
De Oreo, 1997 62 58 
Merkus, 1997 29 53 64 
Shield, 1997 6? 48-79 
Mingardi, 1998 60 56 
M'"''· 1998 63 74-90 
Ozminkowski, 1998 49 72 79 
Reboil o, 1998 64 74 93 
Sloan, 1998 68 47 
Wight, 1998 47 31 65 30 56 69 
Merkus, 1999 70 82 57-57 57-62 
Mental health sub-scale 
Kurtin, 1992 45 62-70 
Benedetti, 1994 61 78 
Meyer, 1994 46 70 
Khan, 1995 43 66 73 79 
Meers, 1995 33 80 
Beusterien, 1996 11 66-70 
Meers, 1996 31 71 84 
Morton, 1996 32 70 70 c 
De 0 reo, I 997 62 70 
Merkus, 1997 29 63 72 
Shield, 1997 6/ 63-75 
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(Table 3D continued) 
First author/year FCHD a HHDa LCHD a CAPO a Non-speci- TX' Pre-
f1ed d·1alysis dialysis 
Mental health sub-scale 
Mingardi, 1998 6 69 
Matas, 1998 63 74-79 
Ozminkowski, 1998 49 72 77 
Rebello, 1998 64 76 84 
Sloan, 1998 68 65 
Wight, 1998 47 60 69 67 66 73 
Merkus, 1999 70 82 68-70 66-70 
a abbreviations of treatment modalities: see Table 3A 
b lower scores indicate a worse quality of life 
c includes APD patients' scores 
Table 3E: Reported scores on l':othingham Health Profile (.'IHP), by treatment modality 
First author/year FCHD a HHDa LCHD a CAPO a Non-speci- Txa Pre-
fied dialysis dialysis 
Energy dimension 
Auer, 1990 76 62-11 
Evans, 1990 78 50-23 
Schrama, 1991 58 24' 
Auer, 1992 75 76-24 
Badia, 1994 50 31-36 
Essink, 1996 44 33 
Niechzial, 1997 65 39 
Niechzial, 1999 66 12-18 
Pain dimension 
Auer, I 990 76 12-7 
Evans, J 990 78 15-16 
Schrama, 1991 58 0' 
Auer, !992 75 IS-II 
Badia, 1994 50 20-21 
Essink, 1996 44 13 
Niechzial, 1997 65 39 
Niechzial, 1999 66 8-13 
Emotional Reactions dimension 
Auer, 1990 76 22-9 
Evans, 1990 78 20-13 
Schrama, 1991 58 9' 
Auer, 1992 75 30-14 
Badia, I 994 50 27 
Essink, 1996 44 18 
Niechzial. 1997 65 18 
Niechzial, 1999 66 5-9 
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(Table 3E continued) 
First author/year FCHD a HHDa LCHD a CAPO a Non-sped- TX' 
fied dialysis 
Sleep dimension 
Auer, 1990 76 32-24 
Evans, I 990 78 34-28 
Schrama. 1991 58 23 ' 
Auer, 1992 75 42-29 
Badia, 1994 50 35-37 
Essink, 1996 44 39 
Niechzial, 1997 65 32 
Niechzial, 1999 66 9-12 
Social isolation dimension 
Auer, 1990 76 19-10 
Evans, ! 990 78 19-14 
Schrama, 1991 58 O' 
Auer, 1992 75 24-12 
Badia, I 994 50 14-15 
Essink, 1996 44 13 
Niechzial, I 997 65 10 
Niechzial, 1999 66 2-4 
Mobility dimension 
Auer, 1990 76 32-10 
Evans, 1990 78 21-19 
Schrama, 1991 58 II ' 
Auer, 1992 7 5 33-22 
Badia, I 994 50 26-27 
Essink, 1996 44 26 
Niechzial, 1997 65 18 
Niechzial, 1999 66 11-17 
a abbreviations of treatment modalities: see Table 3A 
b lower scores indicate a better quality of life 
c reported scores are median scores 
Table 3F: Reported scores on (Spitzer's) Quality of Life Index (QLI), by treatment 
modality 
First author/year 
Churchill, 1987 40 
Mozes, 1997 71 
FCHD a 
77 
58-67 
LCHD a 
75 75 
a abbreviations of treatment modalities: see Table 3A 
b lower scores indicate a worse quality of life 
CAPD a Non-speci- TX' 
fied dialysis 
79 86 
57-78 
Pre-
dialysis 
Pre-
dialysis 
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Abstract 
Background. Health-related quality of life (HRQOL) of haemodialysis (HD) and peritoneal 
dialysis (PD) patients has been assessed with health profiles and health preferences meth-
ods. Few studies have used both types of HRQOL instruments. The main objective of this 
study was to assess the relationship bet\~reen information from the two types of HRQOL 
instruments in dialysis patients. 
iVIethods. \"Xle intervie\ved 135 patients, using t\vo health profiles (Short Form 36 and 
EuroQol/EQ-SD) and two health preferences methods (Standard Gamble and Time Trade 
Off). Socio-demographic, clinical and treatment related background data \Vere collected 
from patient charts and during the interview. Relationships between the outcome measures 
were assessed with Pearson correlation coefficients. 1Iultiple regression models were used 
to study the relationship of HRQOL outcomes to background variables. 
&stdts. HRQOL of dialysis patients as measured with health profiles was severely impaired. 
The health preferences scores were higher (0.82 to 0.88) than scores previously reported in 
the literature. Correlations between health profiles and health preferences were poor to 
modest. HRQOL outcomes were poorly explained by background characteristics. 
Differences between HD and PD groups could not be demonstrated. 
Conclusiom. Health profiles and health preferences represent different aspects of HRQOL. 
An impaired health status may not be reflected in the preference scores. Coping strategies 
and other attitudes towards health may affect the preference scores more than they do influ-
ence health profile outcomes. The added value of health preferences methods in clinical 
research is limited. 
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Introduction 
J\ifany different questionnaires and interview techniques, either generic or disease~specific, 
have been used for the assessment of health-related quality of life (HRQOL) in end-stage 
renal disease (ESRD) patients.1-2 Generic HRQOL measures cover all important aspects of 
health and are intended to be applicable in a wide variety of conditions, patients and demo-
graphic groups. Therefore, they can be used to compare a patient group suffering from a 
certain disease with other patient groups and with general population samples. \\lithin the 
group of generic measures, a distinction can be made bet\veen health profiles and prefer-
ence or utility based measures) Health profiles describe the health status of a person on a 
number of domains, such as physical, psychological and social function. Preference based 
measures aim to express HRQOL in a single indicator, often a number between 0 and 1, 
where 0 represents death and 1 represents full health. 
The experience with preference measurements in dialysis patients is relatively limited. A 
1IedLine literature search identified 16 studies using preference measurements in dialysis 
and renal transplant patients.4-19 1Iost studies that applied preference measurements have 
assessed small patient groups and focused on renal transplantation and haemodialysis (HD). 
Peritoneal dialysis (PD) was only covered in two Canadian studies from the 1980s,4 7 and in 
one more recent publication that included 30 PD patients. 14 Only hvo studies reported on 
the relationship between health profiles and health preferences in ESRD patients. 10 18 Both 
studies found low to moderate correlations between the nvo types of instruments (correla-
tion coefficients between 0.15 and 0.31). The purpose of the present cross-sectional study 
was to compare health preference methods with health profiles in HD and PD patients. 
Two health preferences methods (Standard Gamble and Time Trade Off) and two health 
profiles (Short-Form 36 and EuroQol/EQ-5D) were used to study HRQOL. 
Subjects and methods 
Study design and patients 
A total number of 135 dialysis patients participated in this study. These patients participat-
ed in a prospective cohort study on the adequacy of dialysis, the i\:ECOSAD-1 study20 The 
135 patients interviewed were treated in 13 of the 49 dialysis centres in the Netherlands. 
The study was approved by the ethical committees of all participating centres. In the peri-
od October 1993 - March 1995, all new patients in these 13 centres \Vere asked to partici-
pate in NECOSAD. All patients who had not been withdrawn from NECOSAD by the 
time we started the present HRQOL study and who had received the same dialysis treat-
ment for at least three months were considered for inclusion. Further inclusion criteria were 
written informed consent, age above 18 years, adequate eyesight to enable the administra-
tion of questionnaires and an adequate understanding of the Dutch language. Interviews 
were conducted at patients' homes by one of three trial nurses, who received a training to 
administer the HRQOL questionnaires. For HD patients, interviews were carried out on 
non-dialysis days. 
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Background variables 
At the interview, data were collected on sex, age, marital and employment status and edu-
cational level. Data on primary diagnosis, dialysis adequacy, current treatment, treatment 
history, length of time on dialysis and presence of comorbid diseases at the start of dialy-
sis were obtained from the NECOSAD study and the patient's nephrologist. Primary diag-
nosis of renal failure was classified according to the EDTA-ERA classification. Adequacy 
of dialysis was expressed as weekly total Kt/Vurea in HD and PD patients. Hemodialysis 
Kt/Vurea was estimated using a second generation Daugirdas formula.21 The weekly 
Kt/V urea in PD patients was calculated as the peritoneal Kt/V urea per 24 hours multiplied 
by 7. 
Questionnaires used to assess health-related quality of life 
HRQOL was assessed '>'rith the Short Form 36 Health Survey, EuroQol/EQ-SD, Standard 
Gamble and Time Trade Of£ The four questionnaires were always administered in this 
sequence. The first t\vo questionnaires were self-completed. The interviewer then contin-
ued with the administration of the Standard Gamble and Time Trade Off. 
The Short-Form 36 Health Survry (SF-36) generates a profile of scores on 8 dimensions of 
quality of life22 These dimensions are (1) Physical Functioning, (2) Role Functioning -
Physical, (3) Bodily Pain, (4) General Health perception, (5) Vitality, (6) Social Functioning, 
(7) Role Functioning - Emotional, (8) Mental Health. Raw scores on the eight scales are 
transformed to calculate a score bet\veen zero and hundred, where a higher score indicates 
better health. The physical and mental components of the eight scales are combined into a 
Physical Component Summary (PCS) and a Mental Component Summary (MCS). The two 
summary measures are standardized to have a mean of 50 and a standard deviation of 10 
in the general population and therefore allow for easy comparison of patient scores with 
general population scores. SF-36 scores of persons of similar age (55-64 years) were derived 
from a validation study in the Dutch population.23 
The EQ-5D or EuroQol (EQ-5D) is a generic questionnaire, consisting of a classification 
system (EQ-5DprofiJJ and a visual analog scale (EQvAs).24 The EQ-5Dprofik covers 5 
domains of health (mobility, self-care, usual activities, pain/discomfort, anxiety/depres-
sion), each \Vith three levels of functioning: Oevel 1: no problems; level 2: some problems; 
level 3: severe problems). The EQvAs is a graduated, vertical line, anchored at 0 (worst imag-
inable health state) and 100 (best imaginable health state). The patient is asked to mark a 
point on the EQvA_s that best reflects his/her actual health state. 
The Standard Gamble (SG) is a method to measure preferences for health states2 5 The 
respondent is presented with tv.ro alternatives and asked to choose the one most preferred. 
The first alternative offers the certainty of staying in the current health state for the remain-
der of the respondent's life. The second alternative is a gamble with specified probabilities 
for both the positive outcome of the gamble (a normal health state for the remainder of 
time) and the negative outcome (immediate death). These probabilities are varied until the 
respondent is indifferent benveen the gamble and living in his/her current health state. The 
SG score, a score bet\veen zero and one, is calculated as one minus the risk percentage at 
the point of indifference, divided by hundred. An SG-score of 0.80 implies that a person 
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is prepared to take a gamble with 20 percent risk of dying immediately and 80 percent 
chance to improve his current health to normal health. The SG score reflects the value a 
person assigns to his own health state. In our study, the concept of the SG was practiced 
with a visual aid, using imaginary health states. Afterwards, the patient was asked to value 
his own current health state. 
The Time Trade Off method (TTO) is also a preference-based method4 7 Patients are asked 
whether they are prepared to give up some remaining time of their lives, in order to 
improve their current health state to normal health. The time perspective that is presented 
to the patient corresponds with statistical life expectancy of people of the same age and 
sex. The quotient of the chosen number of years in a normal health state over statistical 
life expectancy yields the TIO score. A TIO score of 0.80 implies that a person is indif-
ferent ben..veen living 8 years in excellent health versus 10 years in his current health state. 
\Xle practiced the ITO concept with imaginary health states, before the patient was asked 
to value his/her own current health state. 
Statistical analysis 
Differences ben..veen HD and PD treatment groups were tested by means of Student's t-
test or :&Iann-W1Utney U test, as appropriate. Categorical variables were compared using the 
Pearson Chi-square test. Iviann-\Xi'hitney C test was used for non-response analysis. In order 
to be able to control for case-mix differences, the association between background variables 
(see above) and main quality of life outcomes was studied with multiple regression models. 
A fonvard stepwise selection strategy was chosen, using the F -statistic with P=O.OS as the 
criterion level for selection. To search for violations of necessary assumptions in multiple 
regression, normal plots of the residuals of the regression models were produced. The rela-
tionship between health profiles and health preference measures was assessed with Pearson 
correlation coefficients. Analyses reported here are based on treatment at the time of the 
interview. A two-sided P-value of 0.05 was chosen as cut off for statistical significance. 
Results 
Patient characteristics 
In April1995, 193 patients still participated in the NECOSAD study. Eight patients (4 %) 
could not be interviewed because they were medically unstable or had language problems. 
A group of 24 patients (13 %) was withdrawn from follow-up in the NECOSAD study 
before an interview could be scheduled, either because of transplantation, death or trans-
fer to a non-participating dialysis centre. Finally, 26 patients (14 %) refused to participate in 
the present study. This resulted in 135 patients (70 %) who were interviewed. Table 1 lists 
the main demographic, clinical and treatment characteristics of the 135 patients inter-
viewed, according to treatment modality. Sixty-nine patients were treated with HD and 66 
with PD (59 CAPD and 7 APD). The HD and PD groups differed significantly with respect 
to age and educational level. On average, PD patients were 5 years younger and better edu-
cated than HD patients. No other demographic and clinical differences were found between 
the groups. 
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Table 1: Patient characteristics according to treatment modality (mean, SD, range or%) 
HD (n=69) PD (n=66) 
Age a 60 (IS) 21-87 55 ( 13) 25-79 
Male 52% 66% 
Married/living together 75% 86% 
Employed 19% 30% 
Educational level a 
-low 32% 20% 
- intermediate 64% 73% 
-high 4% 12% 
Primary kidney disease: 
- glomerulonephritis 10% 13% 
- renal vascular disease b 25% 23% 
- nephritis 16% II% 
-cystic kidney disease 10% II% 
- diabetes mellitus 7% IS% 
- others and unknown 32% 27% 
Number of comorbid conditions 1.75 ( 1.40) 0-6 1.80 ( 1.29) 0-7 
Type of comorbid condition: 
- cardio-vascular 62% 77% 
- diabetes mellitus 12% 18% 
-malignancy 9% 3% 
Weekly Kt/V urea (total) 3.7 (0.89) 2.0-5.8 2.0 (0.43) 1.3-2.9 
Therapy change in past 6 months 12% 8% 
Months on dialysis IS (3) 7-23 IS (4) 7-22 
Months on this modality 12 (5) 3-23 13 (5) 3-21 
a P<O.OS, HD versus PD 
b including hypertensive nephrosclerosis 
Table 2: Mean (SD and range) scores on health-status and health-preference question-
naires 
Outcome parameter 
Health profiles 
SF-36 PCS a b 
5F-36 MC5" 
Visual Analog Scale 
EQy ·\S (scale 0-100) 
Health preferences 
SG (scale 0-1) 
TTO (scale 0-1) 
HD (n=69) 
37.6 (10.6) 15-58 
47.9 (12.3) 14-66 
60.3 ( 17.7) S-1 00 
0.86 (0.19) 0.2-1.0 
0.89 (0.17) 0.15-1.0 
a standardised to general population mean (mean 50, SD 10) 
b P<0.001, compared to a similar age-group from the general population 23 
PD (n=66) 
38.3 (I 0.7) 16-56 
48.4 (I 1.0) 23-65 
62.4 (20.3) I 0-95 
0.82 (0.23) 0.0-1.0 
0.87 (0.21) 0.0-1.0 
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Results of SF-36 
The upper part of Table 2 contains the two SF-36 summary scores for physical (PCS) and 
mental (:'>!CS) HRQOL. HD and PD patient groups did not differ with regard to PCS and 
11CS scores. The mean PCS score of this sample of dialysis patients was 1.2 standard devi-
ations (P<0.001) below the mean score for a general population sample of the same age. 
The mean ~fCS score of both groups of dialysis patients was not different from the refer-
ence group. 
Results of EQ-SD 
As shown in Table 2, self-rated health status on the EQvAS was similar for both patient 
groups, with scores of 60 and 62 on a scale from 0 to 100. Table 3 shows the proportion 
of HD and PD patients that indicated to have some or severe problems on the 5 dimen-
sions of the EQ-SDprofile· None of the differences between HD and PD patients were sig-
nificant. Patients turned-out to have problems on all 5 dimensions. J\Iost problems were 
present with 'daily activities': 61 percent of the patients could not perform their daily activ-
ities normally. Approximately half of the patients reported some or severe difficulties with 
'mobility' and 'pain'. Fourteen percent of the patients had difficulties "\Vith self-care, such as 
bathing and dressing independently. In this patient sample, 24 percent of responders felt 
anxious and/ or depressed. 
Table 3: Proportion of HD and PD patients showing none Oevel 1), some Oevel2) or 
severe Oevel 3) problems on EQ-5Dpwf>k 
EQ-SD dimension a HD PD 
level I level 2 level 3 level I leve12 level 3 
mobility 46.4 53.6 0.0 57.6 39.4 3.0 
self-care 82.6 14.5 2.9 89.4 9.1 1.5 
daily activities 40.6 39.1 20.3 37.9 50.0 12.1 
anxiety/depression 78.3 20.3 1.4 74.2 22.7 3.0 
ain 59.4 36.2 4.3 53.0 42.4 4.5 
a differences berureen modalities not significant (P>O.OS) 
Results of Standard Gamble and Time Trade Off 
Answers to SG could not be obtained in 5 patients (3.7 %) and answers to ITO could not 
be obtained in 14 (10.4 °/o) patients. This non-response was caused by patient refusal to 
answer and/ or cognitive problems in understanding the SG and TTO concepts. The rea-
sons for refusal were diffuse and included religious reasons, familial circumstances and 
patient fatigue. Responders and non-responders to SG and/ or TTO were compared with 
respect to age, number of comorbid conditions, time on dialysis and HRQOL as measured 
with health profiles. Results of the non-response analysis are shown in Table 4. Compared 
to responders, non-responders were older and had a worse self-rated health as assessed with 
the EQvAs. The lower part of Table 2 shows the mean SG and ITO scores of both patient 
groups. HD and PD patients groups valued their health status equally high (P>O.OS), with 
scores between 0.82 and 0.89. 
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Table 4: Analysis of non-response to Standard Gamble (n=5) and/ or Time Trade Off 
(n=14) 
Feature Non-responders Responders 
mean (SD) mean (SD) 
Age' 67 (II) 56 (14) 
No. of comorbid conditions 1.9 ( 1.6) 1.8(1.3) 
Time on dialysis (months) 14 (2.4) IS (3.9) 
SF-36 PCS score b 34 (12) 38 (10) 
SF-36 MCS score b 44 (16) 49 (II) 
EQVAS score a 48 (16) 63 (19) 
a P<O.Ol, responders versus non-responders 
b standardised to the general population mean (mean 50, SD 10) 
Association between background variables and health-related quality of life 
outcomes 
The results of the multiple regression analyses to explain the independent associations 
between demographic, clinical and treatment variables on the one hand and outcome vari-
ables on the other hand are shown in Table 5. The number of comorbid conditions was 
negatively associated with all HRQOL outcomes, except 1TCS. Age was negatively associ-
ated with PCS and with the EQvAS score. Employed patients had better PCS and EQvAS 
scores. The number of months on dialysis was negatively associated -with fvfCS and EQv,'\S 
scores. Treatment modality was not associated with any of the HRQOL outcomes. The 
models constructed sho\ved that HRQOL \vas poorly explained by the background vari-
ables under study (total Adjusted R2 from 1.9% to 18.2 %). 
Table 5: J\Tultiple regression analysis to study the association between demographic, clini-
cal and treatment related variables and outcome variables, expressed as standard-
ised regression coefficient p, partial R 2 and total R 2 b 
SF-36 PCS SF-36 MCS EQ: SG TTO 
Age -0.14 (2.0 %) -0.19 (2.6 %) 
Employment status 0.18 (3.3 %) 0.16 (7.0 %) 
No. of comorbid conditions -0.28 (8.9 %) -0.20 (3.7 %) -0.19 (3.0 %) -0.14 (1.9 %) 
No. of months on dial:z:sis -0.17 (3.3 %) -0.24 (4.9 %) 
Total R2 IS.!% 3.3% 18.2% 3.0% 1.9% 
a N"o violations of necessary assumptions in multiple regression analyses were detected. 
b Associations shown in the table were the only significant associations found. The number in each cell 
refers to the standardised regression coefficient !3, indicating the relative importance of the independent 
variable: the higher the !3 coefficient the higher the contribution of the independent variable in the 
regression equation. The bracketed number in each cell symbolises R2 , the explained variance of the 
dependent variable accounted for by the single independent variable. Total R2 is the percentage of varia-
tion of the dependent variable score that is accounted for by the independent variables together. 
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Relationships between health prof:tles and health preferences 
The correlations between health proftles outcomes and health preference measurements are 
shown in Table 6. Correlations between the tvm types of questionnaires were poor to mod-
est (r= 0.03 to 0.31). W'ith regard to the ITO, the highest correlations were found with SF-
36 scales Social Functioning (r =0.29), Bodily Pain (r =0.23) and Vitality (r =0.21). The SF~ 
36 domains that correlated best with the SG scote were Vitality (r =0.31), Mental Health (r 
=0.29) and Social Functioning (r =0.24). 
Table 6: Correlations (Pearson's r) between descriptive instruments and preference meas-
urements 
Time Trade Off Standard Gamble 
Short-Form 36 a PF 0.18 0.16 
RP 0.15 0.23 c 
BP 0.23 b 0.23 c 
GH 0.14 0.16 
VT 0.21 b 0.31 c 
SF 0.29 c 0.24 c 
RE 0.11 O.Q7 
MH 0.15 0.29 c 
PCS 0.21 b 0.21 b 
MCS 0.19 b 0.23 c 
Mobility - 0.15 - 0.18 b 
Selfcare 0.03 - 0.07 
Daily activities - 0.19 b - 0.20 b 
Pain - 0.16 - 0.13 
Anxiety/depression -0.18 b - 0.20 b 
a abbreviations: PF:::: Physical Functioning, RP:::: Role Functioning Physical, BP:::: Bodily Pain, GH :::: 
General Health Perceptions, 1/T :::: Vitality, SF :::: Social Functioning, RE :::: Role Functioning Emotional, 
MH :::: :i\fental Health, PCS :::: Physical Componem Score, !vfCS :::: Memal Component Score 
b P<0.05 
c P<0.01 
Discussion 
The present cross-sectional study using four different HRQOL measures showed a similar 
impairment of quality of life in HD and PD patients. Compared to a general population 
sample of similar age, impairments were most obvious in the physical components of 
health proftles, but much less for the mental components. The preference based measures 
yielded relatively high scores for dialysis patients. !dult:iple regression analysis showed that 
background variables, such as the presence of comorbid diseases, explained 15 % of phys-
ical HRQOL and 18 % of the Visual Analog Scale. Correlations between the different 
HRQOL tests were poor to modest. These findings will be discussed in the following sec-
tions. 
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The severely reduced physical HRQOL of dialysis patients in comparison with the general 
population has been reported in many other studies. [reviewed in 26] The equivalence of 
HRQOL in HD and PD patients found in the present study is in accordance with the 
results of other recently published investigations,27-28 but could also be related to inade-
quate power to detect differences between groups. Given the number of patients included 
in our study, the power was adequate (13 > 80 %) to detect differences of 5.3 (PCS) to 5.7 
(MCS) units in the scale scores between PD and HD patient groups. Our study adds to the 
existing nephrologic HRQOL literature because we have not only applied health status 
measures but also health preference measurements. Preference based instruments have 
been used less often than health status measures and only three studies have reported on 
health preferences of PD patients.4 7 14 The present study has shown that health prefer-
ences of HD and PD patients were similar. A remarkable finding of the present study were 
the high scores (0.82 to 0.89) obtained using the preference measurements. These values 
indicate that patients on average valued their current health state as 82 to 89 % of normal 
health. The average TTO value found in the present study (0.88), was similar to the value 
found after renal transplantation (0.87) in a study from the 1980s4 Typical values of preva-
lent dialysis patients are in the 0.40 - 0. 70 range, with t\V"o exceptions of patients reporting 
values above 0.80.10 19 Highest scores were found in patients with a renal transplant,4 16 in 
patients using erythropoietin,9 and in more recently published studies.6 10 1219 
\'\'hy do our scores differ from scores previously found? We excluded patients with lan-
guage or vision problems from our study, but, due to the nature of preference measure-
ment, such positive patient selection must also have been present in other series. Besides, 
the SF-36 outcomes in our patients are similar to other published SF-36 scores of dialysis 
patients,29-30 making it less likely that our higher preference scores are caused by selection 
bias. Our patients were recruited from a clinical study on adequacy of dialysis. 
Consequently, patients were monitored intensively by highly motivated staff members. This 
may have had a positive influence on perceived HRQOL. Further, wide-spread use of EPO 
among study patients (85 %) may have played a role. Most of the previous work on pref-
erences of dialysis patients stems from the pre-EPO period. Of the three studies that have 
reported on the contribution of EPO to health preference scores, one small study (n=28) 
showed higher TTO scores after introduction of EP09 However, a large (n=118) placebo-
controlled randomised trial 5 and an observational study in 40 patients 17 showed stable 
TTO scores after the introduction of EPO, despite improvements in the physical and 
fatigue domains of HRQOL. Given the fact that the best evidence is provided by the ran-
domised trial, we consider EPO use not as an important factor to explain our relatively high 
preference scores. 
The influence of non-responders on the high average preference scores has at best been 
limited. The patients in our sample that did not respond to SG and/ or TTO (12 %) were 
older and had a worse self-rated health than responders. In the unlikely event that all non-
responders to the TTO had valued their current health state at 0, the average TTO score 
still would have been 0. 79. Finally, it has to be considered that preference-based methods 
are less-reliable than suggested,4 7 31 at least in a cross-cultural context, because cultural dif-
ferences present benveen countries or continents might have a strong influence on the val-
uation of health. In the present study, some patients refused to answer SG and TTO for 
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religious reasons. It is possible that this religious factor resulted in unwillingness of patients 
to trade-off quality and quantity of life or to accept a gamble with a negative outcome, 
resulting in higher scores than in non- or less religious populations. Also, cultural differ-
ences in the attitude towards risk may exist. Our finding of high preference values in Dutch 
dialysis patients is in accordance with data from other international comparative research,32 
which showed that the Netherlands, among 48 countries, scored highest on several well-
being scales. A positive general attitude to life in the Netherlands might therefore have 
influenced preference scores in our study. \X/e suggest that health preference scores of sim-
ilar patient populations may not easily be compared if elicited in different countries or con-
tinents. The influence of cultural differences on health preferences and the transferability 
of study results to other countries remains a subject for future study. 
Correlations benveen health preferences methods and health profiles were absent to mod-
erate (maximal Pearson's r 0.31). This finding is in accordance with results of previous 
research in ESRD patients,10 18 pre-dialysis patients,33 and other seriously ill patients,34-3 5, 
but could also be contributed to insufficient variance in the data or insufficient statistical 
power to detect correlations. Correlation as a measure of association depends on the vari-
ance of values found. Because patients' preference scores in the present study concentrat-
ed at the upper end of the scale, high correlations are unlikely. The sample size used was 
large enough to detect correlations as low as 0.25 with adequate statistical power, but most 
correlation coefficients were below that threshold. Two studies \Vhich have used multiple 
regression analyses to study the independent associations between health profiles and 
health preferences found R2 of 19% and 0 %.33-34\X.re have not reported such multivariate 
analyses because it is instantly clear from the low Pearson correlation coefficients (Table 6) 
that health preferences scores cannot be explained by health profile outcomes. The impli-
cation of this finding is that both types of questionnaires truly reflect different aspects of 
the HRQOL concept. The health profiles assess patients' functioning on different domains 
of quality of life, whereas the health preferences methods elicit individual judgements of 
the value of the current health status, relative to full health and death. The implication is 
that the t\VO types of questionnaires may lead to different conclusions on HRQOL of dial-
ysis patients. The descriptive questionnaires SF-36 and EQ-5D indicated that quality of life 
of dialysis patients in this study was severely impaired. Despite these impairments, patients 
valued their health status as high as 82 to 89 percent of normal health. The discrepancy 
between the results of the descriptive questionnaires and the preference measurements 
might be explained by the fact that the coping mechanism, through which patients gradu-
ally learn to adapt to their new situation and to accept the fact that it will remain unchanged, 
is more reflected in the preference based methods than in the descriptive questionnaires. 
The reality for many ESRD patients seems to be that, despite the severe physical limitations 
experienced in everyday life, they subjectively experience a relatively high quality of life. 
The multivariate regression analyses (Table 5) failed to show obvious relationships 
between social-demographic, clinical and treatment related variables and health preferences 
scores. Previous research showed that health preferences were also not correlated with clin-
ical variables, such as hematocrit, hemoglobin and glomerular filtration rate.33 If health 
preferences scores are poorly explained by both health status (Table 6) and social-demo-
graphic, clinical and treatment related variables (Table 5), what else constitutes a person's 
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preference score? Besides by coping behaviour of patients, the preference scores may be 
influenced by beliefs about health, previous experiences and knowledge, a person's attitude 
towards risk and time and non-health related factors, such as financial status, family cir-
cumstances and social support. 31 These confounders hamper the strict interpretation of the 
preference scores as the valuation of health status only and, consequently, the use of health 
preference methods in clinical HRQOL studies, especially in populations of chronic 
patients. In such populations, the coping process may prevent patients from using the whole 
range of possible scores. 3G Two of the three prospective EPO studies that used the TTO 
instrument reported no difference in health values after treatment with EPO had been 
started.5 17 Also, a study in survivors of myocardial infarction concluded that health values 
are stable over time, despite changes in health status.37 This further reduces the usefulness 
of health preference methods, especially in prospective studies. Other disadvantages of 
health preferences methods include the necessity of an interviewer situation, the relatively 
high non-response and the unknown influence of cross-cultural factors on health values of 
patients. Until these issues are resolved, the use of health preferences methods should be 
limited to a research context. 
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Abstract 
Objective. Data on health-related quality of life (HRQOL) of Automated Peritoneal Dialysis 
(APD) patients are scarce. The objectives of this study were (1) to explore HRQOL of 
APD patients, to compare it with HRQOL of CAPD patients and a general population 
sample and (2) to study the relationship between HRQOL outcomes and background vari-
ables. 
Design. Home interviews of APD and CAPD patients. HRQOL, social-demographic, clin-
ical and treatment related background data were collected at the interview and from patient 
charts. 1Iultiple regression analysis and logistic regression analysis were used to study the 
relationship of HRQOL outcomes towith background variables. 
5 etting. Sixteen Dutch dialysis centres. 
Patients. Convenience sample of 37 APD patients and 59 CAPD patients matched for total 
time on dialysis. 
1\1ain outcome measures. Four HRQOL instruments: Short Form 36, EuroQol/EQ-SD, 
Standard Gamble and Time Trade Off. 
i\1ain results. Physical functioning of both APD and CAPD patients was impaired in com-
parison with the general population, while mental functioning was not different. In multi-
variate analyses, mental health of APD patients was found to be better than that of CAPD 
patients. In addition, APD patients were less anxious and depressed than CAPD patients. 
Regarding physical aspects of HRQOL and role-functioning, no differences were observed 
between APD and CAPD patients. Other variables to explain HRQOL outcomes were age, 
the number of comorbid diseases and primary kidney disease. 
Conclusions. HRQOL of APD patients is at least equal to HRQOL of CAPD patients. 
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Introduction 
The concept of Automated Peritoneal Dialysis (APD) was first described in 1981, five years 
after the introduction of continuous ambulatory peritoneal dialysis(CAPD).1 APD has been 
used by relatively few patients in the almost rt:vo decades of its existence. From the United 
States Renal Data Registry, it appears that 4.4% of all American dialysis patients was using 
APD in 19972 In the Netherlands, 6.2% of all dialysis patients were treated with APD in 
1997, mostly with Continuous Cycling Peritoneal Dialysis (CCPD).3 Although many papers 
on health~related quality of life (HRQOL) of dialysis patients have been published! it is 
surprising that quality of life of APD has hardly been studied yet. A 1IedLine literature 
search identified four earlier studies that had incorporated APD patients. 5-8 Two of those 
studies 6 7 only reported data on the aggregate level, making it impossible to draw conclu-
sions on the relative performance of APD patients. One study focused on the impact of 
different types of APD equipment on quality of life-' Only one study was aimed at a for~ 
mal assessment of HRQOL of APD patients8 This was a small randomised trial (n=25), 
comparing APD and CAPO with regard to quality of life. C sing a standardised and vali-
dated questionnaire, no differences between both groups were found. 
Health-related quality of life is an important outcome of patient care.9 The term includes 
different concepts as functional status, health status, well being, patient satisfaction and 
patient preferences. Over the past 30 years, many different questionnaires and interview 
techniques have been developed to measure HRQOL.9 Generic questionnaires allow for 
comparisons with other patient groups and with general population samples. They may be 
distinguished in health profiles and in preference based measures, also called utility meas-
ures.lO Health profiles aim to describe various dimensions of quality of life, including phys-
ical, psychological and social functioning. Health preference measurements explicitly seek 
to value the quality of life in a single indicator, a number between zero and one, where zero 
represents death and one represents full health. 
The purpose of the present study was to explore the HRQOL of a sample of APD 
patients and to compare it with HRQOL of CAPO patients and a general population sam-
ple of similar age. Both health profiles and health preference methods were used to assess 
the HRQOL of patients. Results were analyzed with regard to social-demographic, clinical 
and treatment related variables. 
Subjects and methods 
Data collection 
\X-'e recruited APD patients from three Dutch dialysis centres that were known to treat rel-
atively much APD patients. We compared HRQOL of these APD patients with HRQOL 
of CAPO patients who were recruited from 13 dialysis centres that participated in a Dutch 
prospective cohort study on the adequacy of dialysis, the Netherlands Cooperative Study 
on the Adequacy of Dialysis (NECOSAD~I Study)11 APD and CAPD patients were 
matched for total time on dialysis, all of them had started dialysis after October 1st 1993. 
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All patients in these 16 centres who had been treated with their current modality for at least 
three months, were above 18 years, and had adequate eyesight and understanding of the 
Dutch language to enable the administration of questionnaires were asked to participate in 
this study. Interviews were conducted at patients' homes by one of three trial nurses with 
experience in end-stage renal disease treatment. The nurses received a training to adminis-
ter the various HRQOL measures. The ethical committees of all dialysis centres approved 
the study and all patients consented before study entry. The funding organisation neither 
had interference with data collection, data analysis and writing the manuscript, nor did it 
have the right to approve or disapprove the manuscript. 
Background variables 
Data on background variables were collected atduring the interview and included age, sex, 
marital status, employment status, educational level, number of hospitalisations in last six 
months, and number and type of comorbid conditions. Comorbidity at the time of the 
interview was evaluated using a validated list of chronic conditions from the annual Dutch 
National Health Survey.12 Major diseases such as diabetes mellitus, myocardial infarction, 
stroke and malignancy are included in this list. Respondents were asked to indicate for each 
condition whether they suffered from the condition at present or in the year preceding the 
interview. Data on primary diagnosis, treatment history, length of time on dialysis and cur-
rent treatment, and dose of dialysis in terms of dialysis related urea clearance were obtained 
from the patient's nephrologist. Primary diagnosis was classified according to the EDT A-
ERA classification.13 The weekly Kt/Vurea was calculated as the peritoneal Kt/Vurea per 24 
hours multiplied by 7. 
Questionnaires used to assess HRQOL 
The interview consisted of the administration of four generic questionnaires, including rtvo 
health profiles (Short-Form 36 Health Survey and EuroQol/EQ-SD) and two health pref-
erences methods (Standard Gamble and Time Trade Off). The four questionnaires were 
always administered in this sequence. The first two questionnaires were self-administered. 
After completion, the interviewer continued with the administration of the Standard 
Gamble and Time Trade Off. 
The Short-Form 36 Health Survey (SF-36) generates a profile of scores on eight dimensions 
of quality of life.14 These dimensions are: (1) physical functioning, (2) role limitations due 
to physical functioning, (3) bodily pain, (4) general health perceptions, (5) vitality, (6) social 
functioning, (7) role limitations due to emotional functioning, and (8) mental health. Raw 
scores on the eight scales are transformed to calculate a score between zero and hundred, 
where a higher score indicates better health. The physical and mental components of the 
eight scales are combined into a physical and a mental summary score.15 The two summa-
ry measures are standardized to have a mean of 50 and a standard deviation of 10 in the 
general population and therefore allow for easy comparison of patient scores with general 
population scores. SF-36 scores of persons of similar age (55-64 years) were derived from 
a validation-study in the Dutch population_16 
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The EQ~5D or EuroQo! (EQ~SD) is a validated generic questionnaire that includes a clas~ 
sification system (EQ-5DprofiJJ and a visual analogue scale (EQvAs) 17 18 The EQ-5Dprofile 
records the level of self-assessed problems on 5 domains of health (mobility, self-care, 
usual activities, pain/ discomfort, anxiety/ depression), each with three levels of functioning: 
(level 1: no problems; level 2: some problems; level 3: unable to perform/extreme prob-
lems). The EQvAs records the respondents rating of his/her overall health status on a grad-
uated, vertical visual analogue scale. The EQvAs is anchored at 0 (worst imaginable health 
state) and 100 (best imaginable health state). 
The Standard Gamble (SG) is a method to measure preferences for health states. 19 The 
respondent is presented with two alternatives and asked to choose the one most preferred. 
The first alternative offers the certainty of staying in the current health state for the remain-
der of the respondent's life. The second alternative is a gamble with specified probabilities 
for both the positive outcome of the gamble (a normal health state for the remainder of 
rime) and the negative outcome (immediate death). These probabilities are varied until the 
respondent is indifferent between the gamble and living in his/her current health state. The 
SG score, a score between zero and one, is calculated as one minus the risk percentage at 
the point of indifference, divided by hundred. An SG score of 0.80 implies that a person 
is prepared to take a gamble with 20 percent risk of dying immediately and 80 percent 
chance to improve his current health to normal health. The SG score reflects the value a 
person assigns to his own health state. In our study, a visual aid was used to explain the con-
cept of the SG. Before the patient was asked to value his own current health state, the con-
cept was explained and practised using imaginary health states. 
The Time Trade Off (ITO) is also a preference-based method. 20 Patients are asked whether 
they are prepared to give up some remaining rime of their lives, in order to improve their 
current health state to normal health. The time perspective that is presented to the patient 
corresponds with the statistical life expectancy of people of the same age and sex. The quo-
tient of the chosen number of years in a normal health state over statistical life expectan-
cy yields the TTO score. A TTO score of 0.80 implies that a person is indifferent between 
living 8 years in excellent health versus 10 years in his current health state. \~'e practised the 
TTO concept with imaginary health states, before the patient was asked to value his/her 
own current health state. 
Statistical analysis 
Differences between treatment groups were tested by means of the Student's t-test in case 
of continuous variables. \Xlhere the distribution of scores deviated from normality, non-
parametric methods were used (lvfann-\'\lhitney U Test). Categorical variables were com-
pared using the Pearson Chi-square test. In order to be able to control for case-mix differ-
ences, the association between continuous HRQOL outcomes (SF~36, SG, TTO, EQvAsl 
and background variables was studied -with multiple regression models. Logistic regression 
analysis was used to study the relationship berureen background variables and categorical 
HRQOL outcomes (EQ-5DprofiJJ- These EQ-5Dprofi.le outcomes were dichotomised into 
tbe presence of problems, either at level 2 (some problems) or level 3 (severe problems), 
and the absence of problems. A forward stepwise selection strategy "\\lith P=O.OS as the cri-
terion level for selection was chosen for all regression analyses. Analyses reported here are 
70 
Chapter 4 
based on treatment at the time of the interviev.~ A two-sided P-value of 0.05 was chosen as 
cut-off for statistical significance. 
Results 
Patient characteristics 
A total number of 96 patients were inten~ewed (37 APD, 59 CAPD). Table llists the main 
demographic and clinical characteristics of patients. The proportion of males in the CAPD 
group was significantly higher than in the APD group. APD patients more often had 
glomerulonephritis as primary disease, while there was a trend towards more renal vascular 
diseases and diabetes mellitus in the CAPD group. The total number of months on dialy-
sis was the same in both treatment groups (15 months), but CAPD patients had on average 
been treated longer with their current treatment modality (13 months) than APD patients 
(10 months). No other demographic and clinical differences were present between tl1e 
groups. 
Table 1: Patient characteristics according to treatment modality (mean, SD, range or%) 
Age 
Male a 
Married/living together 
Employed 
Educational level 
w low 
- intermediate 
-high 
EDTA-ERA primary disease 
- glomerulonephritis a 
- renal vascular diseases b 
- interstitial nephritis 
w cystic kidney disease 
- diabetes mellitus 
- others and unknown 
Number of comorbid conditions 
Number of hospitalizations in last six months 
Months on dialysis 
Months on this modality a 
Dialysis Kt!Y urea 
a P<0.05 
b including hypertensive nephrosclerosis 
CAPO (n-56) 
56 ( 13) 25-80 
69% 
86% 
25% 
17% 
73% 
10% 
12% 
25% 
7% 
12% 
17% 
27% 
2.6 (1.9) 0-9 
0.6 (1.0) 0-5 
IS (4) 7-21 
13(4)7-21 
2.0 (0.4) 1.3-2.9 
APD (n-37) 
55(13) 28-76 
49% 
81% 
29% 
24% 
68% 
8% 
29% 
II% 
14% 
II% 
5% 
30% 
2.3 ( 1.6) 0-6 
0.6 (0.8) 0-3 
IS (8) 3-31 
I 0 (7) 3-29 
1.9 (0.5) 1.3-3.6 
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Results of SF-36 
Table 2 presents patients' and reference group scores on the eight SF-36 sub-scales and the 
two SF-36 summary scores for physical and mental functioning. Comparison with scores of 
a general population sample showed that the mean SF-36 physical summary score of both 
patient groups was 1.0 to 1.2 standard deviations lower than the mean score of the gener-
al population (P<0.001). The SF-36 mental summary score of both patient groups was not 
different from the general population. Analysis of the differences in SF-36 scores between 
CAPD and APD patients showed that APD patients scored equal to or slightly better than 
CAPD patients on all SF-36 sub-scales, but that only the difference in Social Functioning 
was significant (P=0.03). 
Table 2: lvfean (SD) scores on eight SF-36 sub-scales and two SF-36 summary scores, by 
treatment modality, and for a general population sample of similar age (55-64) 
CAPO APD General population 
(n=59) (n=37) (n= 140) 
Physical functioning 61 (28) a 66 (28) 73 (24) 
Role functioning- physical 37 (43) ' 52 (43)' 77 (38) 
Bodily pain 66 (30) ' 75 (26) 75 (25) 
General health 42(21)' 42 (21)' 64 (22) 
Vitality 51(22)' 57 (20) a 67 (21) 
Social Functioning (SF) b 65 (33)' 79 (29) 87 (21) 
Social functioning 65 (33) a 79 (29) b 87 (21) 
Role functioning- emotional 77 (37)' 86 (34) 90 (25) 
Mental health 74 (18) 78 (16) 77 (19) 
SF-36 physical summary score 38 (I I) ' 40 (II)' 50 (10) 
SF~36 mental summary score 48 (II) 51 (9) 50 (10) 
a P<O.OS, vs. general population 
b P<O.OS, APD vs. CAPD 
Results of EQ-SD 
Figure 1 shows the proportion of CAPD and APD patients that indicated to have some or 
severe problems on the five dimensions of the EQ-5Dprofile· Compared to CAPD patients, 
APD patients showed somewhat fewer problems with mobility, daily activities and pain, but 
the differences were not significant. CAPD patients were more anxious and/ or depressed 
than APD patients (P<0.05). With a score of 61 (SD 0.20), self-rated health status on the 
EQvAs was similar for both patient groups. 
Results of Standard Gamble (SG) and Time Trade Off (TTO) 
The mean SG score of CAPD patients was 0.81 (SD 0.24), the mean SG score of APD 
patients was 0.74 (SD 0.24). The TTO scores of patients were somewhat higher than SG 
scores: 0.86 (SD 0.23) for CAPD and 0.93 (SD 0.14) for APD patients. The differences 
bet\Veen CAPD and APD patients were not significant. 
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Figure 1: Percentage of patients reporting some or severe problems in 5 domains of EQ-
.5Dprofilo by treatment modality 
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Associations between background variables and HRQOL outcomes 
Independent explaining variables of HRQOL are shown in Table 3. Regarding the SF-36 
physical summary score, a higher number of comorbid conditions was associated -with 
impaired HRQOL, while glomerulonephritis as primary kidney disease was associated with 
better HRQOL. The SF-36 mental summary score was also negatively associated with the 
number of comorbid conditions, while diabetes mellitus as primary kidney disease and 
APD treatment were positively associated with mental QL of patients. A higher number of 
comorbid diseases and a longer time on dialysis were negatively associated "'W-ith self-rated 
health status (EQv.As)· Regarding health preferences, the ITO score of patients was nega-
Table 3: Regression models to explain quality of life outcomes in peritoneal dialysis 
patients (standardized regression coefficient B, (partial R2) and total R2)a 
SF-36 physical SF-36 mental EQ-5DvAS Time Trade Off Standard 
summary summary Gamble 
Standardized regression coefficient (partial R2) 
No. of comorbidities -.59 (35.2%) -.36 (9.9%) -.48 (27.0%) -.27 (7.3%) -.39 (12.9%) 
Diabetes mellitus b .26 (4.5%) 
Glomerulonephritis b .22 ( 4.8%) -.31 ( 7.7%) 
Cystic kidney disease b -.21 ( 4.1%) 
APD .22 (4.9%) 
Time on dial sis -.28 7.7% 
Total R2 40.0% 19.3% 34.7% 7.3% 24.7% 
a B denotes the relative importance of the explaining variable: the higher the B coefficient, the higher the 
contribution of that variable in the regression equation. Partial R2 symbolizes the explained variance of 
the dependent variable accounted for by the variable. Total R2 is the percentage of the total variation of 
the quality of life score that is explained by the independent variables together 
b as primary kidney disease 
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tively associated with the number of comorbid diseases. The SG score of the patient could 
be explained by the number of comorbid conditions and by primary kidney disease: patients 
with glomerulonephritis and cystic kidney disease as primary disease showed lower SG 
scores. The models constructed had a low to moderate capacity to explain the variation in 
scores on the HRQOL outcomes (Total Adjusted R2 from 7.3% to 40.0%). 
Logistic regression analysis (fable 4) showed that more comorbid diseases were associat-
ed with an increasing likeliness to indicate problems on the EQ-5Dprofllc dimension "mobil-
icy". Employed patients and patients \\lith glomerulonephritis as primary kidney disease 
were less likely to have problems with "daily activities" than unemployed patients and 
patients with other primary kidney diseases. Again, a higher number of comorbid diseases 
was associated with a higher risk of not being able to performing daily activities without 
Table 4: Logistic regression models to explain the association betv.reen EQ-5Dprofile scores 
(absence/ presence of problems) and background variables (odds ratios with 
95% C.L') 
mobilicy selfcare b daily activities anxiety/depression pain 
Odds ratios with 95% Confidence Intervals 
Age 1.06 (1.01-1.11) 
No. of comocb;d;c;es 1.85 ( 1.33-2.58) 1.56 ( 1.02-2.40) 1.78 ( 1.22-2.58) 1.37 ( 1.0 1-1.86) 1.30 ( 1.0 1-1.68) 
Employed 0.33 (0.11-0.96) 
Diabetes mellitus c I 0.58 ( 1.80-61.95) 
Glomerulonephritis c 0.13 (0.04-0.58) 
Renal vascular disease c 0.21 (0.05-0.83) 
APD 0.1 0 0.01-0.79 
a The odds ratio indicates how much more likely (or unlikely) the presence of problems is in patients 
\vith the characteristic than in patients without that characteristic or, for continuous variables, the relative 
increase in likelihood to have problems associated with one extra unit of the continuous variable 
b results given for reasons of completeness; however, results unreliable because few subjects showed 
problems with selfcare 
c as primary kidney disease 
problems. Elderly people and patients with more comorbidities were more likely to be anx-
ious and depressed, while APD patients were less likely to be anxious and depressed than 
CAPD patients. A higher number of comorbid diseases was associated with a higher likeli-
hood to experience pain. Renal vascular disease as primary kidney disease was associated 
with less pain. 
Discussion 
This paper presents an explicit assessment of HRQOL of APD patients, in comparison 
with CAPD patients. A general conclusion drawn from the four HRQOL instruments used 
is that HRQOL of APD patients is equal to HRQOL of CAPD patients, and slightly bet-
ter in a few HRQOL domains. The differences in health preference scores (SG and TTO) 
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of both patient groups were not significant, indicating that on average CAPD and APD 
patients valued their current health status equally. 
After adjustment for case-mix variables, APD treatment appeared an independent indica-
tor of better mental health (measured with SF-36 mental health summary score) and of the 
absence of problems of anxiousness and depression (measured with EQ-SDprofilJ· 
Inspection of the SF-36 sub-scales that compose the mental health summary score showed 
that especially social functioning of APD patients was better, compared with CAPD 
patients. The better social functioning of APD patients might be related to the fact that 
daytime in these patients is free from treatment, thus facilitating a normal social life. An 
explanation for the factour finding that APD patients were less anxious and depressed than 
CAPD patients is more difficult to find. Possibly, treatment selection may have played a 
role. Patients with higher an.xiety levels may not have chosen the APD technique, because 
they find it scary to be attached to a machine while sleeping. Because our study was of 
cross-sectional nature, it remains difficult to differentiate between a real treatment effect 
and treatment selection. A longitudinal study also controlling for possible base-line differ-
ences in social functioning and anxiety/depression levels would be preferential to deter-
mine the independent influence of treatment modality on these HRQOL outcomes. 
Four earlier HRQOL studies that had incorporated APD patients were identified. 5-8 Two 
of those studies6 7 only reported data on the aggregate level, making it impossible to draw 
conclusions on the relative performance of APD patients. Of the two studies that provid-
ed with data of APD patients, one study reported SF-36 scores that were similar to scores 
of our patients,s the other study found slightly lower SF-36 scores.5 However, patients in 
that study had more comorbid diseases than patients in our study. The health preference 
scores elicited in our study are relatively high in comparison with previously published 
scores of dialysis patients, which fell in the 0.42 21 to 0.81 22 range. The general implication 
of the health preference scores as found in our study is that peritoneal dialysis patients val-
ued their current health status as 74 to 92% of a normal health state. Most previous stud-
ies on health preferences of dialysis patients have been performed in the United States and 
Canada. An explanation for our higher scores may be that health values are not compara-
ble cross-nationally and cross-continentally. A similar phenomenon was described by 
Veenhoven et al, who found that the perception of happiness and wellbeing was very dif-
ferent benveen countries and continents.23 Their study comprised 50 countries, and identi-
fied the Netherlands as one of the countries with highest levels of wellbeing. Besides to this 
more general cultural phenomenon, the relatively high values of patients for their own 
health status might be attributable to successful coping strategies of patients or may as well 
reflect the high quality of healthcare for Dutch dialysis patients. The variance in all 
HRQOL outcomes was only poorly to moderately explained by the clinical, socio-demo-
graphic and treatment-related variables that were included in our study, as was found by 
others. 6 24 This implicates that HRQOL outcomes may be determined by other factors than 
the ones we have explored. Although the health preference instruments explicitly ask 
respondents to value their current health state only, financial circumstances, attitudes to 
risk, religion and family support may also influence its outcomes.19 Furthermore, the health 
preference outcomes depend on cognitive processes such as remembering past experiences 
and integrating beliefs and biases about health.25 \"'\le found that patients with glomeru-
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lonephritis as primary kidney disease had lower SG scores, while at the same time showing 
a higher SF-36 physical summary score and less problems with daily activities than patients 
\Vith other primary diseases. This could as well be an incidental finding as an indication of 
the fact that health preference scores reflect more than health status alone. 
In comparison with a general population sample of the same age, both CAPO and APD 
patients showed worse SF-36 physical summary scores. However, the SF-36 mental sum-
mary scores of patients were similar to those of the general population. The differences 
bet\veen the general population and PD patients were especially large (P<0.001) on the sub-
scales physical role functioning, general health perceptions, vitality and social functioning 
(CAPO patients only). Two recent publications reported also that physical functioning of 
dialysis patients is impaired in comparison with the general population, but that mental 
functioning is not essentially different from mental functioning of the general population. 
26 27 The SF-36 physical and mental summary scores in both studies \Vere similar to scores 
of our PD patients. 
Since APD is more expensive than CAPD,28 HRQOL information should be involved in 
the assessment of the relative merits of alternative PO treatment modalities.29 Our study 
suggests a slightly higher mental QOL of APD patients, compared to CAPO patients. If 
this finding is confirmed by other studies, the higher costs of APD might be justified. Such 
future studies should be of a longitudinal nature, facilitating better control for possible dif-
ferences in base-line characteristics of patient groups. 
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Abstract 
This paper reports on a systematic review of the literature on economic evaluation of end-
stage renal disease treatments. The purpose of this study was t\vofold: (1) to review and 
compare current kno"\vledge about the costs and effects of renal replacement therapies, and 
(2) to assess the methodological quality of the economic evaluations. Six bibliographic data-
bases 0\'IEDLINE, EMBASE, HEED, NHS-EED, INAHTA Database, ECONLIT) were 
searched to identify original studies published bet\veen 1988 and 2000. Inclusion criteria 
were (1) full economic evaluation; (2) publication in English, French, German or Dutch; (3) 
sufficient methodological quality (assessed "\Vith a standardised rating system). Of the 127 
publications initially selected, 11 remained after further selection based on study quality cri-
teria. The main conclusions of this literature review are that few good quality economic 
evaluations have been published; that studies appeared especially week in the costing parts, 
including lack of discounting; and that full care haemodialysis was consistently found to be 
less efficient than renal transplantation and continuous ambulatory peritoneal dialysis. 
Future studies should concentrate on cost-effectiveness of treatments for subgroups of 
patients with similar age and comorbid status. 
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Introduction 
Renal replacement therapies (RRT) have first come into clinical use in the 1960s. The most 
commonly used techniques are haemoclialysis (HD), peritoneal dialysis (PD) and renal 
transplantation (TX). \X~'ith haemodialysis, the blood is cleaned from waste products 
through an extracorporeal artificial kidney. Haemodialysis can either be performed by the 
patient at home (home haemodialysis - HHD), or in a dialysis centre or hospital, with more 
(limited care haemoclialysis - LCHD) or less active (full care centre haemodialysis - FCHD) 
input of the patient in the treatment. \Xlith peritoneal dialysis, waste products are removed 
through a cleaning fluid in the abdominal cavity. PD has t\vo main treatment varieties, either 
with manual exchange of dialysis fluid (continuous ambulatory peritoneal dialysis - CAPD) 
or with automated exchange of dialysis fluid at night (automated peritoneal dialysis- APD). 
Kidney transplantation eliminates the necessity of dialysis as long as the recipient does not 
irreversibly reject the graft. 
The treatments currently available are lifelong, complex, and costly, and have always been 
so. Therefore, from the early beginning there has been an interest in the evaluation of costs 
and effects of RRT.1-4 Such economic evaluations aim to inform policy makers on the rel-
ative efficiency of several competitors for healthcare money, in order to allocate scarce 
resources as rational as possible.s In recent years, the research discipline of economic eval-
uation of healthcare interventions has matured, both in the number of analyses performed 
6, and in the definition of the methodological characteristics that are a prerequisite for good 
quality studies. 5-9 However, reviews of economic evaluation in several areas of medicine 
and healthcare have shown the paucity of much of the published research.lO-lS No earlier 
systematic review of the quality and outcomes of economic evaluation studies in the field 
of RRT has been found in the literature. However, one review that concentrated on the 
analysis and interpretation of cost data in dialysis was published recently.16 It was conclud-
ed that costing information in this field was often handled inconsistently and unsatisfacto-
rily, and that the analysis and reporting of costs needs improvement. 
The purpose of this study was twofold: (1) to review and compare current knowledge 
about the costs and effects of renal replacement therapies, and (2) to assess the method-
ological quality of the economic evaluations. We limited our search to studies published 
between 1988 and 2000, to be sure that major therapeutic improvements such as the intro-
duction of cyclosporin as an immunosuppressant for transplanted patients and the intro-
duction of erythropoietin for the treatment of renal anaemia were incorporated in the out-
comes of studies. Also, PD did not come into widespread use before the second half of the 
1980s. Furthermore, it was anticipated that older studies would not adhere to current 
methodological standards for economic evaluations. 11 
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Inclusion of studies 
Inclusion criteria were (1) full economic evaluation (to be explained later in this section) 
considering two or more RRT; (2) publication in English, French, German or Dutch lan-
guages; (3) the fulfilment of minimal quality standards for full economic evaluation studies 
(see separate paragraph). 
Studies were identified by searches in the following databases: 
• MEDLINE (from 1988 until December 1999). MEDLINE is maintained by 
the United States National Library of J\!Iedicine. :\.IEDLINE was accessed with 
WINSPIRS software. 
• EMBASE (from 1988 until December 1999). EiVffiASE is a database primarily 
oriented at European biomedical literature, maintained by Elsevier Science. 
EiVffiASE was accessed with DIALOG software. 
• HEED (Health Economic Evaluation Database). This database is maintained 
by the Office of Health Economics of the Department of Health and Social 
Security (London) and is accessible through CD-ROM. 
• INAHTA Database. The International Network of Agencies of Health 
Technology Assessment (INAHTA) maintains a database of publications by its 
member organisations. This database is accessible through CD-RO~I (via 
Cochrane Collaboration) and Internet (http:/ /www.york.ac.uk/inst/ crd/). 
• NHS-EED (NHS ECONOMIC EVALUATION DATABASE). This database 
is maintained by the National Health Service Centre for Reviews and 
Dissemination, University of York, and is accessible through CD-ROiYI (via 
Cochrane Collaboration) and Internet (http:/ /wwwyork.ac.uk/inst/crd/). The 
database includes standardised descriptions of published economic evaluation 
studies. 
• ECONLIT. This database is maintained by the American Economic 
Association and contains economic literature. The database was accessed using 
DIALOG software. 
The search strategy that was used for the :Yledline search is specified in Appendix 1. 
Basically, similar worded strategies have been used for searches in other databases, but each 
search was adapted to the requirements of the specific database. The .iYiedline search was 
used as the "reference search", in a sense that results from searches in the other five data-
bases were compared against these I'vfedline results. The references of all articles that were 
assessed and the references of a published bibliography of economic evaluations 6 were 
also checked for relevant articles. Furthermore, some unpublished studies we knew of, such 
as PhD theses and other "grey" literature were considered for inclusion as well. 
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A full economic evaluation is a study describing all necessary input and all relevant out-
comes of healthcare interventions.s One basic principle of economic evaluation is that at 
least one intervention is compared to another: either a status quo intervention or doing 
nothing. Four basic types of full economic evaluations may be distinguished: cost-minimi-
sation-analysis (Clv1A), cost-benefit-analysis (CBA), cost-effectiveness-analysis (CEA), and 
cost-utility-analysis (CUA).5 In a CNiA, equal effectiveness of the healthcare interventions 
under study is assumed. Only relevant costs are compared, and the cheapest intervention is 
assumed to be the most efficient. \Xlith a CBA, interventions for which the consequences 
are not identical and clinical success is measured in very different units may be compared. 
Both input and output of healthcare interventions are valued in monetary terms. Because 
of the inherent problems of valuing all relevant outcomes in monetary terms, especially the 
intangible ones, this type of economic evaluation is relatively rare in medicine. CEA is the 
evaluation technique used most frequently. In a CEA, the outcome measure can be any nat-
urally occurring unit relevant for the intervention under study, such as infections averted, 
hospitalisations avoided, or units of blood pressure reduced. However, the number of life-
years gained is an outcome measure used relatively frequently in CEA. One special form of 
CEA is CCA, where outcomes are measured in healthy years gained. Life-years gained have 
to be adjusted for the quality of life in those years, using a utility-index for the different 
health states a person can be in. A utility of 1 corresponds to perfect health, while a utility 
of 0 corresponds to death. The outcome unit in a CUA usually is the QAL Y (Quality 
Adjusted Life Year) or Healthy Years Equivalent (HYE). 
Exclusion criteria 
The following studies were not considered in our systematic review: (1) studies evaluating 
interventions relevant to patients receiving RRT, but not RRT itself, such as the compari-
son of erythropoietin use and blood transfusion for anaemia17, the cost-effectiveness of 
screening to prevent renal failure in insulin dependent diabetic patients1S, evaluation of par-
enteral iron administration in haemodialysis patients19, or the comparison of two immuno-
suppressive agents for transplanted patients20, (2) multiple publications on one study, (3) 
editorials, reviews and letters, (4) studies concentrating on cost of therapy alone (partial 
economic analyses3), (5) cost of illness studies, and (6) studies that presented insufficient 
data to assess the merits of the study, such as short reports and abstracts. 
Quality rating 
For each paper under review, a quality rating was completed, according to Bradley et al.21 
and Sacristan et ai.22 This checklist consists of 13 items and is based on widely accepted 
standards of economic evaluation methodologys, but has the additional advantage of com-
posing a numerical score for the quality of the paper. Studies with an average quality rating 
2:: 2.5 per applicable item (out of a maximum score of 4 per item) were selected for the cur-
rent rev"iew. The quality rating form is included in Appendix 2. 
84 
Chapter 5 
Results 
The results of the searches in the six databases that were mentioned in the methods section 
are shown in Table 1. Often, it was immediately clear from either the language of the paper, 
content of the abstract, or publication type, that the paper was not suitable for further 
assessment. Table 1 shows the number of papers retrieved, the number of papers that were 
initially removed from the selection because either inclusion criteria did not apply or exclu-
sion criteria did apply, and the remaining number of papers that were considered for inclu-
swn. 
Table 1: Results of literature searches in 6 databases 
Database #of hits #removed #assessed 
Medline 1,186 1,124 62 
Em base 514 (unique non-Medline) 467 47 
HEED 77 ( 17 unique non-Medline, non-Em base) 74 J 
INAHTA 26 19 7 
NHS-EED 178 ( 13 not found before) 165 s 
Econlit 324 (316 duplicate Medline) 324 0 
As appears from Table 1, 1,764 unique documents were found with the various literature 
searches. Of these, 1,640 were removed initially because exclusion criteria applied. Besides 
the 124 papers reported on in Table 1, three additional unpublished reports have been 
assessed for this revie\\~ After reading those 127 papers and reports, a further selection was 
made on the basis of criteria discussed in the methods section. Finally, 11 papers were 
selected for this review ;yfost studies that were not selected appeared to be partial economic 
evaluations, although they were labelled as full economic evaluation studies in either title or 
abstract. Also, studies often appeared to be cost studies only. Other studies were not select-
ed because they lacked quality. There were for instance many clinical studies that included 
an undiscounted and othet\Vise inadequate cost calculation, while at the same time not 
reporting on a sensitivity analysis and lacking the integration of costs and outcomes in a 
sensible measure. 
Table 2 shows a comprehensive overview of all 11 selected studies 'Nith the follo-wing key 
features: first author and year of publication, interventions compared, study design, num-
ber of patients, economic study design, viewpoint of study, type of costs included, valua-
tion of costs, ~year of study, time span of study, discounting of costs and effects with dis-
count rate, (type of) sensitivity analysis, and main outcomes. In the remainder of the results 
section, we will discuss some of the findings of selected studies. 
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~ 
< -
First m 5. E- ::'! ~ ?t;"' 
author a..8 !2. n ~ Year and Q..3 "'3 ~;.;; 
/year of RRT assessed a f m. 5 View- §_ no 8 ~r Main Source effec- country ::::1 ! Dis- ~ rn e!.. a: 
. • . . O'<l3 . "'..,;:;! . . c-o '<::J ';jl:S .. 
publication type of pat1ents Des1gn a ~ ;::;· pomt a..o-tl n ~effects d t1ve-ness of study .Q-- ~ counting t;i· [ ;;:;·~ Mam outcomes n 
Croxson, FCHD, HHD, Markov- CEA Health- I I ,2 LYG Data from literature New Zea 5 yrs !0% costs No Yes, Average cost per LYG for FCHD 
1990 23 CAPD,TX for all chain-like care and 2 hospitals land, 1988 I 0% ef one- $35,270, TX $18,463, CAPO $25,395 
ESRD model s stem fects wa -26,390, HHD $28,175. 
De FCHD, HHD, Markov- CEA Health- 1,3 1,2 LYG Dutch and European The Neth 5 yrs 10% costs No Yes, Cost per LYG all ESRD treatment-
Charro, LCHD, TX, CAPO chain care patient cohorts erlands, 10 % ef one- NLG 58,000, no separate analysis for 
1988 2<l for all ESRD model system 1984-1985 fects way different treatment modalities. 
De Wit, FCHD, LCHD, Markov- CEA, Health- I ,3,5 I ,2 LYG, utilities N 165 patients, The Neth 5 yrs 5 %costs Yes, Yes, Cost per LYG all ESRD treatment 
1998 25 CAPD,APD, HHD, chain CUA care (patients), national registry erlands, 5 %effects also one- NLG 78,700, cost per QALY = NLG 
TX, for all ESRD model + system- utilities data 1996 way 98,300. Cost per LYG all dialysis = 
cohort (population) NLG 133,100, cost per LYG TX = 
stud NLG 25,000. 
Douzdjian, TX + PAK, SPK for Decision- CUA Health- I 2 LYG, utilities Literature US, 1996 5 yrs No No Yes, SPK was more cost-effective than TX 
1999 26 type I diabetics analytic care (patients) one + + PAK: Cost per QALY were 
model system two $110,828 and $153,911, respectively. 
W' 
Douzdjian, FCHD,TX-CAD, Decision- CUA Health- I 2 LYG, utilities N-17 patients, US, 1996 5 yrs No Yes, Yes, Average cost per QALY for dialysis 
1998 27 TX-LD, SPK for analytic care (patients) literature also one- $317,746, TX-CAD $1 56,042,TX-LD 
type I diabetics model system way $123,923, SPK $102,422. Incremental 
analysis shows TX-LD to be most 
cost-effective. 
Greiner, TX versus FCHD Cohort CUA Health- 2,4 I ,2 Utilities N-1 023 (waiting Germany, I 0-20 5 % costs Yes Yes, TX was dominant (more QALY's, less 
1999 28 for all ESRD study care (population) list), n= 172 (TX) 1993 yrs 5 % effects one- cost) strategy. Average cost per 
system way QALY for FCHD OM 147,000, versus 
OM 38,000 for TX. 
Hamel, Initiating FCHD for Cohort CUA Health- 2,5 2 LYG, utilities N-491 patients US, 1994 Max. 3 %costs Yes Yes, Incremental cost per QALY for initi-
1997 29 acute renal failure study care (patients) 4.4 yrs one- ating dialysis compared to withhold 
in very ill patients system 3 % effects way ing dialysis $128,200. Cost per QAL Y 
for best prognostic group $61,900, 
for worst prognostic group $274,100. 
':: 
(Table 2 continued) 
First 
author w 
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-· ~ 
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0 • 
=! 
0 3 ~. 
5" q ~ 
• • 0 
/year of RRT assessed a I 
publication type of patients Design a 
~0 
• 0 
d&· ~ 
;;: n· 
View-
point 
c n 8 !:!. ~ ~ [;l g Main 
D--a n 2.. effects a 
Source effec-
tive-ness 
Year and 
country 
of study 
~ tl, 
c~ 
~·  0 
Dis-
counting 
•• 0 3 
~§ 
~- [ 
=' ~ . iJ Main outcomes a 
Horn-
berger. 
1993 30 
Horn-
berger, 
199731 
Laupacis, 
1996 32 
Sessa, 
1990 33 
High-flux FCHD Retro- CEA Health 2 LYG N=253 patients US, 1990 Un 5 %costs Yes Yes, Incremental cost per LYG of high-flux 
versus conventional spective care clear 5 % effects one- dialysis compared to conventional 
FCHD cohort system way dialysis, was $28,188- $29,743, de-
Repeated TX for 
patients with graft 
failure 
study___ pending on model. 
Decision- CUA Health I ,3 2 LYG, utilities N=878 patients, US, 1995 Life- 5 %costs Yes Yes, Incremental cost per QALY of a re-
analytic care (patients) literature time 5 % effects one- transplantation policy compared to 
model system way no re-transplantation policy was 
$9,659. 
TX versus dialysis Prospec- CUA Soci I ,3,4 I ,2 LYG, utilities N=269 patients Canada, 2 yrs No Yes No Transplantation was dominant strategy 
{n.s.) for patients on tive co- ety (patients) 1994 {more effective, less costly) for all 
waiting list hart study subgroups of patients examined. 
FCHD,TX-CAD, Retro- CEA Health I 2 LYG N=121 patients Brazil, 1985 2 yrs No Yes, Yes, Average cost per LYG for FCHO 
TX-LD, CAPO for spective care also one- $10,065, TX-CAD $ 6,978,TX-LO 
non-diabetic ESRD cohort 
study 
system way $3,022, CAPO $ 12, I 34. Incremental 
analysis shows TX-LD to be most 
cost-effective. 
a RRT = Renal Replacement Therap); ESRD = end-stage renal disease pntients, I ID = hacrnodialysis, PD = peritoneal dialysis , FCHD = full care centre 
haernodialysis, LCHD =limited care centre haemodialysis, IIHD =home haemodialysis, CAPD =continuous ambulatory peritoneal dialysis, APD :::automated 
peritoneal dialysis, TX =kidney transplantation, n.s. = non-specified, Ci'vlA = Cost J'vlinimisation Analysis, CBA = Cost Benefit Analysis, CEA =Cost 
Effectiveness Analysis, CUA =Cost Utilit)' Analysis, LYG =Life Years Gained, QAI.Y =Quality Adjusted Life Year Gained, PAK =Pancreas aft<:r Kidney 
Transplantation, SPK = simultaneous pancreas and kidney transplantation, TX-CAD = kidney transplantation with cadaver donor organ, TX-LD = kidney 
transplantation with living-related donor 
b 1 ::;;; direct healthcarc costs (complete), 2 = direct healthcare costs (partially), 3 =direct non-healthcare costs, 4 =indirect non-healthcare costs (productivity 
costs), 5 ::;;; indirect healthcare costs 
c 1 =real (opportunity) costs, 2 =charges/tariffs, 3 =unclear, not stated 
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RRT assessed / type of patients 
Not surprisingly, most selected studies concerned the FCHD technique (9/11) and/or renal 
transplantation (9/11). Four studies included the CAPD technique, while APD was covered 
in only one study.25 The majority of studies (8/11) were targeted at all end-stage renal dis-
ease patients. Two studies from the same research group were exclusively evaluating avail-
able transplantation techniques for diabetic patients. 26 27 One study focused on initiating 
FCHD for acute renal failure in very ill hospitalised patients. 29 
Study design 
Five economic evaluations were conducted alongside a clinical study. These studies were 
either retrospective30 33 or prospective28 29 32 cohort studies. Randomised controlled trials 
could not be selected for this review, inherent to the fact that to date randomised studies 
have never been conducted in the field of renal replacement therapies. Six selected studies 
were model-based economic evaluations, combining data from patient cohorts, literature, 
national and international patient registries.23-27 3l Four selected studies applied the CEA 
format,23 24 30 33 six studies used the CUA approach,26-29 31 32 while one study combined 
the t\\'O economic study designs.25 
Viewpoint 
Almost all studies took a healthcare system perspective. Only one study chose a societal per-
spective32, although some other authors claimed this perspective too.24 25 30 31 
Costs incurred and valuation method used for costing 
All studies incorporated direct healthcare costs, although not all of them reported on all rel-
evant direct healthcare costs. For instance, only one study reported on healthcare use out-
side the hospital, such as general practitioners visits and use of community nursing. 2S Some 
papers lacked own costing studies, but quoted cost data (i.e. charges) from the literature.26 
27 29 30 31 33 None of the studies succeeded in applying the opportunity cost principle for 
the entire cost study. At best, studies combined the use of charges for some cost categories 
(i.e. drugs) with the use of a more realistic costing concept for other cost categories, such 
as dialysis unit staff costs and hospitalisations.25 32 Indirect non-healthcare costs (produc-
tivity costs) were included in only one study, the same study that took a societal perspec-
tive.32 Two studies included indirect healthcare costs, the costs of non-renal medical care in 
future life years.25 29 
Valuation of quality of life within CUA approach 
Five of the seven CUA studies used patient utilities to calculated Quality i\djusted Life 
Years.26 27 29 31 32 Two studies applied utilities from the general population25 28, and one of 
these also applied patient utilities in sensitivity analysis.25 
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Discounting 
Discounting of costs and benefits \vas applied in most studies with a time-span longer than 
one year. However, four studies omitted to discount costs and benefits.26 27 32 33 In two of 
these studies, this may have been related to the short time horizon of two years32 33, but in 
the other ru.ro studies discounting was simply ignored.26 27 The discount rates applied var-
ied between 3 and 10 percent, but this may be related to differences in timing of the eleven 
selected studies and cross-country differences in appropriate discount rates. 
Incremental analysis 
Economic analyses should include an incremental analysis: the additional costs of one pro-
gramme over another should be related to the additional benefits of that programme. Of 
the 11 studies selected, 8 have reported such incremental analyses. In general, transplanta-
tion programmes were found to be dominant over dialysis programmes, because they pro-
vide more effects at less cost. Three studies have only reported average cost-effectiveness 
figures. 
Discussion 
Because RRT are expensive, the economic aspects of RRT have received attention from the 
early beginning in the 1960s1-4. This paper points out that few good quality studies have 
been published. We reviewed 127 srudies published in 1988 or later that dealt with eco-
nomic aspects of renal replacement therapies. Many studies appeared of insufficient 
methodological quality and \vere therefore rejected for this review. Only eleven studies of 
sufficient quality could be identified. To identif.Y these eleven studies, we had to stretch qual-
ity criteria in comparison with an earlier review that was prepared by one of the authors ll, 
dealing with healthcare programmes directed at the prevention of infection with the hepa-
titis B virus. In this earlier review, studies '-'rith an average quality rating 2: 3 per applicable 
item (out of a maximum score of 4 per item) were selected, while the current review used 
a threshold of 2.5 per applicable item. Should the criterion of 3 out of 4 points per appli-
cable item have been used, even less than eleven studies would have been selected. None of 
the eleven selected studies reached the maximum score in every applicable item, implying 
that each of the studies selected showed at least one major drawback in the application of 
standard methodology. 
In general, studies appeared especially weak in the costing parts, including lack of dis-
counting and not applying the opportunity cost principle. I'vlany of the studies that were not 
selected for the review were in fact clinically oriented studies, were some but insufficient 
economic data were gathered or were some unfounded economic conclusions were drawn. 
The lack of quality of costing studies in the RRT field was identified recently by other 
authors16. In other fields of medicine, the paucity of economic research and the scarcity 
of full economic evaluation studies have also been reported10-15. As such, the review's find-
ings in the RRT field fit into a broader picture. However, a general improvement of study 
methodology in more recently published studies was identified. The majority of studies 
selected for the current review was published in the last four years. i\'fore widespread knowl-
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edge on economic evaluation methodology and the introduction of quality standards by 
journal editors 34 may account for further improvement of economic studies in the near 
future. As an example, a large number of recent good quality economic evaluations in the 
field of prevention of progression of end-stage renal disease in diabetes mellitus patients 
were found. They were excluded for this review but would merit a separate review of these 
studies. 
Although the "main conclusions / main outcomes" column (Table 2) is presented in a 
league table like format, the ratio's presented in this column can not be compared directly. 
The ratio's mentioned in this table are compiled directly from the selected studies, but refer 
to different points in time, different study designs, different sizes of programmes being 
compared and different healthcare systems in different countries. However, one conclusion 
that may be drawn is that FCHD was consistently found to be less efficient than CAPD and 
renal transplantation. 'W'ould it therefore be appropriate to conclude that healthcare money 
could be spend better in the CAPD field than in the FCHD field? It is difficult to arrive at 
such a conclusion because not all therapies are available for all patients. For instance, renal 
transplantation is hampered by long waiting lists, and many patients will never receive a 
transplant at alL Furthermore, the case-mix of each RRT may be entirely different, making 
it difficult to compare effects of therapy directly over the different RRT. For instance, it is 
well established that patients who receive a transplant are relatively healthy. Also, patients 
may have medical or social contra-indications to the use of the more efficient CAPD tech-
nique. Besides, the status quo in RRT is that clinicians tend to consider all patients, regard-
less of age or comorbidity, for the initiation of the less efficient FCHD technique. 
However, as Hamel and colleagues showed, initiation of dialysis in the frailest elderly, with 
cost per QALY as high as$ 274,000 is relatively inefficient in comparison with other health-
care provisions.35 None of the other studies reported cost-effectiveness at the level of sub-
groups of patients with similar age and comorbid status. Future studies should concentrate 
on such subgroup analysis, because this adds to the existing knowledge on the relative cost-
effectiveness of different RRT 
A further limitation to the interpretation of the cost-effectiveness and cost-utility ratios 
as shown in Table 2 is that, despite the limited time span of the current review, treatment 
options in older studies may be incomparable to the same treatment options in more recent 
studies. Especially on the cost side, older studies may underestimate the cost of therapy, 
because the techniques of both haemoclialysis and peritoneal dialysis have been subject to 
change over the last 10 years. For instance, new dialysis membranes in haemodialysis and 
non-dextrose based dialysate solutions in peritoneal dialysis have been introduced. Some of 
the selected studies were cohort studies published around 1990. The data that were used in 
these publications often are from the 1980s. The effects of changes in technology or 
improvements in the management of patients during recent years may not be fully meas-
ured by these analyses. For example, the peritonitis rates have dropped following the intro-
duction of the Y-set connection technique for CAPD patients. 36 As a result, hospitalisation 
rates have dropped, "\vith subsequent consequences for the relative cost-effectiveness of the 
CAPD technique, compared with other dialysis techniques. In order to eliminate these time 
effects, we could have limited our review to an even smaller time period, but then the num-
ber of good quality studies selected would have been even more limited. 
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\Ve conclude that the methodological quality of the published economic evaluations is 
disappointing in general. The quality of future studies to be conducted should be improved 
by applying basic principles that are widely acknowledged to be standard methodology in 
this research fieldS 7. Othenvise, the ambition of economic evaluation to serve as a reliable 
aid in healthcare policy and decision making can not be fulfilled. To guarantee the highest 
possible level of conduction of health economic studies, skilled health economist should 
be consulted in an early phase of the design of clinical studies and form part of the 
research team during the entire study. 
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Appendix 1: Medline search strategy 
No. Records Request 
26612 (explode "Hemodialysis"/ all subheadings} in mjme 
2 9714 (explode "Peritoneal-Dialysis"/ all subheadings) in mjme 
3 1058 (explode "Dialysis"/ all subheadings) in mjme 
4 223309 explode "Kidney-Diseases"/ all subheadings 
5 22 #3 and #4 
6 34230 ("Kidney-Transplantation"/ all subheadings) in mjme 
7 69306 (explode "Renal-Replacement-Therapy"/ all subheadings) 
in mjme 
8 39565 (explode "Kidney-Failure"/ all subheadings} in mjme 
9 952 ("Nephrology"/ all subheadings) in mjme 
10 97938 #l or #2 or #5 or #6 or #7 or #8 or #9 
II 43803 ((renal near transplant*) or (kidney near transplant*) or 
renal disease* or renal therapy or renal replacement or 
renal failure or kidney failure) inti 
12 32765 (haemodialysis or hemodialysis or dialysis or (allocation 
near kidney*) or capd or apd or esrd) in ti 
13 73470 #II or#l2 
14 64798 explode "Costs-and-Cost-Analysis"/ all subheadings 
15 10436 explode "Health-Care-Costs"/ all subheadings 
16 37041 (cost* or econom*) inti 
17 80182 #l4or#ISor#l6 
18 1001 (#10 or #13) and #17 
19 1186 #10 or#l8 
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Appendix 2: Checklist to evaluate economic studies 
N Items 4 3 2 I 0 N/A a 
I Definition of study aim: 
Does a well-defined question exist? 
Are the perspective and alternatives compared clearly specified? 
2 Sample selection: 
Are the types of patients chosen suitable and are they specified? 
Are the diagnostic criteria adequately specified? 
3 Analysis of alternatives: 
Are all the relevant alternatives analysed? 
Is I are the comparison alternative(s) suitable? 
Is this the most commonly used treatment, or one that will be replaced by 
the new drug? 
Is the indication the most relevant one? 
Are adequate doses used? 
Are the treatment reproducible (e.g. doses, interval, duration)? 
Is the "do nothing" option analyzed or should it be analyzed? 
Is a decision analysis applied? 
4 Analysis of perspective: 
Is it clearly specified (e.g. society, patient, hospital)? 
Is it justified for the question asked? 
5 Measurement of benefits: 
Is it adequate for the question asked and the perspective? 
Are the data on the effectiveness of alternatives adequately established? 
Is the main assessment variable (endpoint) objective and relevant? 
Is the time fixed for the evaluation sufficient and is it specified? 
Are the results quantified by time? 
6 Measurement of costs: 
Is it adequate for the question asked and the perspective? 
Are the costs up to date and are the prices those of the market? 
Is an adjustment for future costs and benefits performed? 
7 Is this type of analysis suitable? 
Financial terms: cost/benefit 
"Physical units": cost-effectiveness 
Quality of life/utility: cost utility 
Equal benefits: cost minimisation 
8 Analysis of results: 
If intermediate variables are used, are they representative of the end benefit? 
Is a marginal analysis performed? 
Are the costs and consequences of adverse effects analysed? 
9 Is the evaluation suitable if made within a clinical trial? 
Is the suitable methodology used? 
Are the staf1stical methods used adequate? 
Is an analysis according to "intention to treat" made? 
Are costs resulting from the trial, which differ from those in normal practice, 
taken into account? 
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(Appendix II continued) 
Nc Items 4 3 2 I 0 N/A a 
10 Are the assumptions and limitations of the study discussed? 
Is a sensitivity analysis performed? 
Do the assumptions have a bias? 
Is the execution of any important variable analysed or justified/ 
If intermediate endpoints are assumed, are limitations discussed? 
II Are possible ethical problems discussed and identified? 
12 Conclusions: 
Are they justified? 
Can they be generalised? 
Can they be extrapolated to daily clinical practice? 
13 Overall impression of the quality of the paper/ 
a~/ A::: nor applicable 
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Abstract 
0/:jectitJe. To evaluate the cost of illness of end~stage renal disease in the Netherlands in 
1994, to evaluate the number of Disability Adjusted Life Years (DALYs) associated with 
end~stage renal disease, and to predict developments in patient numbers and cost to socie~ 
ty until 2003. 
Setting. The Netherlands. 
i\!Iethods. The costs of five dialysis modalities and renal transplantation were estimated using 
data from a clinical study (NECOSAD~ I), data collection in dialysis centres, interviews with 
165 patients and published data. Detailed 1994 data on patient numbers and changes 
between treatment modalities were derived from the Dutch Renal Replacement Registry. 
Indirect costs were estimated using the friction cost method. DALY s were calculated from 
death notifications to the Dutch Renal Replacement Registry and estimates of severity of 
renal disease. Predictions were made using a Markov~chain modeL The predictions took 
account of expected demographic changes and trends in incidence and treatment of renal 
disease. 
Results. In 1994, 7,340 persons were being treated with renal replacement therapy. The cost 
of renal replacement therapies varied bet\veen NLG 18,000 for renal transplantation and 
NLG 142,000 for centre haemodialysis, per patient per year. Total direct medical cost of 
care for renal patients were NLG 584 million in 1994, that was about 1 percent of total 
healthcare spending in that year. Indirect cost amounted to NLG 3.5 million. Renal diseases 
were associated with a loss of 14,000 DALYs. In 2003, the number of patients in the renal 
replacement programme will be around 11,500, with expected societal costs of more than 
NLG 900 million. 
Conclusions. Renal insufficiency is a frequent health problem in the Netherlands, associated 
-with a considerable loss of DALY s and high costs to society, Renal disease was not covered 
in recent health policy documents and underreported in other national studies and health-
care registries because disease classification systems are less suitable to describe diseases 
-with multiple aetiology. 
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Introduction 
According to the data of the Renal Replacement Registry of the Netherlands (Renine), 
9243 persons were treated with a form of renal replacement on January 1, 1999 in the 
Netherlands.1 Of these patients, about half lives with a functioning donor kidney, the other 
half is treated with dialysis.1 Besides patients who have to rely on renal replacement thera-
py, some estimated tens of thousands of people suffer from reduced renal function. In 
future, dialysis or transplantation may be necessary for them. Approximately 1300 persons 
are admitted to the Dutch renal replacement programme annually, be it as a dialysis patient, 
or after having undergone a successful kidney transplant.1 A multiplicity of illnesses can 
cause chronic renal failure. In the Netherlands, hypertension (21 °/o of new patients) and 
diabetics (16% of new patients) are the most frequent causes of kidney failure. 1 In addi-
tion, age is a distinct determinant of kidney failure: the occurrence of chronic kidney fail-
ure increases from 49 per million in the age category of 0 to 15 years of age to 1290 per 
million among 65 to 7 4 year olds.1 
Dialysis and transplantation are often, in particular in the popular media, described as 
examples of expensive medical technology. Research in the eighties has shO\vn that, 
dependent on the form of treatment, dialysis cost NLG 60,000 to NLG 85,000 per patient 
per year.2-3 At that time, the costs of kidney transplantation were estimated at NLG 69,000 
in the first year after transplantation and NLG 6,200 in later years.2 The total costs within 
public health care were estimated (1988) at NLG 380 million. 2 This estimate of direct med· 
ical costs of care for kidney patients deviates from the assessment of the costs of kidney 
disease in a study by the Department of Public Health of Erasmus University Rotterdam, 
in which the costs of all diseases in the Netherlands in 1994 are described in clusters derived 
from the International Classification of Diseases-9th version.4 \Xlithin the group "Renal and 
Urogenital Diseases", a sum of 85 million '\Vas allocated to the diagnosis group "nephri-
tis/nephrosis/nephropathy", the most obvious diagnosis group for patients with chronic 
kidney failure. The substantial difference in the two estimates can be explained mainly by 
the t\vo completely different methods of approach that were used. The estimate of NLG 
380 million was arrived at following the "bottom-up" method, the estimate of NLG 85 mil-
lion was made according to the "top-down" method. The top-down method has an etio-
logic orientation: costs of medical care are classed as much as possible under the underly-
ing disease, for instance renal care for a patient with diabetic renal failure will be registered 
under diabetes mellitus. Costs that are primarily made because of additional diseases are 
accounted for under the additional disease, so as to avoid double counts. In the bottom-up 
method, in which medical consumption is examined at a patient level, double counts can-
not always be avoided. 5 Because chronic kidney failure is not a disease in itself, but a result 
of damage to the kidneys due to an array of various diseases, kidney patients have remained 
relatively invisible in the top-down method. 
The technique of renal replacement has developed further since the eighties. The afore-
mentioned cost estimates are therefore no longer up to date. Furthermore, in a report from 
the Health Council of the Netherlands it has been stated that the number of patients with 
renal replacement will rapidly increase in future years, especially in the older age groups.6-7 
The objective of our research is to determine the current costs of renal replacement 
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according to the bottom-up method, to estimate the societal costs of end-stage renal dis-
ease in 1994 and to make a prognosis of numbers of patients and cost developments for 
the period 1999-2003, based on demographic and epidemiological developments. In addi-
tion, we have made an estimate of the number of Disability Adjusted Life Years (DALYs) 
in the Dutch population, in order to provide insight in the public health burden of kidney 
disease and to compare it with the burden of other diseases. 
Data and methods 
Deji12itiom. Included in the societal costs are the direct costs within and outside public 
healthcare, the costs resulting from absenteeism and incapacity for work. In this study kid-
ney disease has been defined as the diseases that can lead to the application of renal replace-
ment, such as dialysis and transplantation. 57 different underlying clinical pictures have 
been defined by the European Dialysis and Transplant Organisation. 8 Because of this 
divers aetiology, it is not possible to reproduce a defined codification of the International 
Classification of Diseases. 
Patient numbers. Data of the number of patients with renal replacement in 1994, age and 
type of therapy of these patients and variations of the various therapies were obtained from 
the Renine Foundation. This registry has a percentage of cover of 100 percent.9 
The cost research (general remarks). The costs of the five different forms of dialysis were 
analysed in a detailed cost research, in accordance with the guidelines of the Steering 
Committee on Future Health Scenario's)O Details of the cost research have already been 
described elsewhere.ll 12 Three forms of haemodialysis (HD), namely full care centre 
haemodialysis (FCHD), limited care centre haemodialysis (LCHD) and home haemodialy-
sis (HHD), and t\vo forms of peritoneal dialysis (PD), namely continuous ambulatory peri-
toneal dialysis (CAPD) and automated peritoneal dialysis (APD), were included in the cost 
research. In the case of haemodialysis, the blood of the patient is purged of waste prod-
ucts two or three times a week by linking the patient up to an artificial kidney for a few 
hours. In the case of peritoneal dialysis, the patient himself purges the blood by applying a 
douche to the abdomen and removing it after a couple of hours. The costs entailed at start 
of dialysis and the costs of change of therapeutic modality were estimated separately, 
because of the additional costs of operations, hospitalisation, training of the patients and 
adjustments to the home. 
Direct costs witbin the public health sector. For the cost research, among others data was used 
from a prospective study in which 250 new dialysis patients from 13 Dutch dialysis centres 
were monitored, the Netherlands Cooperative Study on the Adequacy of Dialysis 
(NECOSAD- J)13 In the Case Record Forms of this study, data was recorded of the use 
of medical care (hospitalisation and intake of medicine) by the patient. The monitored hos-
pitalisation for the duration of NECOSAD (October 1993-December 1996) was itemised 
per patient group (HD versus PD), per indication (whether or not related to start of dialy-
sis or change of therapeutic modality) and by age (younger than 45 years, 45-64 years of 
age, 65 and older). For each stratum, the total monitored hospitalisation in days was relat-
ed to the duration of the follow-up in days, resulting in an estimate of the anticipated hos-
pitalisation degree per patient per year. The costs per day in a hospital ~LG 568) were 
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taken from a Dutch study from 1996.14 This cost estimate is exclusive of the costs of diag-
nostics and laboratory research. \Xle calculated these costs separately (see below). The costs 
of medication were determined in two ways. In NECOSAD the percentage of patients that 
uses erythropoietin (EPO) was determined. The costs of use of EPO were taken from cal-
culations of the Dialyse Groep Nederland (Dialysis Group of the Netherlands), a cooper-
ation of all Dutch nephrologists (NLG 101 for FCHD, J\:LG 67.50 for LCHD and HHD, 
NLG 32 for PD patients, per day). Secondly, detailed information about the use of all other 
medication was obtained from 111 patients (89 HD and 21 PD patients) at one large dial-
ysis centre. The costs of medication were estimated on an annual basis for each patient, 
using the recommended daily dose and prices as stated in the Farmacotherapeutisch 
Kompas. 15 The labour costs were calculated with the help of data provided by 13 dialysis cen-
tres participating in NECOSAD (2 academic hospitals, 7 general hospitals, 3 centres for 
active haemodialysis and 1 centre for home dialysis). For every dialysis centre, data con-
cerning the number of haemodialyses performed in 1994, the number of available 
haemodialysis stations, the number of doctors, nurses (specialised in either HD or PD), 
social workers, dieticians and technicians, were related to the number of HD and PD 
patients that were treated in 1994. Thus, the average yearly "production" (number of 
patients/ dialyses) per professional group was determined. For the calculation of the labour 
costs, the middle of the salary scale most frequently used (Functie \Xlaardering 
Gezondheidszorg) was taken, including bonuses for irregular hours. Because detailed data 
concerning labour costs of dialysis centre employees who are not in immediate contact \Vith 
the patients (e.g. reception, security and administration) were lacking, the staff expenses 
monitored in 1994 in two active dialysis centres were extrapolated to all other dialysis 
modalities. In the two centres these labour costs amounted to 20 percent of the total annu-
al labour costs. The costs of equipment that is necessary for centre haemodialysis were 
obtained from two independent dialysis centres with a separate annual balance. The total 
costs of inventory, depreciation and maintenance of equipment over 1994 and 1995 were 
divided by the average number of patients that were treated during these years. The cost of 
equipment that is only used by one patient (with CAPD, APD and home haemodialysis) was 
depreciated in seven to ten years, depending on the kind of equipment. From the adminis-
trations of five dialysis centres information was gained about the costs of other medical neces-
sities, such as artificial kidneys and dialysis fluids. For HD patients, the average cost per 
haemodialysis was multiplied with the number of dialysis treatments that a NECOSAD 
patient received on average per year (n=143). For PD patients the average costs per day 
were determined. The costs of feeding dming HD treatment were taken from previous 
research. 16 LaboratOf)·' tests are performed regularly for dialysis patients. Previous research 
has shown that the cost of laboratory research differs greatly between dialysis centres.16 In 
that study, the annual costs lay between NLG 2,145 and NLG 6,150 per patient. In the cur-
rent cost estimate the average figure from this previous study (about NLG 4,000) has been 
included as the annual cost of laboratory tests. There were no observations available on the 
volume of diagnostic services, such as a thorax photo or an electrocardiogram. An approximate 
estimate of NLG 500 per patient per year was therefore included. Furthermore, 165 
patients who participated in NECOSAD were interviewed about their JJse of other medical and 
healthcare services during the six previous months, so as to gain insight in medical consump-
tion outside the dialysis ward. From patient recalls of such use of medical services over the 
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last 6 months, the consumption on an annual basis was estimated. Patients were asked how 
often they had been in contact with the following healthcare workers: general practitioner, 
social \vorker, physiotherapist, dietician, medical specialists and other workers to be speci-
fied further on. In addition, they were asked about assistance received at home from district 
nurses, home help, alpha help and other workers to be specified in hours per week. \\lith 
the 1hnn-\Xlhitney C test, it was examined whether the differences in medical consumption 
between HD and PD patients were statistically significant. The costs of medical consump-
tion were determined by multiplying the volumes determined in this study by the tariffs that 
applied in 1994. To be able to offet a facility such as dialysis, costs are made that are diffi-
cult to differentiate to individual patients (programme costs), such as energy, cleaning and 
insurance. These costs have been estimated for haemodialysis patients by dividing the pro-
gramme costs that were observed in two independent dialysis centres in 1994 and 1995 by 
the average number of patients that was being treated. For home dialysis, CAPD and APD, 
data were obtained from one centre that in particular treated these patient groups. 
Furthermore, certain costs are associated with onset of dialysis and changes in therapeutic 
modality. At onset of therapy, usually a few acfjustments will have to be made to the home of 
those patients whose treatment mostly takes place at home, such as installation of electric-
ity and waste outlet. Data concerning these costs were obtained from a centre for home 
dialysis. Costs of surgical procedures! such as the instalment of an appropriate vascular access 
for HD patients or the placement of a peritoneal catheter for PD patients, were taken from 
previous research.17 
Direct costs outside the public health sector. During the intervie\vs the patients were also asked 
how many kilometres they lived from the dialysis centre and how often and with what kind 
of means of transport they travelled to the centre. The cost of transport were estimated 
conform guidelines. tO Time costs of patients were left aside. 
Direct costs of transplantation. The costs of kidney transplantation have not been reassessed 
\\!]_thin the framework of this costing study, because a recent Dutch study was available.18 
This study estimated the costs in the first year after transplantation at NLG 54,000 exclu-
sive of the costs of the transplantation operation. For the costs of mediation by the 
Eurotransplant Foundation, the transplantation operation and the post-surgical period until 
release from the hospital, the current COTG reimbursement rates were used (NLG 18,000). 
The single costs entailed in a kidney transplant were thus estimated at NLG 72,000. The 
annual costs of aftercare, including medication, are estimated to be approximately NLG 
18,000 per patientl8 
Total direct costs for kidnry patients in 1994. In the estimation of the total costs of care for 
dialysis and transplantation (i.e. direct costs within and outside the public health sector), the 
fact that dialysis patients regularly experience changes in therapeutic modality was explicit-
ly taken into account. This is a matter of concern to the cost estimation because variations 
of therapy involve high costs. The Renal Replacement Registry of the Netherlands provid-
ed data about the changes between therapeutic modalities in 1994 and the influx and efflux 
of patients per type of therapy. For the patients who did not change therapy during the 
whole year, the average costs per patient per year per dialysis modality were included in the 
estimation of the total costs of care. For those patients who started with a therapy or 
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changed therapy in 1994, the related extra costs were added to the average costs per patient 
per dialysis modality, in addition to which adjustments were made for the part of the year 
during which the patient was being treated. 
Indirect costs ottfside the public health sector (productivity costs). Two methods of calculation are 
available for the estimation of the costs of absenteeism and more permanent incapacity to 
work (productivity costs): the "human capital method" and the "friction cost method". The 
last method was used in the current study. The friction cost method assumes that in a situ-
ation of structural unemployment the costs of absenteeism and incapacity to work are lim-
ited to a relatively short period, the so-called friction period. Because a person who up until 
that time has not been working can replace the sick employee, the costs for society are lim-
ited to the costs of absenteeism during the friction period and possibly to the costs of 
employment agencies and training of the new worker. In 1990 the friction period lasted for 
96 days on average.19 Because the economical climate largely remained unchanged benveen 
1990 and 1994, the assumption was made that the friction period was also 96 days in 1994. 
To determine the productivity costs, 165 dialysis patients were presented with the Health 
and Labour Questionnaire during the aforementioned interviews.20 21 Absenteeism during 
the weeks prior to the interview was thereby documented in detail. For each patient, absen-
teeism as a result of kidney disease \Vas related (in hours) to the number of hours that the 
patient involved would normally work. Thus, an estimate could be made of which part of 
the absenteeism "\Vas related to the kidney disease and which part to other reasons. 
Absenteeism as a result of other disorders was left aside in this cost estimate. Only absen-
teeism that occurred during the friction period of 96 days was included in the calculation 
of productivity costs. A cost estimate \Vas made by multiplying the kidney disease associat-
ed absenteeism recorded in the current study, with the 1994 average gross annual pay per 
sex, including employer's costs.22 23 To make an estimate of the total costs of productivity 
losses of Dutch kidney patients, the per sex data from the sample survey were extrapolat-
ed to all known kidney patients in the Netherlands younger than 65 years of age. 
Disability AdJusted Life Years (DALYs). The number of DALYs associated with kidney dis-
ease in the Dutch population was calculated as follows. On request, the Renine Foundation 
provided data concerning the number of deaths of kidney patients in 1994 and the average 
age at moment of death. To calculate the number of years of life lost in 1994, the remain-
ing life expectancy at the time of death was calculated per sex from survival tables 24 and 
aggregated over all deceased kidney patients. The number of years lived with disability was 
calculated as follows. The 165 dialysis patients who were intervie ... ved each answered the 
EQ-SD questionnaire to determine their health status.11 A score system is available for the 
EQ-SDprofile to translate the health state to a valuation of the quality of life of the 
patient. 25 In order to calculate the number of years lived with a disability, the reciprocal 
value (0.27) of the average valuation of the health state of the dialysis patient (0.73) was 
taken and multiplied by the average number of dialysis patients in 1994. The number of 
years lived with a disability of transplantation patients was calculated by multiplying the 
average number of transplantation patients in 1994 by a "\Veight of 0.1 0, the reciprocal value 
of the presumed valuation of the health state of a transplanted patient. 11 The total num-
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ber of DALYs related to kidney disease was calculated by aggregating the number of years 
of life lost and the number of years lived with disability of patients on renal replacement 
therapy in 1994. 
Prog11oses. \\lith the help of a ~\Jarkov chain model,2 6 prognoses were made for the devel-
opment of the number of kidney patients and the societal costs of care for these patients 
in the period bertveen 1999 and 2003. The year 1999 was taken as point of departure 
because full information \vas available about patient numbers and types of treatment via the 
Renal Replacement Registry of the ~etherlands (Renine Foundation). In the Basic scenario 
expected developments in demography and incidence are combined. For the calculation of 
the expected incidence in the period between 1999 and 2003, the trend observed in the peri-
od 1989-1998 was continued. This was done separately for three different age categories (0-
44 years, 4.5-64 years, 65 years and older). The annual transition probabilities, the chance 
that a patient would make a transition from one treatment to another was simulated based 
on the observed transitions from one treatment to another in the period 1996-1999. To cal-
culate the expected costs in the year 2003, the cost level of 1994 was used, so as to be able 
to compare both years. In the IncidencePlus scenario, the expected extra influx of new 
patients in the oldest age category (65 and older) has been taken into account.6 7 ln this sce-
nario, additional incidence of 4 percent per year in the oldest age group was assumed, so 
that the influx of 65 year olds and older \vould be 20 percent higher after five years, com-
pared to the Basic scenario. 
Results 
Direct costs Jl!ithin and outside of the public health sect01: Table 1 shows the costs of 5 renal 
replacement therapies, per patient per year, excluding costs of start of therapy and changes 
benveen different types of dialysis. The estimated direct costs ranged from NLG 92,000 per 
year in the case of CAPD to }ZLG 142,000 per year for full care centre haemodialysis. The 
other three types of dialysis cost between NLG 111,000 and NLG 123,000 per patient per 
year. Table 2 sho\vS the additional costs surrounding the start and change of therapy for 
five dialysis modalities. The single costs of the 5 types of dialysis varied from NLG 7,000 
to NLG 15,000 and were the highest in the case of home haemodialysis, because of the 
necessary adjustments to the home. 
Total direct costs if kidnt!)'patients in 1994. Table 1 sho"\VS the average number of patients in 
1994 per type of therapy. Table 2 shows how many patients started dialysis or experienced 
a change of therapy per type of therapy. J'vfultiplication of numbers of patients and costs 
per patient resulted in an estimate of the total direct costs of healthcare for kidney patients 
in 1994 of NLG 584 million, including all costs associated with changes in therapy. An esti-
mated NLG 97 million thereof was related to kidney transplantation, and NLG 487 million 
regarded dialysis. 
Indirect costs outside the pHblic health sector. Of the 165 interviewed patients, 102 were younger 
that 65 years of age. Of these patients, 38 percent had a paid job, on average for 25 hours 
a week. 
10:5 
Cost of illness of end stage renal disease in the t\ietherlands 
Table 1: Direct costs of renal replacement therapy in 1994 a, per patient per year in NLG 
(excluding costs of start and change of therapeutic modality), and number of 
patients in 1994 
Therapeutic modality b FCHD LCHD HHD CAPD APD 
Average number of patients c 2,056 516 93 971 132 
Direct healthcare costs 
Hospitalisation 9,917 9,917 9,917 11,593 11.593 
Medication 16,930 12,651 12,651 12,538 12,538 
Personnel costs 47,662 36,473 48,056 19,101 19,101 
Equipment 5,500 5.500 10,750 368 10,225 
Medkal supplies 18,590 16,445 18,590 34,675 54,750 
Food 2,000 2.000 
Laboratory research 4,000 4,000 4,000 4,000 4,000 
Other diagnostics 500 500 500 500 500 
Extramural care 4,550 4,550 4,550 7,370 4,550 
Programme costs 10,757 10,757 2,419 2,419 2.419 
Direct costs outside healthcare 
Travel costs 22,097 22,097 986 986 986 
Total per year 141,505 123,961 111,315 92,165 118,394 
a The annual costs after kidney transplantation were estimated at :t'\LG 18,000 per patient. The costs of 
transplantation were taken from the literature and therefore cannot be reproduced exactly in cost cate-
gories. The average number of persons \vho had a transplant in 1994 was 3,565. 
b FCHD :::: full care centre haemodialysis, LCHD :::: limited care centre haemodialysis, HHD :::: home 
haemodialysis, CJ\.PD :::: continuous ambulatory peritoneal dialysis, APD = automated peritoneal dialysis 
c Data received on request from the Renine Foundation, Rotterdam 
Table 2: Direct costs of start of renal replacement therapy and change of therapeutic 
modality, per patient per episode in NLG, and number of patients involved in 
1994 "b 
Therapeutic modality c FCHD LCHD HHD CAPD APD 
Number of patients d 1,242 262 32 588 121 
Hospitalisation 4,409 4,409 4,409 5,640 5,640 
Adjustments to the home 7,739 967 967 
Surgery 2,419 2,419 2,419 1,451 1,451 
Total costs at start I change of therapy 6,828 6,828 14,567 8,059 8,059 
a This concerns patients who Ilrst started with a dialysis in 1994 and patients who changed beb.veen tv.ro 
types of therapy in 1994. Data concerning numbers of patients were obtained on request from the 
Renine Foundation, Rotterdam 
b The single costs surrounding a kidney transplant were estimated at ~LG 72,000 per patient. The costs 
of transplantation were taken from the literature and can therefore not be reproduced exactly in cost cat-
egories. In 1994 450 persons undenvent transplantation 
c abbreviations: see table 1 
d number of patients who started \vith this therapeutic modality or who changed to this therapeutic 
modality 
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Men more often had a paid job (57%) than women (18%). Of the persons with a paid job, 
5 persons (13%) had been absent from work because of their kidney disease (on average 2 
days in a period of t\vo weeks). An estimate was made that on an annual basis a person was 
absent for 3.4 percent of working hours because of kidney disease. For a male kidney 
patient, the cost of productivity loss amounted to ~LG 1,820 a year, taking into consider-
ation that the average appointment among working dialysis patients was 0.68 full-time 
equivalent. For women (part-time factor 0.58 full-time equivalent) the cost of productivity 
loss was estimated at NLG 1,120 per worker per year. Extrapolation of the kidney disease 
associated absenteeism found in this study to the Dutch population of kidney patients 
younger than 65 years of age (2,959 men and 2,166 women) resulted in a cost estimate of 
absenteeism of kidney patients of approximately NLG 3.5 million in 1994. 
Disability Ad;usted Life Years (DALYs). In 1994, 886 kidney patients died (531 men and 355 
women) at an average age of 67.8 years. The remaining life expectancy of men of that age 
was 12.65 years, for women it was 16.93 years. As a result of premature death, 12,727 years 
of life were therefore lost (6,717 regarding men and 6,010 regarding women). In 1994 an 
average 3,768 patients were dialysed and an average 3,565 patients lived with a donor kid-
ney (see table 1). The number of years lived with a disability for dialysis patients (disability 
weight 0.27) was 1,017 and for transplantation patients (disability weight 0.10) it was 356. 
The total number of DALYs of 14,100 is mostly caused by years of life lost (12,727) and 
to a lesser extent by years lived with a disability (1,373). 
Prognoses. On 1 January 1999, some 9,250 patients in the Netherlands received renal 
replacement therapy. Expectations are that by 1 January 2004 this number will have risen to 
11,300 in the basic scenario and to 11,600 in the IncidenceP/m scenario. Figure 1 shows the 
expected development in the societal costs of care for kidney patients between 1994 and 
Figure 1: Expected increase in health care cost of end stage renal disease patients 
between 1994 and 2003 in two scenarios (at cost level of 1994) 
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2003. In 2003 expectations are that the societal costs of care for kidney patients will have 
risen to around NLG 900 million. In the IncidencePius scenario, that takes an additional influx 
of approximately 300 over 65 year olds into account, the costs will rise to NLG 934 mil~ 
lion. 
Discussion 
In this study, the direct costs of care for end~stage renal disease patients were estimated at 
NLG 584 million in 1994. The indirect costs of kidney disease, estimated with the friction 
cost method, amounted to approximately NLG 3.5 million. In 1994, kidney disease was 
associated with a loss of about 14,000 DALYs. Prognoses show that as a result of ageing 
and trends in the influx in the dialysis programme, the intake of additional patients will be 
approximately 2000 patients up to and including 2003. Expectations are that the societal 
costs will increase to approximately NLG 900 million. 
In 1994, about 1 percent of the total expenditure for healthcare that year (NLG 59.4 
thousand million) was spent on end~stage renal disease treatment. It comes as no surprise 
that renal replacement, dialysis in particular, is expensive. In the eighties, Dutch researchers 
estimated dialysis costs at around NLG 60,000 to NLG 85,000 per patient per year2 3 The 
current cost estimate exceeds that by approximately NLG 30,000 to NLG 60,000, depend-
ing on the type of dialysis. However, the cost per dialysis remained roughly the same, as the 
cost per dialysis treatment in 1994 (NLG 593) is almost similar to the cost per treatment in 
1983 (NLG 467 2), adjusted for the cost development in the public health sector between 
1983 and 1994 (NLG 580)26 The NLG 30,000 to NLG 60,0000 cost difference can main-
ly be accounted for by high travelling expenses, which were not included in previous 
research, the introduction of erythropoietin and the increased dialysis frequency. The trav~ 
elling expenses of dialysis patients who dialyse in a centre amount to about NLG 20,000 a 
year, because the majority of the patients travel to the dialysis centre by taxi. Erythropoietin 
is an expensive medicine ~LG 8,700- NLG 13,000 per patient per year) which stimulates 
the production of red blood cells in kidney patients and which is used by up"vards of 80% 
of all dialysis patients. A further factor associated with the increase in costs is the fact that 
the average frequency of haemodialysis has risen since the eighties from more than nvo 
times per week (115 dialyses per patient per year) to nearly three times a week (143 dialyses 
per patient per year). 
The indirect non~healthcare costs, costs of production losses as a result of absenteeism, 
were estimated at NLG 3.5 million in 1994. This estimate was arrived at by the extrapola~ 
tion of observations in dialysis patients to the entire population of kidney patients. It is 
possible that this estimate is an underestimation of the actual costs, because the study pop-
ulation concerned stable dialysis patients and a lot of absenteeism takes place at the onset 
of renal replacement and during change of therapy. On the other hand, measurements in 
dialysis patients could also have led to an overestimation of the costs, because the percent~ 
age of active employees may be higher among transplanted patients than under dialysis 
patients. However, no data on this subject was available. Because the indirect non~ health~ 
care costs form a small part of the total societal costs in comparison \Vith the direct med-
ical costs, the influence of an overestimation or underestimation of the productivity costs 
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on the total societal costs will. not be substantial. However, our decision to value the pro-
ductivity loss with the friction cost method rather than the human capital method has sin-
cerely influenced our results. \Y./e have chosen this method because we believe that the fric-
tion cost method does more justice to the situation of structural unemployment seen on 
the Dutch labour market in 1994, than the human capital method. In our study, the indirect 
costs only form 0.6 percent of the total costs. fviany kidney patients no longer have a paid 
job at the moment they start with renal replacement therapy. Of the population of dialysis 
patients interviewed by us, 41% had been declared wholly or partially disabled. The mone-
tary value of absenteeism and the lifelong production losses of around 5,000 kidney 
patients in \vorking life would certainly amount to a few hundred million guilders. 
According to tl1e human capital method our estimate of societal costs would turn out to be 
much higher. 
The current estimate of direct costs of care for kidney patients strongly deviates from the 
estimated costs of kidney disease in the report "Costs of Illness in the Netherlands, 1994" 
(further to be called iJ'v1GZ report).4 In that estimate the total costs for the diagnostic group 
"nephritis I nephrosis I nephropathy" were NLG 85 million. This estimate includes kid-
ney patients not yet dependent on renal replacement therapy. There are tvm ways to explain 
the large difference. Firstly, the hospital costs in the i1fGZ report were analysed using 
admittance data from the Landelijke J\fedische Registratie (Li\IR), in which dialysis hardly 
occurs.4 Secondly, the iiviGZ report has an etiologic orientation: costs of care are classed 
as much as possible under the disease that lies at the root of the care so as to avoid double 
counts. Costs of kidney disease as a result of diabetes are therefore accounted for under 
diabetes. For a group of disorders with multiple aetiology, such as kidney disease, the iJ'\.fGZ 
report therefore gives an underestimation of the actual costs. The discrepancy between 
both cost estimates is even more marked if it is taken into account that there is another 
group of a couple of ten thousand patients with limited kidney functioning, who in the 
future may need dialysis or transplantation (the so-called pre-dialysis patients).27 Our bot-
tom-up cost estimate only relates to those kidney patients who have reached the final stages 
of the disease and not to pre-dialysis patients. The costs for the care of predialysis patients, 
the indirect costs as a result of production losses and DALY s of this group have not been 
included in this paper due to a lack of available data. Fact is that our cost estimate of :NLG 
587 million would be much higher if these patients in the preliminary stages of renal insuf-
ficiency had been included in our calculations too. 
The substantial differences bert:veen the costs of the various forms of dialysis and trans-
plantation leads one to suspect that a policy aimed at substitution of patients from more 
expensive to cheaper types of treatment would be advisable. In a cost -effectiveness analy-
sis, we demonstrated that such a policy only has a limited influence on the total costs of the 
renal replacement programme of the ~ etherlands.ll By substituting patients from more 
expensive types of therapy such as centre haemodialysis to cheaper forms of therapy such 
as CAPD and kidney transplantation, more changes of therapy are induced overall. The 
savings resulting from substitution hardly "\veigh up to the additional costs of changes of 
therapy. The segmentation of patients over the various types of therapy is already reason-
ably optimal in the ~ etherlands, in a sense that patients that qualify for the use of less 
expensive types of therapy are already being treated "\Vith these modalities. 
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It is our opinion that far more attention should be paid to the secondary prevention of 
renal disease. The deterioration of the kidney function can be delayed in patients with a kid-
ney disorder, among others by better control of hypertension, low-protein foods and the 
use of specific medication such as angiotensin-com'ertin enzyme (ACE)-inhibitors.28 29 
According to model calculations, dialysis and transplantation could be delayed for 5.8 years 
for insulin dependent diabetics who receive an intense treatment, in comparison with 
patients who receive a conventional treatment. 30 The feasibility of the realisation of results 
of such modelling studies in clinical practice should be object of further research. 
The number of DALYs calculated by us, 14,000, indicates that the public health burden 
of kidney disease is substantial. In the Volksgezondheid Toekomst Verkenning (Public 
Health Status and Forecasts (PHSF)), which was published in 1997, the "burden of disease" 
of a large number of diseases and disorders was estimated.31 The number of DALYs for 
kidney disease is of the same order of the number of DALYs associated with diseases as 
AIDS, Parkinson's disease, influenza and schizophrenia. Despite the high costs and the sub-
stantial burden of disease, kidney disease has hardly been visible in important research and 
policy documents, such as the i1IGZ report,4 and the Public Health Status and Forecasts.31 
32 In the 1993 and 1997 Public Health Status and Forecasts reports, diseases and disorders 
were predominantly selected based on mortality burden, disease burden, costs of disease 
and prevention possibilities.31 32 Kidney disease was not selected as a subject for the PHSF, 
\vhich illustrates the previously described invisibility of kidney disease in the various health-
care registrations and the fact that kidney disease is spread over several ICD-9 chapters. \X?e 
conclude that a classification system such as ICD, entirely orientated towards the aetiology 
of diseases, is not suitable to classify diseases with multiple aetiology. In future versions of 
the ICD, kidney disease should not only be included in the diagnostic group "renal and uro-
genital diseases", but also incorporated as a complication of disorders in other chapters. 
In the Netherlands, the prioritising of healthcare research on the basis of societal rele-
vance has received a lot of attention over the past years. 33 The Advisory Council on Health 
Research, the Healthcare Insurance Board and the Council for :Niedical and Health Research 
all reflected on the selection of research subjects for the near future. Kidney diseases could 
hardly be found in these initiatives either. In this article, we have shown that kidney disease 
can lead to high societal costs and to a substantial burden of disease. As van Roijen en 
Rutten rightly remarked in an article in this journal,34 this cannot in itself be a legitimisa-
tion to spend more healthcare resources for the prevention and treatment of kidney 
patients. The results of our study can however be helpful in establishing priorities in fun-
damental and applied studies. Kidney disease certainly deserves to be a subject of such 
studies. 
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Abstract 
This paper examines the cost-effectiveness of end-stage renal disease (ESRD) treatments. 
Empirical data on costs of treatment modalities and quality of life of patients were gath-
ered alongside a clinical trial and combined with data on patient and technique survival 
from the Dutch Renal Replacement Registry. l\ 1Iarkov-chain model, based on the actual 
Dutch ESRD program as of January 1st 1997, predicted the cost-effectiveness and cost-
utility of dialysis and transplantation over the 5-year period 1997-2001. Total annual costs 
amounted to NLG 650 million (1.1 % of the healthcare budget). Full care centre 
haemodialysis was found to be the least cost-effective treatment, while transplantation and 
Continuous Ambulatory Peritoneal Dialysis were the most cost-effective treatments. The 
lvfarkov-chain model was used to study the influence of substitutive policies on the overall 
cost -effectiveness of the ESRD treatment program. The influence of such policies was 
found to be modest in the Dutch context, where a high percentage of patients is already 
being treated with more cost-effective treatment modalities. In countries where full care 
centre haemodialysis is still the only or the major treatment option for ESRD patients, sub-
stitutive policies might have a more substantial impact on cost-effectiveness of ESRD treat-
ment. 
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Introduction 
Six major treatment modalities for patients \vith end-stage renal disease (ESRD) may be dis-
tinguished. Haemodialysis (HD), the cleaning of the blood from waste products through an 
artificial kidney, was introduced in 1960.1 Haemodialysis can either be performed by the 
patient at home (home haemodialysis- HHD), or in a dialysis centre or hospital, with more 
(limited care haemodialysis - LCHD) or less active (full care centre haemodialysis - FCHD) 
input of the patient in the treatment. Kidney transplantation (TX) with non-related donor 
organs has been possible since 1962 and eliminates the necessity of dialysis as long as the 
graft is not irreversibly rejected by the recipient.2 Peritoneal dialysis (PD), the removal of 
waste products through a cleaning fluid in the abdominal cavity, became clinically available 
in the late 1970s. 3 PD has tvm main treatment varieties, either with manual exchange of 
dialysis fluid (continuous ambulatory peritoneal dialysis - CAPD) or "\\-ith automated 
exchange of dialysis fluid at night (automated peritoneal dialysis - APD). 
Although many publications have considered the cost-effectiveness of ESRD treatment, 
few published studies were based on empirical data \Vith regard to costs of treatment, sur-
vival and quality of life of patients. ~lost studies combined empirical data in one of these 
fields with literature-based evidence or estimations in the other fields. 4- 11 One published 
cost -effectiveness analysis included utilities elicited from ESRD patients.12 .i\fost studies 
that have considered two or more treatment options for ESRD patients described a hierar-
chy in the cost-effectiveness of treatments. I(jdney transplantation is described as having 
the best ratio between costs and effects of treatment, followed by either HHD or CAPD.B-
10 1'Iost studies reported that haemodialysis, especially when the patient does not contribute 
actively to the treatment (FCHD), resulted in the highest cost per life year gained.6-l113 To 
the best of our knowledge, the cost-effectiveness of the more recently (1980s) developed 
technique of APD has not previously been studied. 
\"X7e performed a cost-effectiveness analysis of ESRD treatments, alongside a clinical study 
on the adequacy of dialysis (the NECOSAD study). \\ie collected empirical data on costs 
of treatment and quality of life and combined these with data on patient and technique sur-
vival from the Renal Replacement Registry of the C\etherlands (RENINE) 1 4 A Markov-
chain model was used to assess the cost-effectiveness and cost-utility of treatment modali-
ties over a period of 5 years. \Xle also used the l'viarkov-chain model to estimate the costs of 
the ESRD treatment program nation-wide and to evaluate the influence of substitution 
bet\veen therapeutic modalities on the estimated societal costs and cost-effectiveness of the 
Dutch ESRD program. 
Subjects and methods 
The NECOSAD study 
This cost-effectiveness analysis was performed alongside a clinical study on the adequacy of 
dialysis treatments, the NECOSAD study.1.5 Thirteen Dutch dialysis centres (27 °/(J of all 
centres) consecutively included all new dialysis patients \vho began treatment between 
118 
Chapter 7 
October 1993 and April 1995 in the :-<ECOSi\D study. Data for the cosHffectiveness 
analysis \Vere gathered between October 1993 and December 1996. 
Quality of life assessments 
We interviewed 165 dialysis patients, of whom 135 participated in the NECOSAD study. It 
was known at the onset of the present study that only a fe\v patients in the NECOSAD 
study were being treated with APD. Therefore, 30 extra APD patients "\vere recruited from 
three hospitals with high numbers of APD patients. The Medical Ethical Committees of all 
16 hospitals involved in the study approved the study. Inclusion criteria for participation in 
the quality of life interviews were: age above 18 years, written informed consent from the 
patient, the same treatment for at least 3 months, adequate eyesight to enable the comple~ 
tion of questionnaires and an adequate understanding of the Dutch language. Trained inter-
viewers interviewed patients at home. Demographic data and data on number and type of 
comorbid diseases were collected at the interview. Quality of life of patients "\Vas assessed 
with the following instruments: EuroQol (EQ-.SD) Instrument,16 17 Standard Gamble,18 
and Time Trade Off.19 The last two methods are preference based measurements, allowing 
the expression of quality of life as a single indicator, usually a number between 0 and 1, 
with 0 representing death and 1 representing full health. This single indicator can be used 
for the calculation of (cost per) Quality Adjusted Life Year (QALY). It is well-known that 
patients who actually experience an impaired health state value their own health state high-
er than healthy persons without experience of the disease. 20 21 In addition to the valuations 
elicited from ESRD patients, we applied data from a UK population sample on the valua-
tion of health states 22 23 to the health status as described by ESRD patients in the present 
study. Therefore, we could dispose of both patient and general population valuations of the 
patients' health states. Differences between treatment groups have been tested by means of 
One 'S/ay Analysis of Variance, Pearson Chi-square test and Kruskall-\X:'allis test (where 
appropriate). A P-value of 0.05 was chosen as cut off for statistical significance. 
The assessment of quality of life of transplanted patients fell outside the scope of this 
study. There were no published Standard Gamble or Time Trade Off scores from trans-
planted Dutch patients available to enable comparison with d1e scores of dialysis patients. 
Studies have shown that quality of life of transplanted patients is close to the quality of life 
as found in the general population. 24~25 A recent study found a 23 percent increase in Time 
Trade Off scores in dialysis patients \vho had received a successful kidney transplant.12 
Based on these studies, and in comparison \Vith the valuations we found for dialysis patients 
(see results section) we have assumed a quality of life factor for transplanted patients of 
0.90. The influence of this assumption was tested in sensitivity analyses. 
Costs of treatment 
The costing study was designed to include the total costs of care for dialysis patients, 
including both dialysis-related and other health care costs. \Xi'e have distinguished costs in the 
first year of treatment, including extra costs at start of treatment, such as hospitalisations, 
vascular access operations and training of patients, from costs in second and later years of 
treatment. In general, resource use was valued at real costs, not charges. A societal per-
spective was taken for the cost-analysis. Time costs and indirect costs resulting from work 
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loss and inefficiency at work have not been included in this study. Costs were calculated at 
a 1996 price level. Costs will be expressed in Dutch Guilders (1 i\:LG = £ 0.31, 1 i\:LG = 
$ 0.50, conversion rates September 1997). 
Data on volumes of resource use, including hospitalisations and use of medication, were 
obtained from the N"ECOSAD study. All registered hospitalisations in the study period 
were related to the total length of follow-up (the hospitalisation rate). Therefore, costs of 
hospitalisation were based on a calculation of hospital days per patient year at aggregate 
level. Hospitalisation is strongly related to the age of the patient.26 '\i/e calculated the costs 
of hospitalisations separately for 3 age groups: 0-44 years, 45-64 years and 65 and older. If 
patients experienced a transition from one therapy to another, the hospitalisation in the first 
month after the change was attributed to the old treatment modality. Such hospitalisations 
are assumed to be associated with the failure of the old therapy and not with the start of 
the new therapy.27 The costs of one day in hospital were taken from a recent Dutch study.28 
Data on the work force in dialysis centres were gathered by means of a questionnaire sent 
to centres participating in the NECOSAD study. Labour costs were calculated using medi-
um salaries from the gross salary scales for healthcare organisations. ~ephrologists servic-
es \Vere casted on the basis of the reimbursement rate of NLG 7,640 per patient per year, 
after correction for differences in time spent on patients in different treatment modalities. 
Costs of staff not directly working with patients, such as reception, safety and administra-
tion, were obtained from t\vo independent dialysis centres. Costs of materials, equipment, 
meals, housing and energy were obtained from the cost-accounting systems of five of the 
sixteen dialysis centres participating. Recent data (1995) on the annual costs of laboratory 
services for dialysis patients were available from a study performed in 4 Dutch hospitals.29 
The annual costs of diagnostic services were estimated from standard protocols of the 
Dutch Organisation of Nephrologists. The costs of vascular access surgery were taken 
from a recent Dutch study)O Data on resource use outside the hospital and dialysis centre 
(primary care services) were obtained directly from patients at the quality of life interviews. 
The ~ ational Association for Home Care provided actual cost data of primary care. Travel 
distance and frequency of travelling from and to hospital and dialysis centres was covered 
at the patient interview. Travel costs were based on reimbursement rate (taxi rides) or val-
ued at a level acceptable under Dutch tax laws (own transport). The costs of transplanta-
tion fell outside the scope of this study. A recent Dutch clinical trial documented costs after 
transplantation in 127 patients who received a renal transplant.3 1 The costs of 
Eurotransplant and the cost of the transplantation operation, based on the reimbursement 
level, yvere added to the cost figures from that study. Total costs Yvere estimated to be NL.G 
90,000 in the first year and NLG 18,000 in second and later years after transplantation. 
Markov-chain model 
A Markov-chain describes the dynamics in a population that is divided over a number of 
states and can be used to predict patient numbers in those states in the (near) future.32 33 l\ 
:\.Iarkov-chain is a discrete statistical process in \vhich the future distribution of the popu-
lation over the states depends on the present distribution, transition probabilities from one 
state to another and the inflow of new patients. ~1arkov-chains have been used to predict 
resource requirements in renal units,34 for regional planning of ESRD facilities 35 and to 
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assess the cost-effectiveness of immunosuppressive regimens after transplantation.36 The 
actual patient numbers in the Dutch ESRD program as of 1st of January 1997 were used 
as a starting-point. Predictions were made for a period of 5 years (1997-2001). For a more 
detailed description of the Markov-process, see the Appendix. 
Approximately 8300 patients were receiving ESRD treatment on January 1st 1997, equal-
ly divided between dialysis and transplantation.37 In the 1./farkov-model, 36 different states 
have been defined (combinations of 6 treatment modalities, 3 age-groups and 2 treatment 
stages). The 6 treatment modalities were FCHD, LCHD, HHD, CAPD, APD and TX. 
Patients were divided into three age-groups: 0-44 years, 45-64 years, and 65 years and older. 
\'Cithin each treatment two stages were distinguished: the first year versus the second and 
later years on the same treatment modality. Two irreversible states, death and recovery of 
kidney function, \Vere added to the model. Patients who returned to dialysis after recovery 
of kidney function were regarded as new patients. 
The matrix of transition probabilities \Vas constructed based on the actual treatment his-
tories of all patients in the Dutch Renal Replacement Registry between 1994 and 1996 
(n==11 ,192). This registry covers all Dutch ESRD patients.14 Death rates and technique fail-
ure rates, related to the necessity to change therapy because of irreversible problems, were 
incorporated in this matrix of transition probabilities. The expected inflow of new patients 
into the ESRD program is both dependent on the incidence of ESRD in the three age-
groups and on demographic developments. A simple linear regression analysis with time as 
the independent variable showed that the inflow of new patients per million population 
over the 10-year period 1987-1996 increased significantly (t > 2.34, df == 8) in all 3 age-
groups. These linear trends were extrapolated to the period 1997-2001. Figures on expect-
ed population numbers were derived from Statistics Netherlands.38 The distribution of new 
patients over the 6 treatment modalities reflected the actual experience in the Dutch ESRD 
program between 1994 and 1996. The linear trend in the number of transplantations per-
formed between 1987 and 1996 was also significant (t = 7.22, df = 8) and therefore extrap-
olated to the period 1997-2001. 
The Base-case 1farkov-chain model that predicts future patient numbers in the 36 defined 
states was supplemented with information on costs of treatments and quality of life of 
patients in different treatment regimens. The cost per life year gained was calculated as total 
discounted costs over the 5 year period related to total discounted life years gained (see 
Appendix). The cost per Quality Adjusted Life Year (QALY) gained was calculated similar-
ly. A discount rate of 5 percent "\Vas used, both for costs and effects of therapy. Box 1 sum-
marises the input into the Base-case 1\hrkov-chain model. 
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Box 1: Input in Base-case iviarkov-chain model 
• Period of prognosis: 1997-2001 
• Patient population at start: Dutch ESRD population as at 1.1.1997 
• Inflow of new patients in 3 age-groups: extrapolation of linear trend over 
period 1987-1996 
• Population prognoses 1997-2001: estimates from Statistics Netherlands 
• Division of new patients over six treatment modalities: as observed 1994-
1996 
• Number of transplantations per million population: extrapolation of linear 
trend over 1987-1996 
• Division over five dialysis modalities after rejection of graft: as observed 
1994-1996 
• Transition probabilities: calculated with data of 11,192 prevalent ESRD 
patients in period 1994-1996 
• Discount rate: 5% 
• Cost of treatments in 1 sr and znd and following years: estimates from costing 
study 
• Quality of life: EQ-5Dindox values as estimated from UK population sample 
23 
Sensitivity analyses I Scenario-analyses 
Several one-way sensitivity analyses were performed to assess the stability of the conclu-
sions derived from the Base-case scenario. The J'vfarkov-chain model was used to study the 
predicted cost per QALY if quality of life valuations from different perspectives (patient 
versus general population) were incorporated in the model. The model was also used to 
explore several scenarios for cost reduction, such as substitution of patients to less expen-
sive modalities. 
Results 
Quality of life 
Table 1 lists the main patient characteristics of the treatment groups, average Standard 
Gamble scores, Time Trade Off scores and EQ-SDvAs scores, and general population val-
ues for the ESRD patients' health states. Because the number of HHD patients in the pres-
ent study was very small (n=S) we have pooled the HHD and LCHD groups. Both treat-
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Table 1: J'vfain patient characteristics (mean, (SD) or%) according to treatment modality, 
quality of life outcomes and general population valuation for ESRD patients' 
health states 
FCHD group a LCHD group a CAPO group a APD group a 
(n=46) (n=23) b (n=59) (n=37) 
Age c 67 (9) 47 (IS) 56 ( 13) 55 ( 13) 
Male(%) 50 57 69 49 
No. of comorbid diseases 2.6 (1.9) 1.9 (1.2) 2.6 (1.9) 2.3 ( 1.6) 
Months on dialysis IS (4) IS (3) IS (4) IS (8) 
Patient SG score 0.84 (0.21) 0.91 (0.13) 0.81 (0.24) 0.74 (0.24) 
Patient TTO score 0.87 (0.20) 0.93 (0.11) 0.86 (0.23) 0.93 (0.14) 
EQ-SDVAS d 0.58 (0.19) 0.65 (0.14) 0.61 (0.20) 0.61 (0.19) 
General population valuation e f 0.66 (0.29) 0.81 (0.24) 0.71 (0.29) 0.81 (0.19) 
a FCHD :::: full care centre haemodialysis, LCHD :::: limited care centre haemodialysis, CAPD =- continu-
ous cycling peritoneal dialysis, APD :::: automated peritoneal dialysis 
b including 5 HHD patients 
c p < 0.01 
d divided by 100 
e according to Dolan 23 
f p < 0.05 
ments require active patient participation. Table 1 shows that the four treatment groups 
(FCHD, LCHD/HHD, CAPD, APD) were comparable with regard to sex, time on dialysis 
and number of co morbid diseases. LCHD /HHD patients were younger on average than 
patients treated with other dialysis modalities. Patients' SG, TTO and EQ-SDVAS scores 
were not statistically different across the four treatment groups, indicating that quality of 
life of patients in the four treatment groups was comparable. The general population valu-
ations of the patients' health states were significantly higher for APD and LCHD /HHD 
patients (0.81) than for CAPD (0.71) and FCHD patients (0.66). The ranking of the quali-
ty of life of patients in tl1e four treatment groups appeared to differ depending on the per-
spective (patient / general population) and valuation method. For instance, APD patients' 
ITO scores were equal to or higher than other groups' ITO scores, while APD patients' 
SG scores were lower than other groups' SG scores. Because of the somewhat conflicting 
results of quality of life measurements and because valuations derived from the general 
population are considered most appropriate in a cost-effectiveness analysis,39 we decided to 
incorporate the general population valuations in the Base-case scenario and to apply patient 
valuations in sensitivity analyses. 
Costs of treatment 
Table 2 shows the results of the costing study. The start of PD treatment (CAPD and 
APD) was associated with higher hospitalisation costs than start of HD treatment, because 
approximately half of the PD patients received a clinical training to perform the fluid 
exchanges themselves. The average duration of hospitalisation at start of dialysis was 8.5 
days. PD patients were hospitalised for 10.0 days and HD patients for 7.8 days on average. 
Patients in the oldest age group were hospitalised 3 more days at start of therapy than 
patients in the youngest age group. Patients who started with HHD therapy experienced 
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Table 2: Results of costing study (all figures in NLG) 
Haemodialysis Peritoneal Dialysis 
FCHD a LCHD a HHD a CAPD' APD a 
Costs associated with start/change of therapy 
Hospitalisation at start of dialysis 
age< 45 2711 2711 2711 3733 3733 
age 45-64 3047 3047 3047 5036 5036 
age<: 65 6030 6030 6030 9003 9003 
Surgery at start dialysis 2500 2500 2500 1500 1500 
Housing adaptations 8000 1000 1000 
Annual costs, excluding costs at start/change of therapy 
Total staff cost 49237 37671 49644 19714 19714 
Total material cost 26090 23945 29340 35043 64975 
Cost of hospital infrastructure 11120 11120 2500 2500 2500 
Hospitalisation 
age< 45 7606 7606 7606 4385 4385 
age 45-64 7918 7918 7918 10497 10497 
age 2>: 65 12519 12519 12519 20380 20380 
Laboratory services 4000 4000 4000 4000 4000 
Other healthcare services 4550 4550 4550 7370 4550 
Diagnostic services 500 500 500 500 500 
Drugs 17501 13077 13077 12960 12960 
Travel cost 22842 22842 1019 1019 1019 
a FCHD ~ full care centre haemodialysis, LCHD ~ limited care centre haemodialysis, HHD ~ home 
haemodialysis, CAPD ~ conrinuous cycling peritoneal dialysis, APD ~ automated peritoneal dialysis 
higher initial costs than other patient groups, because adaptation of water and electrical 
supplies at home was required. 
Table 2 also shows the breakdown of the annual costs of treatment of five dialysis modal-
ities. Staff costs were higher for any form of haemodialysis than for CAPD and i\PD. The 
average nurse to patient ratio was 1 to 2.29 for FCHD, 1 to 3.61 for LCHD and 1 to 13 for 
CAPD and APD. Nursing costs for HHD patients were high because patients received 
assistance from a nurse at home. Costs of equipment "\Vere found to be higher for HHD 
and APD patients, reflecting the fact that equipment at home is not shared among patients. 
Costs of medical supplies, such as dialysis fluids and disposables were higher for PD 
patients, especially APD, than for HD patients. Costs of infrastructure, such as housing, 
energy and cleaning were higher for LCHD and FCHD patients than for the three treat-
ment modalities performed by patients at home. The use of primary care healthcare serv-
ices was not significantly different across patient groups, with the exception of a higher use 
of district nurses by CAPD patients. It was found that 5 percent of CAPD patients need-
ed the assistance of district nurses at the exchange of dialysis fluids. The higher costs of 
medications for FCHD patients were mainly associated with a higher use of Erythropoietin 
(EPO). Travel costs of FCHD and LCHD patients were higher than travel costs of other 
patients, reflecting the fact that these patients were transported to and from the dialysis cen-
tre by taxi. Cost differences between treatment modalities were also associated with differ-
ences in hospitalisation. The annual number of hospital days was highest in patients of 
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older age (average number of days in hospital per patient year 10, 16 and 27 for patients in 
the youngest, intermediate and oldest age-groups, respectively). PD patients were hospi-
talised more often than HD patients (20.5 days versus 17.5 days per patient year, respec-
tively). This reflects a higher technique failure among PD patients. 
Table 3 presents the cost figures that \vere entered into the Base-case scenario of the 
fvfarkov-chain model, distinguished into three age-groups and nvo stages of treatment. The 
cost figures for the first year result from summing both the annual costs and costs associ-
ated with start and change of therapy. Average annual costs ranged from NLG 18,000 for 
transplantation to NLG 95,000 for CAPD to NLG 146,000 for FCHD. Annual costs of 
HHD, APD and LCHD varied from NLG 115,000 to NLG 128,000. This implies that the 
annual costs of the most expensive dialysis therapy (FCHD) were 50 percent higher than 
annual costs of the least expensive dialysis therapy (CAPD). 
Table 3: Total cost of treatment in first versus later years, by treatment modality and age-
groups (all cost figures in NLG) 
0-44 45-64 65+ average 
FCHO year I 148,700 149,300 156,900 152,666 
FCHO later years 143.400 143,800 148,400 145,757 
LCHO year I 130,500 131,200 138,800 134,531 
LCHO later years 125,300 125,600 130,200 127,622 
HHO year I 125,500 126,100 133,700 129,456 
HHD later years 112,300 112.600 117,200 114,547 
CAPO year I 93,700 101.100 115,000 102,839 
CAPO later years 87,500 93,600 103,500 94,699 
APO year I 120,800 128,300 142,100 129,951 
APO later years 114,600 120.700 130,600 121,811 
Transplantation year I 90,000 90,000 90,000 90,000 
Transplantation later years 18,000 18,000 18,000 18,000 
Cost per life-year gained and cost per quality-adjusted life year gained 
The predicted average cost per life year gained of all ESRD treatments over the 5-year peri-
od 1997-2001 was NLG 78,700, the predicted average cost per QALY was NLG 98,300. 
These predictions reflect the current and anticipated distribution of patients over the 
cheaper (transplantation) and more expensive (dialysis) treatments. The average cost per life 
year gained for the five dialysis modalities only was estimated to be ~LG 133,100, versus 
NLG 25,000 for transplantation. The predicted cost per QALY was NLG 190,000 for dial-
ysis and NLG 27,800 for transplantation. Figure 1 shows remarkable differences in cost per 
life year gained and cost per QALY for the 3 age-groups, reflecting the use of cheaper treat-
ments (transplantation and CAPD) in the younger age groups and more expensive treat-
ment (FCHD) in the oldest age group. Among the different dialysis modalities, the ratio of 
costs to life years gained and costs to QALY's was most favourable for CAPD and least 
favourable for FCHD, with intermediate positions for LCHD, HHD and APD. The esti-
mated discounted costs of the Dutch ESRD treatment program over the 5 year period 
1997-2001 were ~LG 3.24 billion. This approximated an annual eguivalent of NLG 650 
million. 
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Figure 1: Cost per life year gained (tvJo left sets of bars) and cost per QALY (ru.ro right 
sets of bars), according to three age groups- Base-case scenario 
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The J\1arkov-chain model was run \Vith the following deviations from the Base-case sce-
nano: 
1. ESRD patients' Standard Gamble valuations instead of societal valuations; 
2. ESRD patients' Time Trade Off valuations instead of societal valuations; 
3. Quality of life after transplantation not better than but equal to dialysis (QALY factor 
of 0.81 instead of 0.90); 
4. Assuming a higher number of transplantations, from a current 30 transplantations per 
million population 40 to 38 per million population. This is due to take effect in 1998, 
when new donor legislation will be introduced.41 This scenario resulted in 273 (= 10 %) 
more transplantations over the 1998-2001 period than in the Base-case scenario; 
5. Assuming a level of 44 transplantations per million population, starting from 1998. This 
scenario resulted in 651 25 %) extra transplantations compared to the Base-case sce-
nano; 
6. Assuming that 10 percent of the patients \vho start with the more expensive FCHD 
modality in the Base-case scenario will be able to start with LCHD; 
7. Assuming a shift of 20 percent of new FCHD patients to LCHD; 
8. Assuming a shift of 10 percent of ne\.V FCHD patients to CAPD; 
9. Assuming a shift of 20 percent of new FCHD patients to CAPD; 
10.Assuming a shift of 10 percent of new FCHD patients to APD; 
11.Assuming a shift of 20 percent of new FCHD patients to APD. 
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The outcomes of the 11 scenarios are shown in Table 4. Because patients' valuations of 
health status "\vere higher than general population valuations, the different quality of life 
indicators incorporated in the sensitivity analyses appeared to have a large influence on the 
cost per Q./\.LY The introduction of patient Standard Gamble scores and Time Trade Off 
scores in the model resulted in an average reduction of the cost per QALY of NLG 10,300 
(10.5%) and NLG 12,000 (12.2%), respectively. The Base-Case assumption that quality of 
life of TX patients is better than quality of life of dialysis patients was also found to influ-
ence cost per Qi\LY Scenario 3 showed a 6% increase in cost per Qi\LY on the assump-
tion that TX quality of life equals quality of life of dialysis patients. The number of trans-
plantations per million population "\vas found to have some influence on the total societal 
costs of the ESRD treatment program, as "\Veil as on cost per life year gained and cost per 
QALY In a scenario with an increase in the annual number of transplants to the European 
maximum of 44 transplantations per million population,40 the total societal costs over the 
5 year period were reduced by 1.82% (NLG 59.3 million). In comparison with the Base-case 
scenario, the cost per life year gained was reduced by 2.06% ~LG 1 ,627) and the cost per 
QALY by 2.53% (NLG 2,491). The CAPD stimulating scenarios (scenarios 7 and 8) were 
found to dominate the Base-case scenario "\Vith less costs and better outcomes. In general, 
the influence of policies to substitute patients from more expensive treatment modalities 
(FCHD) to less expensive modalities (LCHD, CAPD and APD) was found to be small. In 
all six substitutive scenarios, the cost per life year gained was reduced by no more than 1 
percent. The cost per Qi\LY decreased by no more than 1.06 percent. The LCHD stimu-
lating scenarios even resulted in higher societal costs and slightly higher cost per life year 
gained. 
Table 4: Outcomes of the different scenarios over the 5 year period 1997-2001 (cost fig-
ures in ~LG) 
Scenario a 6. Total 6. Life-years ~ QALY's 6. Cost per 6. Cost 
costs gained gained life year per QALY 
gained 
Base·case·scenario 3,240,312,000 41149 32955 78,745 98,323 
I. Patient SG valuations + 3864 - 10,318 
2. Patient ITO valuations + 4583 - 12,004 
3.TX -quality of life= dialysis quality of life - 1862 + 5,891 
4. 38 TX per million population - 25,53 I ,800 +43 +102 - 702 - 1076 
5. 44 TX per million population - 59,267,900 +100 +238 - 1627 - 2491 
6. I 0 % of new FCHD patients to LCHD + 12,694,500 +!40 +168 + 40 - I 16 
7. 20 % of new FCHD patients to LCHD + 25,402,900 +281 +337 + 79 - 23 I 
8. 10% of new FCHD patients to CAPO -9,421,100 +85 +81 - 390 - 525 
9. 20 % of new FCH D patients to CAPO - 18,886,200 +170 +!62 - 781 - 1050 
I 0. l 0 % of new FCHD patients to APD + 80,000 +72 +109 - I 35 - 323 
II. 20% of new FCHD ~atients to APD + 128,000 +144 +219 - 271 - 646 
a for a description of the scenarios, see Results paragraph, section sensitivity analyses /scenario analyses 
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Discussion 
Dialysis is expensive. Average cost per life year gained in the Base-Case scenario was found 
to be NLG 133,000, the cost per QALY were NLG 190,000. The transplantation figures 
were estimated as NLG 25,000 per life year gained and NLG 27,800 per QALY Total 
expenses of the ESRD treatment program were calculated at 3.24 billion guilders over the 
period 1997-2001 or ?-JLG 650 million per annum. This equals 1.1 percent of the total 1997 
healthcare budget of the Netherlands, which is spent on 0.0006 percent of the total popu-
lation. Dialysis may be regarded as an expensive treatment, bridging the gap between the 
onset of end-stage Renal Disease and transplantation. However, transplantation and dialy-
sis cannot be assessed separately. A successful transplantation program requires dialysis 
before a transplantation can be performed and again as back-up for patients who experi-
ence a rejection of the donor organ. The mutual dependency also applies to the different 
dialysis modalities: patients who have or gradually develop contraindications for one treat-
ment modality may benefit from the availability of other modalities. The cost-effectiveness 
of ESRD treatments should therefore primarily be assessed at a more aggregate level, 
before considering the different therapeutic modalities. 
Of the five dialysis modalities, CAPD is the most cost-effective treatment modality, fol-
lowed by HHD, APD and LCHD. The current study was the first to take the cost-effec-
tiveness of APD into account. The cost-effectiveness of APD was equal to that of other 
accepted treatment modalities, such as HHD and LCHD. On the aggregate level, FCHD 
-..vas shown to be the least cost-effective treatment. FCHD was found to be the most expen-
sive therapy and FCHD patients' quality of life, as valued by the general population, was 
lower than other patients' quality of life. The information from the quality of life study was 
somewhat confusing. The general population valuations of patients' quality of life was sig-
nificantly different across groups. And although treatment group differences that were 
found in patients' own valuations were not significant, the three valuation methods result-
ed in different ranking of treatment modalities. For instance, APD ranked highest using the 
ITO instrument and lowest using the SG instrument. In view of these conflicting results, 
and considering the fact that quality of life differences across treatment groups are not huge 
an-y'\.vay, it cannot be justified that quality of life of patients should play an important role 
in policy making with regard to the ESRD treatment program. 
The more favourable outcomes of CAPD, LCHD, APD and HHD compared with 
FCHD suggest that a policy directed towards substitution of patients from the latter treat-
ment modality to one of the former modalities could make sense. \\le have explored the 
influence of such substitutive policies. It was shown that the influence of substitution of 
patients from more expensive to less expensive treatments was only modest. The LCHD 
stimulating scenarios even resulted in higher societal costs, and slightly higher cost per life 
year gained. An important explanation is that there -..vere more patient movements in the 
LCHD, CAPD and APD groups. 11ore frequent movements from one therapy to another 
were associated with higher costs, because costs in the first year of therapy are higher than 
in later years. Patients in the FCHD group, especially in the older age groups, experienced 
fewer changes of therapy. Hence, the positive effect on costs and outcomes of the ESRD 
program that was expected from substitutive policies \vas reduced by increased costs asso-
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ciated with more changes of therapy. A more substantive influence may be expected from 
an increase in the number of transplantations per million population. The Netherlands has 
reached a level of around 30 transplantations per million population. 1-hny European coun-
tries have shown higher numbers over the past years.40 The number of donor organs 
depends on a complex number of factors, including legislation, attitude towards organ 
donation among the population and healthcare workers and the number of traffic injuries. 
Because of the relatively lO\v number of traffic injuries in the Netherlands, it cannot be 
expected that a high level of 44 transplantations per million people will easily be reached in 
the Netherlands. However, if the new donor legislation 41 provides for an increase in the 
number of donor organs, as anticipated, a positive influence on the societal costs of the 
ESRD treatment program and on the cost-effectiveness of the ESRD program may be 
expected. 
The current study was stratified into different age-groups. Other patient characteristics, 
such as sex, employment status, life-style, marital status and comorbid diseases might influ-
ence the cost-effectiveness of treatment as well. A study by Smith and \X-'heeler 42 suggest-
ed that patients using FCHD may have lower charges than if they were using CAPD, and 
vice versa. This result supports the hypothesis that matching patient and treatment criteria 
is an efficient process, resulting in the best outcomes that are possible in individual patients. 
This would further reduce the usefulness of substitutive approaches. Cost reduction in gen-
eral will have a much more significant influence on societal costs of ESRD treatment than 
substitution of patients to more cost-effective treatments. None of the substitutive policies 
explored were expected to have more effect on societal costs and cost-effectiveness of 
ESRD treatments as a cost reduction as low as 2 percent would have. It should be made 
clear that these results and conclusions only apply to the ESRD treatment situation as 
found in the Netherlands. There is equal access to all forms of dialysis. Nephrologists' fees 
are independent of the treatment modality of a patient. \Xlithout medical contraindications, 
patients in general are allowed to choose a treatment modality that best suits them. This 
means that circumstances to "match" patient and treatment characteristics are optimal in 
this country. The Netherlands has had relatively high patient numbers on CAPD from the 
beginning, and APD is now diffusing rapidly into dialysis centres as \veli.37 Thirty percent 
of all dialysis patients are being treated \Vith CAPD or APD.37 It seems that a point of 
diminishing returns is being reached at this level of diffusion of PD treatment. The CAPD 
stimulating scenarios were still found to be dominant to the Base-Case scenario with less 
costs and better outcomes, but the reduction in cost per life year gained and cost per QALY 
in these scenarios was not impressive. The implication of cl1is finding is that countries with 
a lower diffusion rate of PD treatments and similar cost profiles might benefit more from 
PD stimulating policies. This situation applies to many European countries. \\lithin the 35 
European countries covered by the Registry of the European Dialysis and Transplantation 
Association, only 8.8 % of patients received PD treatment in 1995.43 PD "\Vas offered as a 
treatment option in only 45 percent of all dialysis centres covered by the European Registry, 
while there was access to HD in almost all dialysis centres.43 In many European countries 
there is still room for substitution of patients to PD treatment and such substitutive poli-
cies might have a beneficial effect on the cost-effectiveness of the ESRD program in those 
countries. 
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Appendix 
A :0-Tarkov-chain is a discrete statistical process in which the future distribution of the pop-
ulation (i.e. ESRD patients) over several states depends on the present distribution, transi-
tion probabilities from one state to the other and inflow of new patients. The model 
assumes that the patients in the system are always in one of a finite number of states. 
During each time interval, e.g. a month or a year, a patient is at risk of a transition to anoth-
er state. In matrix notation, considering a situation of n different states patients can be in, 
the model can be described as follows: 
.. A, a (n x n) matrix of transition probabilities; ~,i is the probability of transi-
tion from state ito state j, in the period bet\veen timet and time t+1; 
• X' (t), an-sized row vector; X' (th is the population at timet in state k; 
.. I' (t), a n-sized vector; I' (t)k is the flow of new patients into state k, in the 
period bert:veen time t and rime t+ 1; 
The forecast of the distribution of the population at rime t+1, X' (t + 1) equals: 
X' (t + 1) = X' (t) • A+ I' (t) 
A vital assumption of the 11arkov chain model is: 
1. The transition from state ito state j is independent of the history of the patient before 
arriving in state i ('t..hrkovian assumption'). 
Further assumptions of the 1\hrkov-model include: 
2. The transitions from one state to another all take place at the end of a period. 
3. After applying the transitions to patients already in the system, new patients flow into the 
system. 
The model allows for corrections in A, in order to match the total annual number of trans-
plantations to a predefined number. The second assumption plays an important role in the 
calculation of the societal costs of treatment, because the number of patients at the begin-
ning of a calculation-period equals the number of patients during that period. \Xlhen there 
are X~ patients in state k at the beginning of period t and the costs per period t for treat-
ment k are c k,t then the societal costs C ~in period t for treating patients in state k, equals: 
Ct _ * xt k- ck,r .L k 
Costs are discounted to the beginning of the forecast-period. The following assumption 
facilitates calculation: 
4. All costs are made just before the end of a period. 
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The standard discounting formula applies in this situation and the discounted costs in peri-
od t for treatment k, D~, using discount-rate r, equal: 
D~ = C~/ (1 + r) (t-t) 
To calculate the number of life years gained it is assumed that the disease under consider-
ation is an end-stage disease. This implies that: 
5. In the absence of treatment a patient dies within one time period t. 
The number of gained life years in period t for treatment k, L~, equals: 
L /- xt k- .L k 
Multiplication of ~ by a quality factor (indicator for quality of life) gives the number of 
QALY's gained in period t for treatment k. The discount-procedure for life-years and 
QAL Y's equals the one used to discount costs. 
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De Wit GA, Busschbach JJV, de Charro FT. Sensitivity and perspective in 
the valuation of health status: whose values count? Health Econ 2000; 9: 
109-126. 
Abstract 
\\le studied the literature on the existence of differences in valuation for hypothetical and 
actual health states betureen patients and other-rater groups. \Xle found that 9 different study 
designs have been used to study this question and applied 2 of these designs in a study 
involving dialysis patients and other rater groups. In the first study, both dialysis patients 
and students had to value hypothetical health states with Standard Gamble and Time Trade 
Off. Patients assigned higher values to hypothetical health states than students did. In the 
second study, dialysis patients who were being treated with 4 different dialysis modalities 
were asked to value their own health state with Standard Gamble, Time Trade Off and a 
visual analogue scale (EQvAs), and to describe their health state on the EQ-SDprofilc 
Several EQ-SDindex values (health index values derived from general population samples) 
were calculated for the four dialysis treatment groups, based on the EQ-SDprofile· These 
health indexes could discriminate between treatment groups, according to clinical impres-
sions. Treatment groups could not be differentiated based on patients' valuations of own 
health state. Our results suggest that general population samples, using EQ-SDindex values, 
may be more able to discriminate bet\veen patient groups than the patients themselves are. 
The implications of this finding for valuation research and policy making are discussed. 
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Introduction 
Values, sometimes also called utilities or preferences,l are quantitative expressions of pref-
erence for certain health states, on a scale on which 0 represents death and 1 represents full 
health. Values may have several applications in health care research and policy making. In the 
context of cost-effectiveness and cost-utility analyses, values may be used tot calculate 
(costs per) Quality Adjusted Life Years (QALYs) 1 2 In medical decision making, values may 
play a role when a patient or a healthcare professional has to make a choice bet\veen dif-
ferent treatment options) Values may also be used as a direct outcome measure in clinical 
research, for instance in studies comparing different treatment options for a clinical condi-
tion, and for monitoring patient health. Values can be obtained from patients currently 
experiencing a certain health state, from people with past experience of that health state, 
close relatives of patients, healthcare professionals and from samples of the general public. 
But whose values count? This question has been described more as a political or ideologi-
cal topic than as an empirical question.4-Ci Different disciplines have different perspectives 
on the issue "whose values count?". Historically, doctors provided ratings of patients' 
health status (e.g. the Karnofsky Performance Status 7). With further development of qual-
ity of life research, this professional perspective was challenged and over the past t\vo 
decades, the patient perspective has been a major perspective in clinically oriented research 
and in medical decision-making.s 8 The rationale of the patient perspective is given by 
Froberg and Kane .5 as "( ... ) it may be more appropn·ate to lJ!eight more heclJJi/)' the priferences if those 
most directQ1 qf(ected I:J' an intervention or poliry. This seems e.rpecial(y true in clinical decision making'. 
At the same time, researchers oriented towards economic evaluation of healthcare have 
stated that the values of the general population may be more valid in the context of deci-
sions on the alternative allocation of resources. 1 2 9 Hadorn explained this viewpoint as fol-
lows: "( ... ),patients JJJho re(} on others to pq)! their medical bills (...) cannot e>.pect that these others 1vill 
pq_yfor evet)'thing tho' (the patients) might 1vish to receive. Pemzittingpatients tmlimited access to care based 
on post-illness priferences would too ?ften result in the provision of marginai!J: benificial care."9 
Furthermore, it is stated that rational citizens, when operating behind a "veil if ignorance", 
and thus ignorant of their own future health state and needs, would prefer that societal deci-
sions lead to maximum aggregate benefit within that society.2 The aggregate values of peo-
ple without specific interest in particular health states would seem most appropriate from 
this perspective, because a higher level of solidarity with worse-off citizens will be guaran-
teed. 
Hence, the health economists' perspective on the issue of "whose values count" is dif-
ferent from more clinically oriented perspectives. \JVTilliams has put forward that the issue of 
the patient perspective versus the general population perspective should not be regarded a 
matter of right or wrong. 4 Both perspectives may lead to legitimate outcomes, depending 
on the specific decision making context, and in fact the choice for the perspective is pri-
marily a normative choice. However, if values given by patients and other rater groups dif-
fer in magnitude, this normative choice could also have empirical implications. \Xle studied 
the literature on this subject, with a limitation to those papers that compared patient values 
with values of at least one other rater group. \X7e found 35 different publications aimed at 
answering the question whether experience with illness influences the valuation of health.6 
l0-43 These 35 publications included 38 separate studies, in which nine different research 
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designs were applied. These nine designs differ with respect to the amount of experience 
with disease of the rater, the distance of the rater to the patient and the resemblance 
bet\veen the health state to value and the actual health state of the rater. Because we expe-
rienced that it was sometimes quite difficult to get a grip on the exact method that was 
applied in each of the study reports, \Ve have made a classification of study designs. This 
classification is not meant as an exhaustive enumeration of possible research designs, but 
merely to present the subtle differences in designs that were found in the literature. The 9 
different study designs found are described in Box 1. Details on design and conclusions of 
the 38 separate studies can be found in Appendix I. 
Box 1: Classification of different study designs that '\vere found in the literature to 
address the question of the existence of differences in values bet\veen patients and 
other rater groups 
Q) Patient and others (non-patients: doctors, nurses, family members, general popu-
lation, students, convenience samples) value hypothetical health states related to the 
actual health state of the patient (e.g. breast cancer patients value cancer related health 
states) 6 10-16 
0 Patient and other rater-groups value hypothetical health states unrelated to the 
actual health state of the patient (thus entirely hypothetical to both groups) 17-20 
Q) Different patient groups (with different stages of disease) value hypothetical states 
related to the actual health state of the patients 11 21-23 
(D Different patient groups (with different stages of disease) value hypothetical states 
unrelated to the actual health state of the patient 24 
Q) General population samples value hypothetical health states. Values of those in a 
dysfunctional health state are compared with values of those in normal/perfect health. 
The division bet\veen healthy and non-healthy individuals is made aftet\vards 25-29 
G) Patients and proxies (familiar with the patient, such as caregiver, nurse or doctor) 
value the actual health state of the patient involved 13 20 30-34 
C) Patients and non-patients are interviewed on hypothetical treatment choices. The 
choice they make is thought to reflect the value for the hypothetical health states asso-
ciated with the treatment choice 35-37 
(D Values for hypothetical health states are elicited from patients before they enter 
that hypothetical health state. Values are elicited again from the same patient after they 
have obtained experience '\vith the hypothetical health state. The stability of the values 
is studied 38-40 
0 A patient describes his health state on a classification system or profile and subse-
quently values his actual health state. The patient value is compared with a population 
value for the actual health state of the patient (i.e. in terms of the EQ-5DprofilJ of the 
patient 41 -43 
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The results of the 38 studies do not facilitate a univocal conclusion on the subject. Twenty-
seven of the 38 studies concluded that patient values are different or sometimes different 
from other groups' values. Eleven studies found no differences in values between rater 
groups. The studies reporting differences in valuations found in general that patients gave 
higher values than other groups: 22 studies reported higher patient values, 2 studies showed 
lower patient values and 3 studies found contradictory results. Some studies only have small 
sample sizes, and thus may lack power to detect differences bet\veen groups, should they 
exist. Some study designs, such as design 7 (treatment choices) may measure more features 
than the value of the health state alone. For instance, cancer patients' treatment choices may 
reflect their current (impaired) health state at the moment of questioning or may include 
the perceived chances of survival with the respective treatment options. These drawbacks 
further hamper a clear-cut conclusion, but current evidence would be most supportive of 
the conclusion that patients' values are higher than values of other rater groups. The Panel 
on Cost-Effectiveness in Health and J\.1edicine recently supported this conclusion. 2 
If we assume that patients' values are different from other rater-groups' values, then does 
this have implications for the sensitivity of value measurements? This is a less addressed 
issue. The term "sensitivity" is being used differently by different disciplines, but is used by 
us to refer to the capacity to distinguish health states on the basis of values attached to 
those health states.44 45 If it is true that patients in general assign higher values to their 
health state in comparison with other rater groups, then loss of sensitivity to discriminate 
ben.:veen patient and treatment groups might be the result. If patients give higher values in 
general, they will use a smaller part of the scale ("ceiling effect") in comparison with healthy 
people. On the other hand, when healthy people have to value very \.VOrse health states, a 
similar phenomenon ("floor effect") may be observed at the bottom end of the scale. If a 
particular rater group uses a relatively small part of the scale, a reduction of sensitivity to 
differentiate across (treatment) groups could be a consequence. 
In the context of a clinical study involving four different dialysis treatments, we \.vere able 
to study the existence of inter-rater differences and possible consequences for the sensitiv-
ity to discriminate bet\veen patient groups. Our data allowed for the application of rum of 
the nine research designs that were found in the literature. 
Subjects and methods 
General approach 
First, we compared the valuations for hypothetical health states of dialysis patients and stu-
dents, using both Standard Gamble and Time Trade Off instruments (study design 2, as 
described in Box 1). A sample of dialysis patients and a sample of volunteer students "\Vere 
asked to value three hypothetical health states. Outcomes from both rater groups were com-
pared. Second, \.Ve compared the valuations of four different groups of dialysis patients for 
their actual health status with general population valuations for similar health states (study 
design 9, as described in Box 1). 
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Valuation methods used 
Health-related quality of life of dialysis patients was assessed using the EuroQol 
Instrument (EQ-5D).46 47 The EQ-SD is a generic questionnaire, suitable for collecting 
data on health related quality of life. The clinical version of the EQ-SD includes a classifi-
cation system (EQ-SDprofilJ and a visual analogue scale (EQv:\5). The EQ-5Dprofile records 
the level of self-assessed problems on 5 domains of health (mobility, self-care, usual activ-
ities, pain/discomfort, anxiety/depression), each with three levels of functioning: Qevel 1: 
no problems; level 2: some problems; level 3: unable to perform/ extreme problems). The 
EQvr\s records the respondents rating of his/her overall health status on a graduated, ver-
tical visual analogue scale. The EQvAs is anchored at 0 (worst imaginable health state) and 
100 (best imaginable health state). The combination of 5 dimensions y1,rith 3levels of func-
tioning yields 243 3S unique health states. These 243 health states may be converted to a sin-
gle summary index (EQ-5Dindex), by applying scores from a standard set of preference 
weights. The EQ-SDindcx is constructed from values that have been assigned to the health 
states by subjects from the general public. Several methods are available for such valuation 
research,! among which the Standard Gamble (SGJ,4S Time Trade Off (ITOJ31 48 and visu-
al analogue scales. The essence of the .Standard Gamble (SG) is that the respondent is pre-
sented with rum alternatives and asked to choose the one most preferred.48 The first alter-
native offers the certainty of staying in the described health state for the remainder of the 
respondent's life. The second alternative is a gamble \Vith specified probabilities for both 
the positive outcome of the gamble (a normal health state for the remainder of time) and 
the negative outcome (immediate death). The SG score, a score between 0 and 1, is calcu-
lated as 1 minus the risk percentage chosen divided by 100. The Time Trade Qff method 
(TTO) asks responders whether they are prepared to give up some remaining time of their 
life, in order to improve an impaired health state to normal health.31 48 The time perspec-
tive that is presented to the respondent corresponds with statistical life expectancy for peo-
ple of the same age and sex. The quotient of the chosen number of years in a normal 
health state over statistical life expectancy yields the TTO score. Our operation of the TTO 
method did not allow for negative values.31 The visual analogue scale that \Vas used in our 
valuation research was the EQvAS• as described above. These three valuation methods may 
be used for the valuation of both 0potheticalhealth states and the actual health status of the 
respondent, as was done in the present study. 
Patients' versus students' valuations of hypothetical health states 
The patient sample consisted of 165 dialysis patients who were being treated with four dif-
ferent dialysis modalities, with differing impact on patients. Patients participated in a clini-
cal study on the adequacy of dialysis.49 Starting from three months after inclusion in the 
clinical study, patients became eligible for a quality of life study. One of four interviewers 
(trial nurses) visited the patient at home for an interview on the patient's health status and 
their valuations for hypothetical health states and their own current health state. The stu-
dent sample consisted of 105 students of Erasmus Cniversity who volunteered to partici-
pate in a study that was set up to compare different methods to elicit values for health 
states.5° The students \Vere all intervie\ved by one of the authors GJB). Both dialysis 
patients and students, using ITO and SG according to protocols described above, valued 
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three imaginary health states. The three imaginary states "\vere framed within the EQ-
SDprofile and represented a wide spectrum of severity of health states. The three health 
states are presented in Table 1. 
Table 1: Three hypothetical health states as defined by EQ-SDpwfil< 
EQ-50 rofile dimension Mild state Moderate state Severe state 
Mobility No problems Some problems Confined to bed 
Self-care No problems No problems Unable to wash/dress self 
Usual activities Some problems Some problems Unable to perform 
Pain I discomfort No pain Extreme pain Extreme pain 
Anxiety/depression Not anxious Moderately anxious Extremely anxious 
Abbreviated state a 11211 21232 33333 
a 1 = no problems, 2 ::: some problems, 3 = unable to perform / extreme problems 
The comparison of patients' and students' valuations for hypothetical health states in fact 
\Vas a byproduct of the clinical part of the study. The valuation of hypothetical health states 
was used to introduce the valuation methods to the patients and to make patients feel at 
ease with the interview situation. Because the valuation methods used "\vith patients and stu-
dents were identical, we were able to combine the results of both valuation studies. 
Patients' versus general public's valuations of the actual health state of the 
patient 
After the valuation of hypothetical health states, dialysis patients were asked to classify 
themselves on the EQ-5Dprofile· They were also asked to value their own current health 
state using EQvAs' SG and TTO, analogous to the valuation of hypothetical health states 
described above. After the interview, the interviewer completed the Karnofsky 
Performance Status 7 for that patient, as an indicator of functional status of the patient. 
The patients' valuations of their own current health state were compared with valuation 
data (EQ-SDindcJ obtained from several European general population studies. In most 
countries participating in the EuroQol Group,46 47 including the United Kingdom, 51 the 
Netherlands, 52-54 Finland, 55 and Spain, 56 57 EQ-5Dindex weights have been estimated. The 
general background to estimating these EQ-SDindex weights is described by Brooks et al.47 
and is summarized here briefly. Samples from the general population were asked to value 
hypothetical sets of health states in terms of the EQ-SDprofile> using either visual analogue 
scale or Time Trade Off methods. This process resulted in sets of values for a sample of 
the 243 possible health states that can be described by the EQ-SDprofik The health index 
weights for the remaining EQ-SD health states were estimated using mathematical model-
ing. The main characteristics of these European valuation studies of the EuroQol Group 
are summarized in Table 2. 
Based on the EQ-5Dprofile as provided by the patient, we calculated 6 different EQ-
5Dindex weights (as described in Table 2) for each dialysis patient. Thus, for each dialysis 
patient, we had 3 scores reflecting the SG, TTO and EQvAS valuations of the patient 
him/herself, and 6 scores reflecting outsiders' valuations for the actual health status of that 
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patient. \\/e compared the four dialysis treatment groups (full care centre haemodialysis -
FCHD, limited care centre haemodialysis - LCHD, continuous cycling peritoneal dialysis -
CAPD, automated peritoneal dialysis - APD) with regard to these scores. 
Statistical analysis 
Differences in valuations for hypothetical health states bet\veen the patient and student 
groups \Vere univariately tested by means of 1fann-\XThitney U tests. In addition, using a 
fvianova repeated measurements procedure, the pooled scores were tested for the presence 
of a group effect. The latter analysis was performed twice, with and \Vithout adjustment for 
age differences bet\veen the t\vo groups. In the part of the empirical study that was con-
cerned with the valuation of actual health status by patients, "\Ve used non-parametric 
Kruskall-\\?allis tests to test for differences across the four dialysis treatment groups. A P-
value of 0.05 was chosen as the cut-off point for statistical significance in all analyses. 
Table 2: ~fain characteristics of valuation research within the EuroQol Group 
Country Population Number of Number of Hypothetical valuation 
respondents health-states vs. own health method 
UK 51 General 2997 42 Hypothetical no 
Netherlands 52,54 General 217 25 Hypothetical EQVAS 
Netherlands 53 Students 126 243 Hypothetical EQVAS 
Finland 5.5 General 1634 43 Hypothetical EQVAS 
Spain 57 General 300 75 Hypothetical EOvAs 
Spain 56 General 15000 243 Own health a EQVAS 
a ?\lote that this Spanish general population study was different from the others in that respondents were 
asked to value their 0\Vn current health state instead of hypothetical health states 
Table 3: SG and TTO scores of dialysis patients and students, for 3 hypothetical health 
states (as shown in Table 1) 
Method I health state Dialysis patients (n-165) Students (n-! 03) P-value a 
n Mean (SO) n Mean (SD) 
SG mild 159 0.90 (0.13) 103 0.97 (0.06) < 0.01 
TTO mild 148 0.94 (0.11) 103 0.91 (0.10) < 0.001 
SG moderate 157 0.76 (0.21) 103 0.67 (0.25) < 0.01 
TTO moderate 146 0.78 (0.19) 103 0.55 (0.24) < 0.001 
SG severe 155 0.42 (0.3 I) 103 0.3 I (0.32) < 0.01 
TTO severe 146 0.50 (0.28) I OJ 0.20 (0.24) < 0.001 
a I\'Iann-\Y'hitney Ll-tests 
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Results 
Patients' versus JtNdents' valuations rf I?Jpothetical health states. _All165 patients completed the EQ-
SDprofilc and EQvAs· From the sample of 165 dialysis patients, 146 (88.5%) patients were 
able to ans\ver all SG and TTO questions. Six patients (3.6rYo) did not respond to any of the 
8 valuation tasks using SG and TTO methods. Thirteen patients (7.91/'IJ) answered some of 
the SG and ITO valuation tasks, but not all eight questions. Reasons for not cooperating 
in the valuation tasks were cognitive problems, tiredness and religious beliefs. T\vo students 
out of 105 students (1.9%) were not '-Villing to respond to the ITO and SG questions. The 
average age of the dialysis patients \Vas 57 years, the average age of the students was 22.5 
years. 
The mean scores of the t\vo groups are presented in Table 3. In 5 of the 6 valuation tasks, 
patients gave higher scores than students. The Standard Gamble valuation of the mild 
health state \vas scored lo\ver by patients than by students. Differences between students 
and patients were relatively small when the mild health state \vas valued, and relatively large 
when valuing the moderate and severe health state. The largest difference was found at the 
TTO valuation of the severe health state. Students gave a score of 0.20, indicating that they 
were willing to sacrifice 80 percent of their life expectancy in order to avoid the severe 
health state. Patients scored much higher, i.e. an average score of 0.50. \Xle observed that 
patients used a smaller part of both SG and ITO scales than students did. Patients used 48 
% of the range of possible scores on the SG scale, and 40 % of the TTO scale, while stu-
dents used 66 % and 71 % of these scales, respectively. Cnivariate analysis of the differ-
ences benveen students' valuations and dialysis patients' valuations shmved that all differ-
ences were significant. The multivariate analysis showed that there was a significant effect 
of the group (P < 0.001) and that an interaction bet\veen the rater-group and the health 
state existed (P < 0.001), implying that differences bet\veen the two rater groups are not 
constant over the hypothetical health states. Adjustment for age differences benveen the 
ruro groups did not change the results of the analysis. 
Patients' verJHs general public'.s m/uatiom if the patientJ' actual health state. Table 4 shows both the 
Karnofsky score, EQvAS• SG and TTO scores of patients in 4 dialysis treatment groups 
and the 6 European health indexes that \Vete calculated on the basis of the dialysis patients' 
EQ-SDprofik· The flrst entry of Table 4 shows that significantly different Karnofsky scores 
were given by the interviewers to the 4 dialysis treatment groups, indicating that functional 
status of patients in the 4 treatment groups was different. ~o differences were found across 
the 4 patient groups as for their SG, TTO and EQvAS scores. However, five out of six EQ-
SDindex weights were significantly different across the 4 patient groups. The only EQ-
5Diodex that \vas not different across the 4 groups was one of the Spanish indexes. 
However, this Spanish index was fundamentally different from the 5 others, because it is 
based on own actual health status, not hypothetical health status. 
144 
Chapter 8 
Table 4: Mean (SD) valuations for actual health status from dialysis patients (upper part) 
and mean EQ-SDindex \veights (lower part), according to treatment modality 
FCHD a LCHD a CAPO a APD a P-value 
(n=46) (n=23) (n=S9) (n=37) 
Nurses' rating of performance status of dialysis patients 
Karnofsky Performance Status 66 (17) 78 (II) 71 (14) 76 (13) 0.01 
Dialysis patients valuation of actual health state 
EQV,\S c 0.58 (0.19) 0.65 (0.14) 0.61 (0.20) 0.61 (0.19) 0.49 
5G 0.84 (0.21) 0.91 (0.13) 0.81 (0.24) 0.74 (0.24) 0.13 
TTO 0.87 (0.20) 0.93 (0.11) 0.86 (0.23) 0.93 (0.14) 0.33 
General population E.Q-5D;11de_y value based on hypothetical health states 
United Kingdom general population d 0.66 (0.29) 0.81 (0.24) 0.71 (0.29) 0.81 (0.19) 0.04 
The Netherlands general population d 0.69 (0.22) 0.82 (0.19) 0.73 (0.21) 0.80 (0.17) 0.05 
The Netherlands students d 0.62 (0.19) 0.72 (0.17) 0.64 (0.19) 0.71 (0.16) 0.05 
Finland general population d 0.75 (0.20) 0.86 (0.17) 0.78 (0.20) 0.85 (0.16) 0.05 
Spain general population d 0.65 (0.27) 0.79 (0.20) 0.71 (0.24) 0.78 (0.18) 0.03 
General population EQ-SD index value based on self-rated health 
Seain general eoeulation d 0.76 (0.18) 0.83 (0.16) 0.76 (0.18) 0.81 (0.15) 0.12 
a FCHD ::: full care centre haemodialysis, LCHD ::: limited care centre haemodialysis, CAPD ::: continu-
ous cycling peritoneal dialysis, APD ::: automated peritoneal dialysis 
b Kruskall-\X'allis test 
c divided by 100 
d see table 3 for a description of characteristics of the valuation study 
Discussion 
\\le studied cl1e literature on the existence of differences in valuations ben.veen patients and 
other rater-groups. Our conclusion was that evidence that patients assign different values to 
I?Jpothetical health states than "outsiders" is growing compared to the 1989 review of 
Froberg and Kane.5 Studies that found differences reported higher values from patients in 
most cases. This "\vas affirmed in the present study. \\/e compared the SG and TTO values 
for three hypothetical health states from dialysis patients and students and found that in five 
out of the six valuation tasks, patients assigned higher values than students. These differ-
ences could not be explained by age differences bet\veen the t\vo groups, as has been found 
else\vhere.1 1 58-59 One of the six hypothetical health states was valued lO\ver by patients than 
by students. This was the SG valuation of the mild health state. The ~.tlANOVA analysis 
showed that there was an interaction between the group effect and the health state effect. 
The implication of this finding is that, although patients in general do value health states 
higher than students do, this may be different for specific health states, especially the bet-
ter health states. As a result, patients used a smaller part of the scale for their valuations of 
the three health states than did students. Kind and Dolan 26 and Badia et al. 20 gave some 
evidence for a similar phenomenon of lower valuations for mild states and higher valua-
tions for more severe states. They called this "valuation compression". The word "com-
pression" carries the implication of error associated \Vith patient valuations, at least when 
general population valuations are considered the gold standard. However, the opposite 
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could also be true: given the values of the patients, the general public seems to stretch out 
the scale ("valuation expansion"). \'\le will probably never be certain which of the t\:vo phe-
nomena is responsible for the observed differences in valuation benveen patients and other 
rater groups. In this paper, we have focused on the implication of the observed differences, 
rather than speculating about the "true" cause of the existence of differences. 
In our study, patients '\vere first asked to value the three !vpothetical health states using SG 
and TTO. Thereafter, they had to describe their own current health using the EQ-5Dprofik: 
and to value the descriprion of their own actual health using EQv"\S' SG and TTO. :tvfany 
patients described their health state in terms of "some problems" in several domains. Such 
health states resemble the "moderate" hypothetical health state, that was just before valued 
on average with 0.76 (SG) or 0.78 (TTO). But once the valuation task concerned themselves, 
they did not want to take risks or trade-off life years anymore. A ceiling effect at the valu-
ation of own current health state has also been found in other patient populations '\Vith seri-
ous conditions. Tsevat et aL applied the Time Trade Off in 1438 seriously ill patients with 
a projected 6-month mortality rate of 50 percent and found that 35 percent was unwilling 
to sacrifice any longev.ity.30 Fowler and colleagues showed that 35 percent of a sample of 
291 AIDS patients had a high reluctance to give up life; they wanted life extension under all 
circumstances.60 Bosch and Hunink described a median TTO value of 0.80 and a median 
SG value of 0.91 in patients with intermittent claudication.61 The most common explana-
tion for this phenomenon is coping: patients have gradually learned to adjust their expec-
tations to their actual possibilities. Once a (chronic) disease is detected, patients change their 
internal standards to evaluate the situation and the yardstick of '\vhat is acceptable and what 
is not is lowered substantially.62 As a consequence, their evaluation of own health status 
may be leveled off at the upper end of the scale, with a consequent reduction in the vari-
ance of the distribution and the statistical power to detect an effect of clinical differences 
in health status on health values. Besides coping behavior, other explanations for high val-
uations can be found in the literature. Time preferences, religious beliefs, risk aversion and 
reluctance to give up any possible life at all may have influenced the SG and ITO scores.60 
63-65 Furthermore, our interviewers notified that patients, although explicitly instructed only 
to consider their present health state while answering SG and TTO, referred to other 
domains of life to explain the choices they made. For instance, family circumstances such 
as a future wedding anniversary or the wish to see grandchildren grO\vn up were mentioned. 
In answering SG and ITO, it possibly is very difficult for responders to strictly separate 
their impaired health state from other, more flourishing, domains of life. 
Table 4 shows that the SG, TTO and EQvr\S valuations lead to different results within the 
patient-groups. The EQvAS valuation was much lower than SG and TTO valuations. This 
is in accordance with previous research aiming at the comparison of the three valuation 
methods.64 66 67 The differences in health-index values are caused by different scaling meth-
ods, different modeling techniques to estimate the health-index values and population dif-
ferences. However, the ranking of the 4 different dialysis treatments is similar with all 
health-indexes, with highest ratings for LCHD patients, intermediate ratings for CAPD and 
APD patients, and lowest ratings for FCHD patients. The Karnofsky score that was rated 
by trial nurses did differ significantly across groups, also with highest scores for LCHD 
patients. The Karnofsky score has relatively less meaning in itself, because the higher score 
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for LCHD patients could be attributable to the idea that LCHD patients perform better or 
should do better than other patients. However, this explanation cannot be applied to the val-
uation research that was done in the general population, since health states "\Vere framed in 
the general terms of the EQ-SDprofile• without reference to a specific patient group. 
Nevertheless, all health indexes applied to dialysis patients' health states ranked LCHD as 
the treatment "\Vith the highest "quality of life" and thus were in accordance with the clini-
cal impression of the nurse who provided the Karnofsky score. 
It is often thought that general population valuations are less sensitive than patients' val-
uations, because patients experience all the subtleties of their health status that can never 
be explained in sufficient detail to an outsider. Although this is unmistakably true, patient 
valuations may also be contaminated for reasons discussed above. Our tentative conclusion 
is that "outsiders" may be more able to differentiate across treatment groups than patients 
are themselves, at least when the EQ-SD is used. Five out of six estimated EQ-SD health 
indexes showed significant differences across patient groups. The only EQ-SD health index 
that did not show significant differences was the Spanish study of 15,000 people from the 
general population. 5G As previously stated, that study was based on the valuation of oHm 
health state, whereas the other five EQ-SD health indexes are based on ratings of others' 
(I?Jpothetica~ health states. The same phenomenon that is held responsible for loss of sensi-
tivity to discriminate bet\veen patient groups, namely concentration of ratings in the upper 
end of the scale once the valuation is concerned with oneself, might be responsible for the 
fact that this Spanish EQ-SD health index is not able to differentiate across treatment 
groups, "\vhile the others are. So, the essential point of the valuation task seems to be 
whether the task is related to se!f or others. Similar observations "\Vere made in nvo other 
recent studies.GS-69 Once the valuation is concerned with others, coping mechanisms that 
prevent people from using the whole range of the scale are less relevant. Overall, it may 
seem unlikely, and even counterintuitive, that a simple instrument such as EQ-SD could be 
more able to pick up subtle differences bet\veen health states than more sophisticated meth-
ods such as Time Trade Of£ Another recently published study also provided with evidence 
that sensitivity of the EQ-SD was better than the sensitivity of SG and TT070 In fact, 
there is increasing evidence that instruments such as ITO do not pick up clinically mean-
ingful changes in health status of the patient. Researchers have reported stable ITO values, 
despite distinct changes in health status over time.71-73 
One important explanation for our findings has largely remained undiscussed: the stan-
dard error associated with the valuations of different rater groups. For example, prejudice 
against certain aspects of impaired health status may cause a focus of the general public on 
that aspect, thereby reducing standard error of the response and increasing discriminatory 
power. Also, patients may find that the reality of their actual health is far more complex 
than suggested by the hypothetical health state presented, with numerous other attributes 
effecting their valuation. This would increase the standard error and reduce the discrimina-
tory power. Furthermore, when the EQ-5Dindex weights are attached to the EQ-SDprofile• 
they are treated as constants without variances, although in the valuation studies variance 
exists. Thus one can say that one layer of variance is stripped out, making it more likely that 
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particular differences \:vill appear statistically significant. Ho"\vever, if this was an entirely sat-
isfying hypothesis, it should also hold for the Spanish EQ-5Dindcx that \Vas based on own, 
not hypothetical, health states. This is not the case. 
It might be argued that the present study, with relatively few patients in the 4 treatment 
groups, might lack power to detect differences across patient groups. However, the EQ-SD 
health index values were based on the same patient numbers and at least were better able 
to differentiate across treatment groups than patients \vere themselves. The present study 
could easily be replicated in other clinical studies in which the EQ-5Dprofilc and EQvAS 
scores are obtained directly from patients, to see whether our results hold in other circum-
stances. 
\\/hat are the implications of this study? The discussion on the subject of "whose values 
count" seems to be subtler than was previously thought. Critics have questioned whether 
outsiders are knowledgeable enough to make judgments that could have far-reaching con-
sequences, for instance in a resource allocation context. Of course, no outsider knows 
exactly what it is like to be a dialysis patient. But outsiders may be able to make subcle dif-
ferences ben.:veen health states. If patient values are used in societal decision making, "val-
uation compression" and its possible consequence, reduction of sensitivity to discriminate 
bet\veen treatments, could diminish the (possible) marginal benefit of healthcare interven-
tions. This reduction in possible marginal benefit of treatment may lead to higher costs per 
QALY gained than if population values were used. \Xlhen patient values are used in studies 
aimed at the comparison of different therapeutic modalities for one clinical problem, the 
"valuation compression" at the upper end of the scale might result in loss of sensitivity to 
discriminate between the therapeutic modalities, when in fact differences ben.:veen those 
modalities exist. Our study does not present the solution to the "whose values count?" dis-
cussion, but suggests that use of patient values might be more complicated than previous-
ly thought. 
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Appendix I 
Author/year Design 
Sackett 1978 10 I 
Wolfson 1982 6 I 
Boyd 1990 11 I 
Ashby 1994 12 I 
Revicki 1996 13 I 
Dominitz 1997 1 t[ I 
Jalukar 1998 IS I 
Clarke 1997 16 I 
Rosser ! 978 17 2 
;: 
~ 
Number of respondents 
246 general population 
29 dialysis patients 
14 physicians 
IS physical therapists 
13 family members 
I 0 stroke patients 
40 physicians 
59 healthy volunteers 
40 patients with colostomy 
49 nurses 
20 hospital physicians 
24 general practitioners 
28 university staff 
17 breast cancer patients 
49 schizophrenic patients 
49 primary caregivers 
12 osychiatrists 
46 colorectal cancer patients 
I 14 patients at risk for colorectal cancer 
24 patients scheduled for sigmoidoscopy 
62 patients with unrelated conditions 
49 head and neck cancer patients 
50 healthcare professionals. 
86 students 
32 patients with Gaucher Disease (GO) 
38 chronically ill patients 
39 healthy subjects 
I 0 medica! patients 
! 0 psychiatric patients 
I 0 medical nurses 
I 0 psychiatric nurses 
20 healthy individuals 
I 0 doctors 
Conclusion Patients versus 
other rater groups a 
Patients' values were higher than general population values > 
No inter~rater differences in values were found 
Patients' values were higher than other groups' values > 
Patients valued scenarios with good psychosocial response higher ;:;, 
than other groups, no differences in other scenarios 
Some statistically significant differences between the groups' values ;:, ,; 
for hypothetical states were found, but in general few differences 
Patients with related conditions gave higher values to colon cancer ;:., 
screening scenarios than patients with other conditions. No 
differences between groups for cancer scenarios 
Patients valued head and neck cancer health states higher than students, ;:;, 
and equal to or higher than health workers 
Patients with GO valued hypothetical GD scenarios similar or higher ;:., 
than the two other rater groups 
Differences between rater groups were found: medical patients gave < > 
highest scores but psychiatric patients lowest scores 
~ 
0 
(Appendix I continued) 
Author/year 
Balaban 1986 T8 
Selai 1995 T9 
Badia 1996 2U 
Boyd 1990 TI 
Daly 1993 2L 
Samsa 1998 22 
Hall 1992 23 
Llewellyn-Thomas 
2< 
Badia 1995 25 
Kind 1995 T6 
Hadorn 199 5 'Yf 
Gudex 1996 28 
Dolan 1996 29 
Revicki 1996 TI 
Badia 1996 20 
Design 
2 
2 
2 
3 
3 
3 
3 
Number of respondents Conclusion Patients versus 
other rater groups ;1 
26 RA patients No differences between the values of both groups were found 
General population sample 
23 acutely ill hospital patients Patients gave higher values than the general population > 
general population samples from 3 countries 
I 03 ICU patients Patients tended to rate the worst health state higher and the better < > 
360 healthy_ individuals health states worse than healthy individuals 
40 patients with colostomy \nln~tnmv n:o~tiPnt~' v::~l''"'~ """'r"' hio-hPr th:o~n nthPr n::~tiPnt~' v::~J.,,,~ > 
II patients without colostom 
21 menopausal women w'1thout symptoms 
25 menopausal women mild symptoms 
25 menopausal women severe symptoms 
41 5 patients with stroke 
184 patients with TIA 
654 asymptomatic patients at risk for stroke 
60 breast cancer patients 
44 women without breast cancer 
with severe symptoms gave lower values to 
ITO, but similar values for mild health state 
A hypothetical major stroke scenario was valued higher by stroke 
patients than by other patient groups 
< 
> 
Cancer scenarios were valued higher by patients than by non-patients > 
1991 4 30 women with benign breast disease No relationship between actual health status and health values was 
found 60 women with mali~nant breast disease 
5 600 visitors of a primary care centre 
5 
5 
5 
5 
6 
6 
1900 individuals from general population 
612 individuals from convenience samples 
3395 individuals from general population 
1181 individuals from general population 
49 schizophrenic patients 
49 primary caregivers 
12 psychiatrists 
I 03 ICU patients 
Valuations for actual health state did not influence ratings for 
hypothetical health states 
Those who described their current health as impaired gave higher 
valuations for all health states, especially severe states 
No systematic differences in preferences for health states according 
to health status or disease experience were found 
> 
Current self-reported health was found to have influence on ratings in ;;, 
14 % of hypothetical states: those in worse health gave higher valuations 
in these cases. No differences found in 86 % of ratin~s. 
Higher valuations for hypothetical states were given by responders > 
who described their current health as dysfunctional 
No differences in ratings for patients' own health between the 3 groups -
were found 
No differences in valuations of the health state of the patient were 
"' 
(Appendix I continued) 
Author/year Design 
Tsevat 1995 30 6 
Churchill 1987 31 6 
Molzahn 1997 32 6 
Dorman 1997 33 6 
Tsevat 1998 34 6 
O'Connor 1989 35 7 
Slevin 1990 36 7 
Llewellyn-Thomas 1989 37 7 
Llewellyn-Thomas 1993 1Ra 
O'Connor 1987 39 
Christensen-
Szalanski 1984 40 
Jenkinson I 997 4! 
Zethraeus 1999 42 
Hurst 1994 43 
8 
8 
9 
9 
9 
Number of respondents Conclusion Patients versus 
other rater groups a 
I 03 proxies 
1438 seriously ill patients 
I 041 family members 
I 079 physicians 
194 dialysis and transplant patients 
nurses and nephrolo.e:ists 
215 dialysis and transplant patients 
42 nurses 
7 physicians 
152 stroke patients 
152 proxies 
300 hospitalized patients > 80 years 
300 proxies 
found 
Patients rated their current health state higher than their family 
members and their physicians 
Patients gave higher ratings to own health than nephrologists and 
nurses 
Patients valued their own health higher than their nurses did, but 
physicians' values were equal to patients' values 
No differences in valuations of the health state of the patient were 
found 
Patients valued their own health higher than their proxies 
> 
> 
~ 
> 
154 cancer patients Patients choose more often for a toxic treatment over a non-toxic > 
129 healthY volunteers treatment than healthY volunteers 
I 00 cancer patients 
I 00 matched controls 
60 oncologists 
88 radiotherapists 
790 general practitioners 
303 cancer nurses 
Patients were much more likely to opt for 
radical treatment with minimal chance of 
benefit than the other respondent groups 
> 
60 women with breast cance1· Women with cancer were much more likely to undergo adjuvant > 
60 women with benign breast disease radiotherapy, even with a small extra chance ofprevention of recurrence 
66 patients with laryngeal cancer Values for possible treatment outcomes remained consistent when 
those outcomes were experienced 
54 cancer patients underl!oin2: chemotherapy patient preferences remained stable after treatment 
18 pregnant women interviewed on preferences to Long-term preferences were stable, but preferences shifted during 
avoid anesthesia durin£ labor labor , patients were more likely to choose anesthesia 
152 BPH patients Patient and general population valuations were similar 
2:eneral population surveys 
I 04 patients with hormone replacement therapy Mild hypothetical scenarios were valued similar, but severe scenarios 
general population surveys were valued higher by patients than by the population 
55 patients with rheumatoid arthritis 
general population surveys 
Patients rated their actual health status higher than the general 
population 
$ 
~ 
> 
Appendix I continued 
a< patient values [0\ver than other groups' values, ::::patient values identical to other groups' values,> 
patient values higher than other groups' values, :s; patient values lower than or identical to other groups' 
values, 2': patient values higher than or identical to other groups' Yalues 
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Chapter 9 
Introduction 
This thesis deals with an economic evaluation of renal replacement therapies in the 
Netherlands. In the previous chapters, the topics of quality of life of patients, costs of 
therapy, societal costs and cost-effectiveness have been discussed. This chapter presents a 
general discussion of the main results of each study. In addition, some methodological and 
theoretical ideas based on the findings are given and recommendations for future research 
are made. The main conclusions on the studies are discussed below by topic. A more 
chronological presentation of study questions, results and main conclusions can be found 
in the SNmiJJa~)' section of this thesis. 
Comparison of the quality of life of haemodialysis and peritoneal dialysis 
patients (chapters 2 and 3) 
One of the aims of the literature revie\v on quality of life of end-stage renal disease 
patients (chapter 2) was to summarise the current knowledge on differences in quality of 
life bet\veen patients undergoing various tb.erapeutic modalities. Our review was limited to 
well-known generic quality of life instruments (i.e. Short-Form 36, Nottingham Health 
Profile, Sickness Impact Profile, Quality of Life Index, Standard Gamble and Time Trade 
Off). i\Iost of these instruments became available in the late 1980s or early 1990s. 
Inherencly, our review was a priori limited to studies performed in this period. This guaran-
teed that major therapeutic improvements (such as the introduction of cyclosporin for 
transplanted patients and erythropoietin for renal anaemia) were included in the results. The 
literature revie\v clearly showed quality of life advantages of transplanted patients com-
pared with dialysis patients. 1-9 However, these results do not justify the choice of one dial-
ysis modality over the other based solely on perceived quality of life benefits. J'viost studies 
that addressed this issue concluded, when differences in case-mix between patient groups 
were statistically controlled for, that dialysis treatment modality is not a determinant of 
quality of life1 2 57 10 11 
The absence of a difference in quality of life berureen haemodialysis (HD) and peritoneal 
dialysis (PD) found in the literature review was confirmed by our empirical study (chapter 
3). Using four quality of life measures in a sample of 135 patients from the NECOSAD-1 
study, no differences were found between the two patient groups . .i\lthough the similarity 
in quality of life fits the overall experience reported in the literature, the wide variance in 
scores~ especially scores on the nvo health preference methods, may have obscured possi-
ble differences between patient groups. Additional problems in the interpretation of health 
preference scores from dialysis patients will be discussed later in this chapter. 
Quahty of life measurement in dialysis patients is hampered by the fact that no ran-
demised studies have yet been performed. Such a study design is preferable to the obser-
vational designs that were selected in our review, irrespective of bow well statistical control 
for the influence of background variables may have been. Even if quality of life differences 
bet\veen treatment groups were found, it would remain unclear whether these are due sole-
ly to a therapy effect or to patient selection. Only a randomised trial can largely exclude the 
influence of patient selection. However, experience with the NECOSAD-II study,12 intend-
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ed to be the first randomised controlled trial comparing HD and PD, demonstrates how dif-
ficult it is to randomise patients over different treatment modalities. Even •vhen patients 
have no specific indications or contra-indications for either HD or PD, the patients and 
their nephrologists generally have implicit or explicit ideas about the relative advantages of 
a specific therapy in their particular circumstances. In the absence of randomised trials, lon-
gitudinal studies, \vhich follow patients for a considerable time from the onset of dialysis, 
are the best alternative. The minimum set of background variables that should be con-
trolled for in such studies also emerges from our literature review (chapter 2). Important 
independent factors impacting on quality of life of patients are the presence of concurrent 
diseases,2 81013-20 age,2 810111315-18 21 education,210 1119 21 gender,810 race,1.5 16 time on 
dialysis/ total time with end-stage renal disease,8 11 20 haemoglobin level,s 10 13 haematocrit 
level,IO 22 serum albumin,1417l9 and residual renal function. 18 HO\vever, a recent study of 
Korevaar et al. in the Netherlands showed that multivariate adjustment for know case-mix 
differences at the start of dialysis therapy was not sufficient to adjust for all differences in 
quality of life of patients starting \vith HD and PD.12 After proper case-mix adjustment, 
pre-HD patients scored significantly lower than pre-PD patients, indicating that there are 
other unknown variables (possibly difficult to quantify) that influence the process of fitting 
patients to treatments. Korevaar et al. conclude that in future non-randomised studies to 
compare HRQOL of HD and PD patients, assessment of HRQOL just before start of 
dialysis and subsequent adjustment for baseline values should be performed.12 
Quality of life of Automated Peritoneal Dialysis patients (chapters 2 and 4) 
Although Automated Peritoneal Dialysis (APD) as a modification of Continuous 
Ambulatory Peritoneal Dialysis (CAPD) was developed in the early 1980s,23 surprisingly lit-
tle is knO\vn about quality of life of APD patients. However, the number of patients using 
APD has been growing fast in the :.\etherlands:24 on January 1 2000, 376 APD patients 
were registered in the Netherlands, representing more than 25(% of all peritoneal dialysis 
patients (n = 1,438). Between 1998 and 2000 the number of patients on APD rose from 
280 to 376, a 34% increase.24 The growing use of the APD technique is, however, not yet 
reflected in the quality of life literature, because our review (chapter 2) revealed only five 
studies that had included APD patients.25-29 C nfortunately, four of these five studies 
reported quality of life data at aggregate level only, hampering assessment of study results 
at the level of treatment modality. Only one study, a small randomised trial in 25 APD and 
CAPD patients published in 1999, reported data by treatment modality;28 no differences in 
quality of life benveen APD and CAPD patients were found. Another randomised clinical 
trial performed in the Netherlands in the early 1990s compared CAPD and Continuous 
Cycling Peritoneal Dialysis (CCPD), a variant of APD with an extra daytime exchange of 
dialysis fluid. 30 As part of this study, emotional wellbeing of patients was measured with 
the Affect Balance Scale,31 and overall wellbeing and overall satisfaction were measured 
using a 7-point Likert scale. Although these measures do not fit into our operationalisation 
of health-related quality of life (chapter 2), it is interesting to note that no differences were 
found betv:.reen the t\vo patient groups. 
Because little was known about health-related quality of life of APD patients at the time 
we performed our quality of life studies, an exploratory study was conducted (chapter 4). 
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Because the NECOSAD-TAS study included only 7 APD patients, additional interviews 
were held with 30 APD patients from three dialysis centres \Vith relatively large numbers of 
APD patients. To ensure comparability of the two groups, the inclusion and exclusion cri-
teria for APD patients were similar to those for the ::'\ECOSAD-PD patients. After adjust-
ment for case-mix variables, APD treatment appeared to be an independent indicator of 
better mental health (measured with the SF-36 mental health summary score) and of the 
absence of anxiety and depression (measured with the EQ-SDprofiiJ· Especially the social 
functioning of APD patients was better than that of CAPD patients; this might be because 
during the day APD patients are free from treatment, allowing a more normal social/work-
ing life. That APD patients were less anxious and depressed than CAPD patients is more 
difficult to explain, but treatment selection may have played a role. Patients with higher 
basic anxiety levels may avoid choosing the APD technique out of fear if being attached to 
a machine while asleep. Treatment selection in general must be considered when interpret-
ing the positive quality of life results of the APD patients in our study. The results of this 
first exploratory study warrant a larger and better controlled study, preferably a randomised 
trial. It may be less difficult to randomise PD patients to CAPD or APD, than to randomise 
dialysis patients to haemodialysis or to peritoneal dialysis. The small randomised study by 
Bro et aL28 and the Dutch study by de Fijter et aL30 have shown that, in principle, it is pos-
sible to randomise patients over both forms of peritoneal dialysis. 
High health preferences of dialysis patients (chapters 2, 3 and 4) 
Health preferences reported by 165 Dutch dialysis patients revealed relatively high values 
for the actual healcl1 status of patients (chapters 3 and 4). Values elicited with Standard 
Gamble (SG) and Time Trade Off (ITO) methods indicate that patients on average value 
their current health state as 74 to 93% of normal health. Typical values of prevalent dialy-
sis patients reported in the literature (Appendix 3A and 3B of chapter 2) range from 0.40 
to 0.70, with the exception of t\VO studies reporting values above 0.80.32 33 The average 
TTO value found for all 165 dialysis patients interviewed in our studies (0.89), was even 
somewhat higher than that found after renal transplantation (0.87) in another study.1 \\lhat 
could be the reasons for the differences in scores bet\veen previous studies and our work? 
Chapters 3 and 4 present several possible explanations. First, because all previous studies 
\vere performed in Canada or the CSA, one obvious explanation is that health values are 
not comparable across national or international borders. This explanation is supported by 
Veenhoven et aL who found that the perception of happiness and wellbeing differed 
benveen countries and continents.34 In their study, which included over SO countries, the 
Netherlands \Vas identified as having the second highest level of \vellbeing. Additional evi-
dence for the incomparability of health values comes from an American population study: 
the Beaver Dam Healcl1 Outcomes Study.35 Their random sample of 1,356 healthy persons 
(mean age 64 years) had a mean TTO values of 0.86 (s.d. 0.23), even lower than the mean 
TTO score from Dutch dialysis patients (0.89). Although to our knowledge TTO values 
have never been elicited in healthy Dutch persons, basic values around 0.86 seem highly 
unlikely, as long as the median value of dialysis patients in the same age range equals 1. 
Even within the same country, important quality of life differences ben.veen patients from 
different dialysis centres have been described. 19 Thus, another explanation may be the dif-
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ferences in healthcare and social security systems bertveen the Netherlands and north 
American countries. One obvious difference is that the drop in income after the onset of 
serious disease is much greater in the USA than in the Netherlands. 1'Ioreover, data report-
ed by 1'Iatas et al. suggest that patient populations in the USA and the Netherlands are 
incomparable.36 They describe the long-term quality of life after kidney and pancreas-kid-
ney transplantation in a cohort of 1,138 recipients of donor organs. The mean SF-36 scores 
in this transplanted population, supposedly better than scores of dialysis patients (chapter 
2), are similar to the mean SF-36 scores reported from the baseline quality of life measure-
ments of dialysis patients in the NECOSAD-I studyl3 The better quality of life scores may 
be attributable to the selection of healthier patients in the Netherlands, a higher level of 
healthcare for end-stage renal disease patients, or a higher general level of quality of life in 
the Netherlands. Another indication of the incomparability of patient populations between 
the continents is that the mortality rate of patients undergoing dialysis in the USA is 25-
50% higher than in Europe.37 Acceptance in the liSA of older and sicker patients with 
more coexisting conditions may explain these differences. 3! \Xlhatever the explanation for 
the differences, it clearly is difficult to extrapolate health preferences from one country to 
another, because it is unlikely that patient populations are comparable. TTO and SG values 
from north American end-stage renal disease patients may not be extrapolated to European 
patients. The influence of cultural differences on health preferences and the transferability 
of study results to other countries remain a subject for future study. 
(Societal) cost of renal replacement therapies (chapters 6 and 7) 
Although there is no lack of studies on the costs of renal replacement, Peeters et al. have 
shown that the quality of most studies is doubtfuJ.38 A major problem identified by Peeters 
et al. was that the perspective of the cost study was often not mentioned. Furthermore, 
important cost categories (e.g. hospitalisation or costs of nurses assisting with home thera-
py) were often ignored. According to international and recently issued Dutch guidelines on 
the different types of costs that should be included in economic evaluations, all relevant 
costs, irrespective of the payer, should be measured.39-44 All relevant costs include direct 
healthcare costs, direct non-healthcare costs, indirect non-healthcare costs and indirect 
healthcare costs. In our analysis of costs of renal replacement therapy (chapters 6 and 7), 
we have attempted to adhere to these guidelines. For major direct healthcare cost drivers 
such as hospitalisation and staff costs, we used primary data from the NECOSAD trial. \Xle 
believe that our estimates of direct healthcare cost are rather complete, although our cost 
figures for health service use outside dialysis centres (e.g. community nursing and general 
practitioner contacts) may be less reliable because we had to rely on patients' recall during 
face-to-face interviews. 
In our costing study, direct non-healthcare costs were rather high for centre haemodialy-
sis patients, mainly due to high travel costs. One limitation of our costing study is that help 
from the partner or other family members with home-based treatment was not valued in 
monetary terms. This may have led to an underestimation of the direct non-healthcare 
costs, and thus to an underestimation of total societal cost of kidney diseases. 
For indirect non-healthcare costs, "\ve used the friction cost method to value productivity 
losses, as recommended in recent Dutch guidelines for costing studies.43 For end-stage 
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renal disease patients still participating in the paid work, the estimated annual productivity 
losses ranged from NLG 1,120 (€ 510 for females) to NLG 1,820 (€ 827 for males) (chap-
ter 6). Total extrapolated indirect non-healthcare costs were small (:\:LG 3.5 million/ € 1.59 
million in 1994), mainly because most end-stage renal disease patients are older than 65 
years or stopped working long before the onset of renal replacement therapy. Therefore, 
the indirect non-healthcare costs were subsequently excluded from our economic evalua-
tion (chapter 7). In economic evaluation studies with a societal perspective, which should 
include indirect non-healthcare costs as part of tl1e analysis, it is easier to demonstrate the 
cost-effectiveness of therapeutic interventions. Including the effects on absenteeism and 
disablement payments, low net costs or even cost savings may be demonstrated. This is cer-
tainly not the case with renal replacement therapies, partially because most patients are 
around 65 years of age, and partially because younger patients seldom have full-time jobs. 
Thus, the effects of renal replacement therapy on indirect non-healthcare costs are negligi-
ble at group level. 
Especially in the case of ESRD patients, who die more or less immediately without RRT, 
it can be argued that all healthcare use not directly related to dialysis should be valued. \Ve 
have attempted to include indirect healthcare costs by the valuation of costs of hospitali-
sation, medication and other healthcare services, irrespective of the indication for which it 
was used. However, we may have missed considerable cost drivers, such as costs of diag-
nostic and surgical procedures. Interestingly, none of the economic evaluation studies iden-
tified in our literature revie-,.v (chapter 5) included indirect health care costs. In the absence 
of data for such estimates, average healthcare costs for age and gender, for instance as iden-
tified in top-down cost of illness studies,45 could serve as a proxy for indirect healthcare 
costs. 
Future cost studies should give more attention to direct non-healthcare costs. In particu-
lar, help given by partners and relatives should be valued because most home-based thera-
pies, such as home haemodialysis and peritoneal dialysis, require some assistance. In our 
study, only 5% of peritoneal dialysis patients received help from community nurses, imply-
ing that most received assistance from relatives. Information on financial contributions 
from the patients themselves, e.g. for special diets, alternative therapies or adaptations to tl1e 
house for home-based therapies, could further improve the current cost estimates. 
Together \\->ith Dutch incidence and prevalence data, our cost estimates per treatment 
modality were combined into a bottom-up estimate of the 1994 cost of illness of end-stage 
renal disease in the Netherlands (chapter 6). Total direct healthcare costs of kidney diseases 
were estimated at NLG 650 / € 295 million annually, equivalent to over 1% of total health-
care spending in 1994. Although our actual cost study was performed in 1996 (at 1996 price 
levels) (chapter 7), the 1994 disease-specific estimate (chapter 6) was adapted later from the 
1996 estimate, to allow a comparison with estimates presented in a general cost of illness 
study for the Netherlands in 199445 In this stndy (the KVZ stndy), costs of all diseases in 
the Netherlands in 1994 '\vere categorised into 62 disease clusters derived from the 
International Classification of Diseases-9th revision (ICD-9). \'X/ithin the group "renal and 
urogenital diseases", NLG 85 / € 38.6 million was allocated to the diagnosis group "nephri-
tis/ nephrosis/ nephropathy", the most obvious disease cluster for patients with chronic kid-
ney failure. The substantial difference ben.veen the t\vo estimates warranted the study pre-
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sented in chapter 6. It appeared that the difference bet:\veen both estimates is mainly 
explained by the completely different approaches of general and disease-specific cost of ill-
ness methods. The estimate of NLG 650 / € 295 million was arrived at following the dis-
ease-specific estimation, basically a multiplication of incidence and prevalence data by 
annual cost figures for ne\v and existing patients. The estimate of NLG 85 / € 38.6 million 
was arrived at in a general cost of illness study using a "top-dO\vn" method. The aim of 
general cost of illness studies is to categorise healthcare expenses into disease clusters, to 
gain insight into the relative cost of different diseases.46 The top-down method has an eti-
ologic orientation: costs of medical care are classified (as far as possible) according to the 
underlying disease. For instance, renal care for a patient with diabetic renal failure "\vill be 
classified under diabetes mellitus. Costs that are primarily related to comorbid conditions 
are classified under the comorbid condition. Othenvise, healthcare expenses for disease 
clusters would amount to more than 1001);(1 of total healthcare expenses.47 Because chron-
ic kidney failure is not a disease in itself but a result of damage to the kidneys due to vari-
ous diseases, kidney patients have remained relatively "invisible" in the general cost of ill-
ness study. Furthermore, it appeared that haemodialysis "\Vas seriously underreported in the 
Landelijke :J\tfedische Registratie (LMR), the national registration of hospital care in the 
Netherlands. Less than 1 °/G of all haemodialysis treatments in 1994 were registered in the 
L1fR. In the absence of LMR data on dialysis, it was decided to divide the amount of 
money that was earmarked for haemodialysis in the 1994 annual healthcare budget for the 
Netherlands ')aarovetzicht Zotg" (l"LG 227 / € 103.1 million) pro-tata ovet all62 ICD-9 
disease clusters. As a result, the substantial spending for haemodialysis patients disappeared 
completely in the KVZ study. In future reports of the KVZ study, this shortcoming should 
be addressed. One partial solution would be to assign the amount of money earmarked for 
haemodialysis in the national healthcare budget only to diagnostic groups covering end-
stage renal disease patients. Data from the Dutch Renal Replacement Registry (RENI~E), 
which registers the primary disease of all Dutch end-stage renal disease patients, could be 
used for this purpose. A "translation" of the 60 different primary diagnoses used to classi-
fy end-stage renal disease patients in RENINE to the diagnostic groups of the ICD-9 (such 
as used in the KVZ study) has been published by us elsewhete4 8 It appeated that only 12 
of the 62 diagnostic groups that were distinguished in the KVZ study covered end-stage 
renal disease patients. _0..1oreover, analysis of the allocation of all prevalent end-stage renal 
disease patients over these 12 diagnostic groups revealed that two third of all patients orig-
inate from only three disease clusters, namely hypertension (25%), diabetes mellitus (19%) 
and nephritis/nephrosis/nephropathy (22%). These data could be used to assign end-stage 
renal disease expenses pro-rata to relevant diagnostic groups only. Such an approach would, 
to some extent, reduce the "invisibility" of end-stage renal disease treatment in future gen-
eral cost of illness studies. Furthermore, the reporting of data by Dutch dialysis centres to 
the LMR should be dtastically improved. 
\-x:'e have limited our cost of illness study to end-stage renal disease, although originally we 
planned to report on cost of illness of kidney diseases. The latter includes all patients with 
reduced kidney functioning, without the necessity of renal replacement therapy (predialysis 
patients); however, many uncertainties surround the cost of illness of this patient group. 
First, the exact number of predialysis patients is unknown because many persons may be 
unaware of reduced kidney functioning. Based on the annual National Health Survey, it is 
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estimated that between 30,000 to 45,000 persons have kidney diseases, including those 
already using renal replacement therapy.48 However, many more may have a sub-clinical kid-
ney disease. In the future, data from the PREVEND study 49 may allow a more precise 
estimate of the number of patients at risk for end-stage renal disease. PREVEND is a 
cohort study in the general population of Groningen, aiming at the assessment of the 
prevalence of (different levels of) microalbuminuria . .1'\.lso, unknown is the volume and cost 
of healthcare provisions for predialysis patients. An American study on predialysis patients 
and end-stage renal disease patients sho"\ved similar hospitalisation rates and similar dura-
tion of hospital stay. .50 Patients identified with limited kidney function may use expensive 
"cocktails" of medication, such as ACE-inhibitors, calcium antagonists, diuretics, cardio-
vascular and lipid-lowering medication. Besides, regular blood and urine monitoring, renal 
biopsies, ultrasonography and other diagnostic procedures may increase the already high 
annual costs. fvfore studies are needed to identify the number of predialysis patients and the 
level of healthcare use and associated costs. In addition, economic evaluations should quan-
tify the benefits (economic and othenvise) of postponement of renal replacement therapy 
by appropriate management of predialysis patients. 
Cost-effectiveness of renal replacement therapies (chapters 5 and 7) 
The literature review on economic evaluations of renal replacement therapies presented in 
chapter 5 showed the flaws of most published studies. Considering the absolute cost of 
treatments and the relatively large proportion of the entire healthcare budgets spent on 
renal disease treatments (chapter 6), it is surprising that so few good quality economic eval-
uations of these programmes have been published. 
In chapter 7, the conclusion was drawn that it makes little sense to further concentrate on 
substitution policies to improve the cost-effectiveness of the end-stage renal disease pro-
gram. This conclusion is certainly valid for the Netherlands "\vhere the cheaper treatment 
modality, peritoneal dialysis, is widely accepted and patients are generally able to choose 
freely benveen different dialysis therapies. In the Netherlands as much as 30 percent of the 
patients are being treated with peritoneal dialysis.24 Once this high level of peritoneal dial-
ysis use is reached, further substitution from more expensive haemodialysis to less expen-
sive peritoneal dialysis no longer serves to improve the cost-effectiveness of the end-stage 
renal disease treatment program. Higher technique failure, 51 associated with more frequent 
changes of therapy and higher cost, is thought to be responsible for this result. However, 
use of peritoneal dialysis is not so widespread in other European countries (e.g. Belgium, 
Italy and France) where 10% or less of all end-stage renal disease patients are being treat-
ed with peritoneal dialysis. 52 \\!ider diffusion of peritoneal dialysis in such countries might 
contribute to improvement of overall cost-effectiveness of renal replacement therapies and 
may also decrease the total absolute amount spent on end-stage renal disease treatments. 
This assumption is supported by data from de Vecchi et al. who listed the overall amount 
of the national healthcare budget that is spent on dialysis treatment (hence, excluding renal 
transplantation) for several European countries: this ranges from 0.7% (United Kingdom) 
to 1.8% (Belgium), with most countries spending around 1.5% of healthcare budgets on 
dialysis. 53 The Dutch estimate of the national health care budget that was spent on all renal 
disease treatments including renal transplantation (1.1 %) as presented in chapter 7, is in the 
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lower part of the range reported by de Vecchi et al.53 Two explanations for the large dif-
ferences in healthcare spending are: the overall prevalence of end-stage renal disease treat-
ments in terms of the percentage of the population receiving treatment, and the relative 
amount of home-based therapies such as peritoneal dialysis and home haemodialysis. 
Countries where peritoneal dialysis has hardly diffused into the end-stage renal disease 
treatment programme consistently show relatively high spending on the renal replacement 
programme. 53 The only European country where peritoneal dialysis rates are higher than in 
the ~etherlands is the United I<:ingdom, \vhere 45% of dialysis patients are being treated 
with peritoneal dialysis. In the U.K. "only" 0.7% of the healthcare budget is spent on dial-
ysis treatments. The 1farkov-chain model that was presented in chapter 7 could be used to 
further explore the issue of the rationality of substitutive policies for countries other than 
the Netherlands. An example of such an investigation \VOuld be to construct a base-case 
scenario where only 2% of the incident and prevalent patients are being treated with peri-
toneal dialysis, while keeping all other model inputs constant. Then, it could be assumed 
that 10, 20 and 30% of new patients start with peritoneal dialysis. Such modelling work 
could shed further light on the possibility to further increase the cost-effectiveness of dial-
ysis provision. Recently, a similar approach was reported by K..irby and Vale 54 who 
employed a ~hrkov-model to determine "\vhich method of dialysis (CAPD or haemodialy-
sis) a patient should have as the initial method of RRT in the C.K., where approximately 
50% of new patients beginning dialysis receive CAPD. Of the 16 different scenarios 
explored, they found HD to be the dominant strategy (more effective at less cost) in 8 sce-
narios, wh..ile HD was more effective at higher cost than CAPD in the other 8 scenarios. In 
a literature review, they consistently found more treatment changes and lower technique 
survival rates for CAPD patients. I<:irby and Vale concluded that in the U.K., investing in 
more haemodialysis facilities could improve the overall cost-effectiveness of end-stage renal 
disease treatment. Our finding that, given a rate of PD use of 30°/o in the Netherlands, 
transfer of more HD patients to PD would not improve overall cost-effectiveness of the 
RRT programme, is in accordance 'N-ith I<:irby and Vale. 
Two scenarios explored in chapter 7 proved to be totally unrealistic: i.e. scenarios 4 and 5, 
which assumed a higher number of transplantations after the introduction of new donor 
legislation in 1998. This legislation encouraged active registration of the willingness to be a 
post-mortem donor for every Dutch citizen aged 18 years or older. It was expected that the 
number of renal transplantations would rise from 30 to 38 per million of the population,ss 
and perhaps even rise to 44 per million of the population (scenario 5). However, the num-
ber of post-mortem kidneys available for transplantation dropped from 412 in 1997 to 338 
in 1999. The total number of kidney transplants dropped from 505 in 1997 (32 per million 
of the population) to 454 in 1999 (29 per million population), despite a simultaneous 
increase in the number of living-related transplants.24 Thus, the new donor legislation did 
not contributed to a further increase in the cost~effectiveness of the Dutch end-stage renal 
disease programme, as was expected at the time of writing chapter 7. On the contrary, the 
new donor legislation may be regarded as very cost-ineffective because, apart from the cost 
of maintaining the registration, additional dialysis stations are needed to keep eligible 
patients in optimal condition, with associated intangible costs of sub-optimal health status 
and prolonged waiting time to transplant. The donor system may be characterised as a cost-
ly way of causing patient distress. 
166 
Chapter 9 
As was shown in chapter 5, most economic evaluation studies simply count the annual 
cost of therapy and claim this as the cost per life year gained, assuming that this investment 
yields one additional year of life. However, this approach does not reflect the clinical reali-
ty of changes benveen modalities, which occur frequently and at relatively high cost (chap-
ter 7). lvioreover, to state that renal transplantation or CAPD is the most cost-effective ther-
apy simply because it is cheaper than other treatments fails to take into account that a trans-
plantation programme can not exist \vithout the back-up of a dialysis programme. The dial-
ysis programme is needed to keep patients in optimal condition for the awaited transplant 
and to serve as a back-up in case the donor organ is rejected. This mutual dependency 
applies to all different dialysis modalities: patients who have or gradually develop con-
traindications for one treatment modality may benefit from the availability of other modal-
ities. The cost-effectiveness of end-stage renal disease treatments should, therefore, prima-
rily be assessed at an aggregate level, before considering the different therapeutic modali-
ties. For such an aggregate analysis, data on typical treatment patterns and changes between 
the different treatment modalities are needed. \Xle were able to use real-life data on patient 
and technique survival, as well as treatment histories of some 20,000 end-stage renal dis-
ease patients, from the Dutch Renal Replacement Registry. Our approach, an integrated 
analysis of the cost-effectiveness of the total end-stage renal disease treatment programme, 
is different from most other studies because the mutual dependencies in the overall treat-
ment programme are accounted for.56 In the treatment of end-stage renal disease, renal 
transplantation is generally regarded as the gold standard. However, the lack of donor 
organs and the necessity of a dialysis programme as back-up hampers the application of 
renal transplantation for all patients, despite its cost-effectiveness. Our approach ackno"vl-
edges the reality that without renal replacement therapy, patients with end-stage renal dis-
ease will die and that, at present, clinicians tend to consider all patients '\vith end-stage renal 
disease for dialysis, regardless of age or comorbidity. Future economic evaluations should 
report cost-effectiveness of treatment at the level of sub-groups of patients with identical 
case-mix, e.g. patients of similar age and with similar concurrent diseases. Such data report-
ing can contribute to existing knowledge on the cost-effectiveness of renal replacement 
therapy. 
One intriguing question is whether dialysis, if developed nowadays, would be reimbursed 
by public health insurance. Similar to 40 years ago, the strongest argument for reimburse-
ment is the life-saving capacity of this new medical technology. On the other hand, a cost-
effectiveness ratio as high as NLG 100,000 / € 45,500 per life-year gained compares 
unfavourably '\Vith most other new healthcare services. A recent technology with a similar 
high cost-effectiveness ratio that is reimbursed under Dutch health insurance is lung trans-
plantation. 57 Although this is an expensive technology, the budget implications are only a 
fraction of those of the introduction of dialysis, because the scarce availability of donor 
lungs severely restricts its use. Anocl1er example is Viagra; despite its relatively favourable 
cost-effectiveness profile it was not reimbursed, presumably because of the high number of 
possible users. ss For dialysis, given the enormous budget implications and unfavourable 
cost-effectiveness profile, it is likely that its diffusion would be severely restricted to specif-
ic patient groups, should a reimbursement decision be needed nowadays. 
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Methodological problems with health preference methods and the use of 
patient preferences in economic evaluations (chapters 2, 3, 4 and 8) 
Surprisingly few economic studies incorporating quality of life aspects were identified 
(chapter 5). However, because of the far-reaching consequences of being a RRT patient, 
intangible costs/ quality of life losses should be valued in a study. Thus, cost-utility analysis 
seems to be the best research design for the evaluation of interventions for end-stage renal 
disease patients. Preferences to be used in cost-utility analysis can be derived from patients, 
relatives, health professionals and the general population, using methods such as Time 
Trade Off (TTO), Standard Gamble (SG) and rating scale. Although the TTO is claimed 
to be a psychometrically sound measure in general 59 GO and in end-stage renal disease 
patients,61 our literature review (chapter 2) revealed doubts about this instrument. 
Application of the ITO as a valuation method of the own health state was hampered by 
relatively high non-response,1 62 63 and the TTO -.vas not responsive to clinical changes.64-
66 Our own studies (chapters 3,4, and 8) added doubts about the use of both TTO and SG 
as methods for the valuation of the patient's own health status. 
We have used TTO and SG as measures of health-related quality of life (HRQOL). The 
variance in all HRQOL outcomes \Vas only poorly to moderately explained by the clinical, 
socio-demographic and treatment-related variables included in our study (chapters 3 and 4), 
and found by others.2 10 141 61 9 This implies that HRQOL outcomes may be determined by 
factors other than the ones we explored. As in other studies using SG and ITO, patients 
were explicitly instructed to value their current health status only. However, we doubt 
whether patients have followed these instructions, or whether patients can follow these 
instructions. For instance, respondents referred to their wish to see grandchildren grow up, 
or to celebrate a future wedding anniversary when they refused to trade-off time for qual-
ity or to accept a gamble with a small chance of dying immediately. Other respondents con-
sidered it impossible to trade-off any lifetime at all or to accept a gamble, because such deci-
sions (even though hy'Pothetical) were not considered appropriate in the context of their 
religion. This may imply that responders are unable to distinguish bet\veen the h)'POthetical 
nature of the question and their personal or family situation, demonstrating the presence 
of confounding factors in the valuation of health status. It is difficult to control for these 
confounding factors because the sources of bias are very complex. In summary, a serious 
problem with both the TTO and SG is that they fail to distinguish health-related quality of 
life (as influenced by the health problem to be valued) from other factors that contribute to 
overall wellbeing. Health is only one factor that influences the health preference scores, and 
often not the most important one. 
In chapter 8, we discussed the sensitivity of TTO and SG to discriminate between thera-
peutic modalities. As described in chapters 3 and 4, no differences in valuations for the own 
health states were observed at the level of the different treatment groups. However, using 
several general population data sets for the valuation of health states, we observed differ-
ences in the valuation of health states of different patient groups. It was hypothesised that 
outsiders may identify subtle differences in the health status of patients, whereas the 
patients themselves "compress" their valuations in a small (upper) part of the scale, with 
inherent loss of discriminatory power. An obvious explanation for this phenomenon is that 
patients have been successful in applying coping strategies. They have incorporated their 
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expectations of the future into the valuation of their current health status and accept that 
their health status will most likely not improve. The valuation compression adds to the 
problems in the interpretation of preference scores from patients. 
At the time of designing our study (1994-1995), we planned to use patient preferences in 
the economic evaluation, together -with general population values. However, ranking of the 
quality of life scores of patients in the treatment groups appeared to differ depending on 
the perspective (patient/ general population) and valuation method. This observation, as 
well as problems in the interpretation of scores as (described above) and the methodolog-
ical problems identified in the literature review (chapter 2), strongly advocates not to use 
patient valuations in cost-utility analysis. Also, guidelines for and te.-xtbooks of economic 
evaluation published in the last five years have advocated the use of general population val-
ues. 39 44 HO\vever, this advice is often ignored in recent economic evaluations. 67 69 
Researchers planning economic evaluations alongside clinical studies should incorporate 
HRQOL instruments for which general population weights have been determined, such as 
the EQ-SD 70 or the SF-36.71 In comparison "\Vith patient interviews using TTO, SG or sim-
ilar instruments, this is a relatively easy, inexpensive and reliable way to elicit values to be 
used in economic evaluations. 
General remarks and directions for further research 
This thesis presents information on the economic evaluation of renal replacement thera-
pies. In the 40 years of its history, this is not the first attempt to collect data on cost and 
outcomes of end-stage renal disease treatment. On the contrary, our literature reviews 
(chapters 2 and 5) showed much research in this field. The current research builds on ear-
lier Dutch evaluation studies,72 73 but provides more accurate and up-to-date figures. 
Inevitably, areas for further research remain. 
\\lith respect to quality of life aspects, more studies are needed to gain a better under-
standing of quality of life of APD patients. Although \Ve have shown some benefits in 
HRQOL from APD treatment, these tentative results need confirmation. Furthermore, the 
issue of the relatively high health preferences of Dutch dialysis patients remains a challenge. 
Ideally, the relationship between health preference scores and health profile scores should 
be assessed within patient groups from different countries, to assess whether patient groups 
with similar health profiles differ with respect to their valuation of own health status. Data 
sets including at least either the SF-36 or the EQ-SD, and SG or TTO are needed for such 
research. Also, the observation that general population samples may better differentiate 
bet\veen patient groups than the patients themselves (as described in chapter 8), needs fur-
ther investigation. The study could easily be replicated with patient data sets including the 
EQ-SDprofile· Finally, our literature review showed that rl1e relationship bet\veen the process 
of care and HRQOL outcomes of patients has yet hardly been investigated. \V'hy do 
patients in one dialysis centre show better HRQOL than in another centre? Can differences 
in the process of care be identified and quantified? These questions remain to be answered 
by future research. 
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\\lith regard to economic aspects, the question remains whether cost advantages of home~ 
based techniques .._vill remain when the help of relatives with therapy are valued in mone-
tary terms. Furthermore, the current study focused more on dialysis than on renal trans-
plantation. For transplantation, we used estimates of the quality of life and cost figures 
published earlier. EQ-SD data are needed to better estimate patient and general population 
values of transplanted patients' health states. The Ivfarkov-model employed in chapter 7 
could be improved with better empirical data on renal transplantation, although it is unlike-
ly that the cost and outcome advantages of transplantation would change substantially. 
Recent developments in the field of renal replacement therapy have revealed new research 
topics. For example, daily home haemodialysis may be more costly but also more effective, 
as postulated recently in a small study;74 this claim should be further investigated. In addi-
tion, in future studies, cost-effectiveness of renal replacement therapy should be reported 
at the level of patient groups with similar case~mix profiles. Finally, the issue of the opti-
mal mix between treatments in order to organise the end~stage renal disease treatment pro-
gramme at national level in the most cost-effective way, warrants additional study. As was 
shown by Kirby and Vale, 54 a SO% peritoneal dialysis rate nationally may not be the most 
cost-effective way to organise the programme. We found that at a 30% peritoneal dialysis 
rate, the overall cost-effectiveness of the treatment programme could not be much 
improved. Future modelling studies should aim to quantify the optimal mix of treatments 
to ensure that end-stage renal disease treatment is offered in the most cost-effective way, 
not only in the Netherlands but also in countries where peritoneal dialysis has hardly dif-
fused into the healthcare system. 
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Summary 
Patients \Vith end stage renal disease are dependent on one of the three major types of renal 
replacement therapy currently available: haemodialysis, peritoneal dialysis and renal trans-
plantation. In the :\etherlands on January 1 2001, approximately 9,850 patients \Vere being 
treated \Vith renal replacement therapy. Each year more than 1,400 new patients have to 
start renal replacement therapy, which is a lifelong, complex and costly treatment with a 
serious impact on the patient's quality of life. 
The main objective of this thesis is to evaluate the costs and outcomes of end stage renal 
disease treatments in the Netherlands. The material presented in this thesis consists of lit-
erature reviews, empirical research on quality of life of dialysis patients and costs of dif-
ferent therapies, and modelling studies. The empirical work was performed in the context 
of an ongoing clinical cohort study on the adequacy of dialysis treatment, the :0:ECOSAD-
I study (Netherlands Cooperative Study on Adequacy of Dialysis). As a sub-study of 
~ECOSAD-I, the present study, called NECOSAD-Technology Assessment Study 
(NECOSAD-TAS), was initiated in 1995. 
The thesis comprises nine chapters. Chapter 1 gives background information on renal 
replacement therapies and on the epidemiology of renal failure in the Netherlands. The 
research questions addressed in the subsequent chapters are also briefly introduced in chap-
ter 1. 
Chapter 2 addresses quality of life measurements in renal failure patients. A systematic 
review of the literature on health related quality of life (HRQOL) of end stage renal dis-
ease patients is presented. The review focuses on six well-known HRQOL instruments used 
in renal populations: i.e. four health profiles (Short-Form 36, ~ottingham Health Profile, 
Sickness Impact Profile and Quality of Life Index.) and n.vo health preference methods 
(Standard Gamble and Time Trade Off). Studies "\vere identified using bibliographic data-
bases. Of the 114 publications that were initially selected because at least one of the six 
HRQOL instruments were applied, 57 remained after further selection based on study qual-
ity criteria. The main conclusions of the literature review are: (1) the methodological sound-
ness of the use of the Short-Form 36 and the Sickness Impact Profile in renal patients is 
best documented, (2) HRQOL of end stage renal disease patients is worse than HRQOL 
of the general population, especially in the physical dimensions of HRQOL, (3) a higher 
age and the presence of comorbid diseases are strong determinants of lower HRQOL of 
renal disease patients, (4) HRQOL of transplanted patients is better than that of dialysis 
patients, but no major HRQOL differences exist benveen patients treated with the differ-
ent dialysis modalities. 
Chapter 3 presents a cross-sectional study on HRQOL of 69 haemodialysis and 66 peri-
toneal dialysis patients participating in NECOSAD-TAS. HRQOL was assessed with t\vo 
health profiles (Short-Form 36 and EQ-5Dprofile) and two health preference methods 
(Standard Gamble and Time Trade Off). Few studies have applied these two different types 
of HRQOL instruments simultaneously. The main objective of this study was to assess the 
relationship beD.veen information acquired from the rum different types of HRQOL instru-
ments in dialysis patients. A second aim was to compare HRQOL between the t\vo dialysis 
groups and also to compare HRQOL of dialysis patients with a general population sample 
of similar age. The relationship bet\veen socio-demographic, patient-related and treatment-
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related background variables and HRQOL outcomes was also investigated. HRQOL of 
dialysis patients, as measured with health profiles, was severely impaired. The health pref-
erence scores of patients however were higher (0.82 to 0.88) than previously reported in the 
literature. Correlations betvv'een health profiles and health preferences were poor to mod-
est. HRQOL outcomes were poorly explained by background characteristics. There were no 
significant differences in HRQOL ben.veen the haemodialysis and peritoneal dialysis 
groups. It is concluded that health profiles and health preference methods represent differ-
ent aspects of HRQOL. An impaired health status may not be reflected in the preference 
scores. Coping strategies and other attitudes towards health may have a stronger effect on 
the preference scores than on the health profile outcomes. It is concluded that the added 
value of health preference methods in clinical research may be limited. 
Chapter 4 investigates HRQOL of Automated Peritoneal Dialysis (APD) patients. 
Because APD is a relatively new technique, data on HRQOL of APD patients are scarce. 
The objectives of this cross-sectional study were (a) to explore HRQOL of APD patients, 
(b) to compare this outcome with HRQOL of continuous ambulatory peritoneal dialysis 
(CAPD) patients and a general population sample, and (c) to study the relationship between 
HRQOL outcomes and background variables. The srudy sample comprised 37 APD 
patients and 59 CAPD patients from NECOSAD·TAS. HRQOL instruments used were 
similar to those in the study reported in chapter 3. Physical functioning of both APD and 
CAPD patients was more impaired than in the general population, but there were no dif-
ferences in mental functioning. !\Iultivariate analyses sho"\ved that the mental health of APD 
patients was better than that of CAPD patients. In addition, APD patients were less anx-
ious and depressed than CAPD patients. There were no differences bet\:veen APD and 
CAPD patients concerning the physical aspects of HRQOL and role functioning. Other 
variables that influenced HRQOL outcomes \Vere age, the number of comorbid diseases, 
and type of primary kidney disease. It was concluded that HRQOL of APD patients is at 
least equal to that of CAPD patients. 
Chapter 5 presents a systematic literature review on economic evaluations of renal 
replacement therapy published bet\veen 1988 and 2000. The aim of this study \vas to review 
and compare current knowledge on the costs and effects of renal replacement therapies, 
and to assess the methodological quality of the economic evaluations in the field. Of the 
more than 1,700 references found in six bibliographic databases, 127 publications were 
assessed using a standardised quality rating system. Of these, only 11 papers were of suffi-
cient methodological quality. In general, studies were particularly weak \vith regard to the 
costing parts, including lack of discounting and not applying the opportunity cost princi-
ple. Renal transplantation and CAPD were consistently found to be more efficient than 
haemodialysis. The interpretation of this conclusion is, however, hampered by the fact that 
most studies did not correct for differences in casemix bet\\7een patients being treated "\Vith 
different renal replacement therapies. 
Chapter 6 evaluates the cost of illness of end stage renal disease in the ~etherlands in 
1994, including an estimation of the number of Disability Adjusted Life Years (DALYs) 
associated with end stage renal disease. Projections of patient numbers and costs to socie-
ty up to 2003 are also presented. The costs of five dialysis modalities and of renal trans-
plantation were estimated using data from NECOSAD-I, additional data collection in dial-
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ysis centres, published data, and interviews with 165 dialysis patients. Cost per treatment 
modality was combined with detailed 1994 data on incident and prevalent patient numbers 
and treatment changes from the Dutch Renal Replacement Registry, to estimate total direct 
healthcare cost of renal replacement therapy. The cost of renal replacement therapies 
ranged from NLG 18,000 (€ 8, 182) for renal transplantation to NLG 142,000 (€ 64,545) for 
centre haemodialysis, per patient per year. Total direct medical cost of care for renal patients 
were NLG 584 million (€ 265.45 million) in 1994, representing about 1% of total health-
care spending in that year. Indirect costs amounted to NLG 3.5 million (€ 1.59 million). 
Renal diseases were associated \.vith a loss of 14,000 DALYs. In 2003, we expect around 
11,500 patients in the renal replacement programme, with associated societal costs of more 
than NLG 900 million (€ 409.1 million). It is concluded that renal insufficiency is a major 
health problem in the Netherlands, associated with a considerable loss of DALYs and high 
costs to society. 
Chapter 7 examines the cost-effectiveness of end stage renal disease (ESRD) treatments. 
Empirical data on costs of treatment modalities and quality of life of patients were col-
lected alongside a clinical trial and combined 1.vith data on patient and technique survival 
from the Dutch Renal Replacement Registry. A ~hrkov-chain model, based on the actual 
Dutch ESRD program as at January 1 1997, was employed to estimate the cost-effective-
ness and cost-utility of dialysis and transplantation over the 5-year period 1997-2001. At the 
aggregate level, full care centre haemodialysis \.Vas found to be the least cost-effective treat-
ment, while transplantation and CAPD were the most cost-effective treatments. lJsing the 
;vrarkov-chain model, the influence of policies to transfer patients from more to less expen-
sive dialysis modalities on the overall cost-effectiveness of the Dutch ESRD treatment pro-
gram was studied. The influence of such policies in the Dutch context was found to be 
modest, because a high percentage of patients is already being treated with more cost-effec-
tive treatment modalities. In countries \.vhere haemodialysis is still the only or the major 
treatment option for ESRD patients, transfer of patients from haemod.ialysis to CAPD 
might have a more substantial impact on overall cost-effectiveness of ESRD treatment. 
Chapter 8 returns to the topic of the quality of life of patients, but now focusing on 
implications of the use of patient values (or patient utilities) in eYaluative research. The 
chapter is rooted in the observation that for all dialysis treatment groups, patients showed 
similar Time Trade Off and Standard Gamble scores for their own health state, whereas the 
general population valuations for the same health states were found to differ across treat-
ment groups. First, we summarise the literature on differences in valuation for hypothetical 
and actual (own) health states between patient groups and bet\veen patient groups and 
other rater groups. It was found that patients' values are generally higher than outsiders' val-
ues. Second, rum empirical studies on dialysis patients and other rater groups are reported. 
In the first study, dialysis patients and students had to value hypothetical health states with 
Standard Gamble and Time Trade Off. Patients assigned higher values than d1e students to 
hypothetical health states. In the second study, dialysis patients being treated with four dif-
ferent dialysis modalities were asked to value their own health state with Standard Gamble, 
Time Trade Off and a visual analogue scale (EQV..'\S), and to describe their health state on 
the EQ-SDprofile· Several EQ-5Dindex values (health index values derived from general pop-
ulation samples) were calculated for the four dialysis treatment groups, based on their EQ-
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5Dprofile· These health indexes discriminated behveen treatment groups, according to clini-
cal impressions. However, treatment groups could not be differentiated based on the 
patients' own valuations of their health state. \Xlhereas outsiders use almost the entire scale 
for their valuation of different health states, patients' valuations are compressed in the 
upper part of the scale; this may be due to the patients' successful coping behaviour. These 
results suggest that, using EQ-SDindcx values, general population samples may better dis-
criminate behveen patient groups than the patients themselves. The valuation compression 
found in the patient groups may hamper the use of patient values in economic evaluations. 
Chapter 9 summarises the most important findings of the studies addressed in this thesis 
and presents recommendations for further research. The results indicate that there are no 
major differences in HRQOL benveen haemodialysis patients and peritoneal dialysis 
patients. HRQOL of dialysis patients, as measured with health profiles, is more severely 
impaired than that of the general population. However, the high patient preferences elicit-
ed with Time Trade Off and Standard Gamble indicate that HRQOL is much less impaired 
than suggested from the application of health profiles. The fact that health preferences 
measure more than HRQOL alone may explain this contradiction. Factors influencing 
Standard Gamble and Time Trade Off scores include coping behaviour and personal cir-
cumstances. This hampers the interpretation of patient valuations. Therefore, patient valu-
ations of own health status should not be used in evaluative research. A study on the cost 
of illness showed relatively high societal cost and a high public health burden of end stage 
renal disease. A scenario study revealed that there is little room for improvement in the 
overall cost-effectiveness of the Dutch end stage renal disease treatment programme. 
Future studies should focus on elucidation of the high health preference scores of Dutch 
dialysis patients, on improvement of cost estimates, especially direct non-health care costs, 
and on economic evaluation of renal replacement therapy for specific patient groups -..vith 
a similar casemix. 
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De belangrijkste functie van de nieren is om afvalstoffen en overtollig vocht te venvijderen 
uit het lichaam. Hoewel een mens ook goed kan functioneren met niet optimaal werkende 
nieren is er een stadium dat het vasthouden van afvalstoffen, zouten en water fataal kan 
worden. \X1e spreken dan over terminale nierinsufficientie. In dat stadium van nierziekten 
moet gestart worden met nierfunctievervangende behandelingen, anders zullen patienten 
spoedig overlijden. Drie belangrijke vormen van nierfunctie vervangende therapie zijn 
haemodialyse, peritoneale dialyse en niertransplantatie. Bij haemodialyse wordt bet bloed 
ontdaan van afvalstoffen doordat het gespoeld wordt door een kunstnier in een dialyseap-
paraat. De patient wordt meestal drie keer per week gedurende enkele uren gedialyseerd in 
een van de circa 50 Nederlandse dialysecentra. Bij peritoneale dialyse wordt het bloed con-
tinue gezuiverd omdat er enkele malen per dag nieuwe spoelvloeistof in de buikholte wordt 
ingebracht. Het buikvlies fungeert bij peritoneale dialyse als een filter, dat het bloed van 
afvalstoffen zuivert. De patient kan deze handeling zelf thuis verrichten. Bij niertransplan-
tatie krijgt de patient een "nieuwe" nier van een donor. Een succesvolle niertransplantatie 
maakt de continue behandeling van nierinsuffidentie door dialyse overbodig. Vanwege een 
schaarste aan donororganen is niertransplantatie niet voor alle personen die daarvoor in 
aanmerking zouden komen mogelijk. Op 1 januari 2001 "\verden in Nederland circa 9850 
personen behandeld met een van de drie vormen van nierfunctievervangende therapie. 
Jaarlijks starten circa 1400 nieuwe patienten met nierfunctievervangende behandelingen. 
Deze complexe en dure behandelingen moeten levenslang worden volgehouden en be'in~ 
vloeden de l'""\\,.aliteit van leven van de patient in hoge mate. 
Het doel van het in dit proefschrift beschreven onderzoek is om de kosten en effecten van 
nierfunctievervangende behandelingen in Nederland te evalueren. Daarvoor werd gebruik 
gemaakt van literatuuronderzoek, empirisch onderzoek naar de kwaliteit van leven van 
patienten en de kosten van diverse behandelmethoden, en van modellering. Het empirische 
deel van het onderzoek werd uitgevoerd in de context van een groot klinisch patientge-
bonden cohortonderzoek, de zogenaamde NECOSAD-I studie (Nederlandse CoOperatieve 
Studie naar de Adequaatheid van Dialyse). In 1995 ging de NECOSAD - Technology 
Assessment Study (NECOSAD-TAS) van start, als onderdeel van de NECOSAD-1 studie. 
De resultaten van NECOSAD-TAS beschrijf ik in dit proefschrift. 
Dit proefschrift bestaat uit negen hoofdstukken. Hoofdstuk 1 geeft achtergrondinfor-
matie over de epidemiologic van nierziekten in Nederland en beschrijft de belangrijkste 
nierfunctievervangende behandelingen. Tevens biedt dit hoofdstuk een introductie op de 
onderzoeksvragen die in de verschillende hoofdstukken aan bod komen. 
Hoofdstuk 2 gaat over het meten van de kwaliteit van leven bij nierpatienten. Het geeft 
de resultaten weer van een systematisch literatuuronderzoek op bet terrein van gezondhei-
dsgerelateerde kwaliteit van leven van nierpatienten. Dit literatuuronderzoek richt zich op 
zes bekende instrumenten om de kwaliteit van leven te meten. Aileen toepassingen van die 
meetinstrumenten bij nierpatiCnten zijn meegenomen. Vier van de zes meetinstrumenten 
zijn gezondheidsprofielen (Short-Form 36, Nottingham Health Profile, Sickness Impact 
Profile en Quality of Life Index), waarbij aan de patient gevraagd wordt om op een aantal 
aspecten van kwaliteit van leven aan te geven hoe goed of slecht bet met hem of haar gaat. 
De t\vee andere meetinstrumenten (Time Trade Off en Standard Gamble) zijn instru-
menten om de subjectieve waardering van de patient voor zijn of haar gezondheidstoestand 
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te meten. Aan de respondent wordt gevraagd om aan te geven hoe deze zijn of haar 
gezondheid waardeert. Daarvoor -..vordt gebruik gemaakt van een vraag- en ann.:voordspel, 
waarbij de keuzes die de respondent maakt geacht worden de onderliggende waardering 
voor zijn of haar gezondheidstoestand te reflecteren. Dergelijke metingen worden ook wel 
utiliteitsmetingen genoemd. 
Relevante studies voor hct literatuuronderzoek werden geldentificeerd met behulp van 
bibliografische databases. Op basis van vooraf geformuleerde kwaliteitscriteria bleven 57 
van de 114 gevonden studies over voor dit literatuuronderzoek. De voornaamste conclusies 
ervan zijn: (1) dat voor de toepassing van de zes meetinstrumenten bij nierpatienten de 
methodologische eigenschappen van Short-Form 36 en Sickness Impact Profile het best 
zijn gedocumenteerd, (2) dat de gezondheidsgerelateerde kwaliteit van leven van patienten 
met nierinsufficiEntie slechter is dan die van groepen uit de algemene populatie, vooral voor 
wat betreft de fysieke component van h-waliteit van leven, (3) dat een hogere leeftijd en de 
aanwezigheid van andere ziekten sterke determinanten zijn van een lagere kwaliteit van 
leven, en (4) dat de kwaliteit van leven van patiEnten die een niertransplantatie hebben 
ondergaan beter is dan die van dialysepatiEnten, maar dat tussen de verschillende dialyse-
behandelingen geen duidelijke verschillen in kwaliteit van leven worden gevonden. 
Hoofdstuk 3 beschrijft de resultaten van een cohortstudie naar de kwaliteit van leven van 
69 haemodialysepatiEnten en 66 peritoneale dialysepatiEnten die aan 2'\ECOSAD-TAS 
meededen. De kwaliteit van leven werd geevalueerd met t\vee gezondheidsprofielen (Short-
Form 36 en EQ-SDprofiiJ en t\vee waarderingsmethoden (Standard Gamble en Time Trade 
Oft). De EQ-SDprofile is een veelgebruikt instrument om de gezondheidstoestand te meten, 
maar werd niet eerder bij nierpatiEnten toegepast. Ook zijn er weinig studies gepubliceerd 
waarbij zowel gezondheidsprofielen als waarderingsmethoden gelijktijdig worden gebruikt 
om de kwaliteit van leven van een groep patitnten te beschrijven. Daarom was het voor-
naamste doel van dit onderzoek om de relatie te bestuderen tussen informatie die respec-
tievelijk met behulp van gezondheidsprofielen en waarderingsmethoden verkregen wordt. 
Andere doelen van het onderzoek waren de vergelijking van de kwaliteit van I even van beide 
groepen dialysepatiEnten onderling en die van dialysepatiEnten met leeftijdgenoten uit de 
algemene populatie. Ook werd de relatie tussen socio-demografische kenmerken van 
patiEnten, patiEntgerelateerde en behandelingsgerelateerde variabelen en kwaliteit van leven 
onderzocht. De gezondheidsprofielen lieten zien dat dialysepatiEnten op een aantal ter-
reinen van kwaliteit van leven aanzienlijke problemen kennen. De scores op de waarder-
ingsmethoden waren echter boger dan eerder in de literatuur beschreven. De correlatie 
tussen de scores op de gezondheidsprofielen en de scores op de waarderingsmethoden was 
zwak tot matig. Beide vormen van hvaliteit van leven uitkomsten konden niet goed worden 
verklaard door de onderzochte achtergrondkenrnerken. Ook waren er geen significante ver-
schillen in l_·,.valiteit van leven tussen de beide groepen dialysepatiEnten. In hoofdstuk 3 
wordt de conclusie getrokken dat gezondheidsprofielen en waarderingsmethoden verschil-
lende aspecten van kwaliteit van leven representeren. Een slechte gezondheidsstatus hoeft 
blijkbaar niet gereflecteerd te worden in een waardering voor de kwaliteit van het leven. 
Aanpassing (coping) en preferenties voor andere zaken dan gezondheid aileen lijken de 
waardering voor de kwaliteit van het leven veel sterker te belnvloeden dan de scores op de 
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gezondheidsprofielen. In klinisch onderzoek is de meenvaarde van toepassing van patitnt-
waarderingen \TOOt de kwaliteit van het kven boven het gebruik van gezondheidsprofielen 
daardoor waarschijnlijk beperkt. 
De kwaliteit van leven van patitnten die behandeld worden met automatische peritoneale 
dialyse (APD) is bet ondenverp van Hoofdstuk 4. Omdat APD een relatief nieuwe vorm 
van peritoneale dialyse is zijn hierover nauwelijks kwaliteit van leven gegevens bescbikbaar. 
Daarom is bet lastig om k\valiteit van leven overwegingen mee te nemen bij de thera-
piekeuze. De doelstellingen van het in dit hoofdstuk beschreven onderzoek zijn: (a) de 
kwaliteit van leven van APD patitnten te beschrijven, (b) deze te vergelijken met de kwaliteit 
van leven van patitnten die behandeld worden met continue ambulante peritoneale dialyse 
(CAPD), (c) de relatie tussen hvaliteit van leven en achtergrondkenmerken te onderzoeken. 
De onderzochte groep bestond uit 37 APD patitnten uit drie Nederlandse dialysecentra en 
59 CAPD patitnten die aan NECOSAD-TAS meededen. De gebruikte kwaliteit van leven 
meetinstrumenten -,.varen hetzelfde als in het in hoofdstuk 3 beschreven onderzoek. Het 
fysieke functioneren van zowel APD als CAPD patitnten -,.vas slechter dan dat van de ref-
erentiegroep uit de algemene populatie, maar qua psychologisch functioneren werden geen 
verschillen met de algemene populatie gevonden. fviultivariate analyses lieten zien dat de 
mentale gezondheid van APD patitnten beter was dan die van CAPD patitnten. Daarnaast 
waren APD patitnten minder angstig en depressief dan CAPD patitnten. Qua fysiek func-
tioneren en op het gebied van zowel emotionele als fysieke rolfuncties werden geen ver-
schillen tussen beide groepen gevonden. Achtergrondvariabelen die geassocieerd -,.varen met 
k-,.valiteit van leven uitkomsten waren leeftijd, het aantal bijkomende ziekten en de primaire 
nierziekte. De conclusie die in hoofdstuk 4 getrokken wordt is dat de kwaliteit van leven van 
APD patitnten op zijn minst gelijk is aan die van CAPD patitnten. 
In Hoofdstuk 5 worden de economische as pecten van behandeling van nierfalen gelntro-
duceerd. In dit hoofdstuk wordt een systematisch literatuuronderzoek gepresenteerd van 
alle goede economische evaluaties van nierfunctievervangende behandelingen die gepub-
liceerd \Verden tussen 1988 en 2000. Het doel hiervan was om de stand van zaken op bet 
gebied van onderzoek naar kosten en effecten van nierfunctievervangende behandelingen 
weer te geven en om de methodolof:,rische kwaliteit van dit onderzoek te beoordelen. Van 
de ruim 1700 referenties die ik vond in zes bibliografische bestanden, werden 127 relevante 
publicaties beoordeeld met behulp van een kwaliteitsbeoordelingssysteem. Slechts 11 stud-
ies bleken op de meest essentide punten aan de eisen die aan economisch evaluatieonder-
zoek gesteld mogen worden te voldoen. De grootste manco's in de niet geselecteerde stud-
ies bleken op bet gebied van bet kostenonderzoek te liggen; zo werd er vaak niet gediscon-
teerd en ook werd het opportuniteitskostenbeginsel niet toegepast. Vrijwel aile onderzochte 
studies concludeerden dat niertransplantatie en CAPD de meest kosten-effectieve behan-
delvormen zijn. De interpretatie van de conclusies in de 11 studies wordt echter bemoeil-
ijkt doordat vrij~.vel nooit rekening gehouden werd met het feit dat de verschillende behan-
delvormen worden gebruikt voor patitntengroepen die vaak heel verschillend ZlJn qua 
leeftijd, aantal en aard van bijkomende ziekten en gezondheidsstatus. 
Hoofdstuk 6 beschrijft de maatschappelijke kosten en ziektelast van terminale nierinsuf-
ficientie in Nederland. In dit hoofdstuk wordt een raming gemaakt van het aantal Disability 
Adjusted Life Years (DALY's) dat hiermee samenhangt. Tevens wordt een taming gemaakt 
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van de ont\vikkelingen in aamallen patiCnten en maatschappelijke kosten van behandeling 
van nierziekten tot aan het jaar 2003. De kosten van vijf verschillende vormen van dialyse 
en niertransplantatie en de kosten van overgang naar een andere behandelvorm werden ger-
aamd met gegevens uit NECOSAD-I, aanvullende dataverzameling in een aantal dialyse-
centra, gepubliceerde data en een interview met 165 dialysepatiEnten. De Nederlandse reg-
istratie van niervervangende behandelingen (Stichting Renine) leverde gedetailleerde 
gegevens uit 1994 over het aantal nieuwe en bestaande ~ederlandse patiCnten per behan-
delvorm en over het voorkomen van wisselingen tussen de diverse behandelvormen. Deze 
epidemiologische gegevens \.verden gecombineerd met de opgestelde kostenraming per 
behandelvorm en de kosten van verandering van therapievorm om de to tale directe gezond-
heidszorgkosten van nierfunctievervangende behandelingen in 1994 te ramen. De kosten 
van nierfunctievervangende therapie varieren van NLG 18000,- (€ 8182,-) voor niertrans-
plantie tot NLG 142000,- (€ 64545,-) voor passieve centrum haemodialyse (een vorm van 
centrum haemodialyse waarbij aile noodzakelijke handelingen door verpleegkundigen wor-
den verricht), per patient per jaar. De totale directe medische kosten van zorg voor nier-
patiCnten waren 584 miljoen gulden (€ 265,45 miljoen) in 1994, oftewel ongeveer 1 °/o van 
de totale uitgaven aan gezondheidszorg in dat jaar. Kosten van productieverliezen als gevolg 
van de nierziekte \verden geraarnd op ongeveer 3,5 miljoen gulden (€ 1,59 miljoen). 
Nierziekten \Varen geassocieerd met een verlies van 14000 DALY's in dat jaar. DALY is een 
maat waarmee aangegeven kan worden hoe groot de volksgezondheidslast is van een 
bepaalde ziekte, in vergelijking met andere ziektes. De volksgezondheidproblematiek als 
gevolg van nierziekten blijkt vergelijkbaar te zijn met die \Tan bijvoorbeeld AIDS, influenza 
en schizofrenie. Naar venvachting zullen er in het jaar 2003 ongeveer 11500 patiCnten met 
nierfunctievervangende therapie behandeld worden, en zullen de maatschappelijke kosten 
van nierziekten oplopen tot circa 900 miljoen gulden (€ 409 miljoen). De conclusie van dit 
onderzoek is dat nierinsufficientie in Nederland een belangrijk gezondheidsprobleem is met 
een aanzienlijk verlies aan DALY's en hoge kosten voor de sarnenleving. 
Hoofdstuk 7 behandelt de kosten-effectiviteit van niervervangende behandelingen. Voor 
deze studie werden gegevens verzarneld over de kosten van vijf verschillende dialysebe-
handelingen. Om het effect van de verschillende behandelingen in kaart te brengen werden 
de gegevens die over de 1._,.valiteit van leven van patiCnten verzarneld zijn (zie hoofdstukken 
3 en 4) gecombineerd met gegevens over de overlevingsduur van patiCnten en de "technis-
che overlevingsduur" van behandelingen ( dit is de tijdsduur totdat een definitieve overs tap 
naar een andere behandelingsvorm wordt gemaakt). Deze gegevens werden verkregen van 
de Stichring Renine, die een registratie bijhoudt van alle nierfunctievervangende behan-
delingen die in Nederland worden uitgevoerd. J\Iet behulp van een 1Jarkov-keten model 
werd de kosten-effectiviteit en kosten-utiliteit van alle niervervangende behandelingen, 
inclusief transplantatie, geraamd over de vijfjaarsperiode 1997-2001. Uitgangspunt van deze 
modelleringsexercirie waren de empirische gegevens over nierfunctievervangende behan-
delingen in Nederland per 1 januari 1997. Op geaggregeerd niveau bleek haemodialyse de 
behandeling te zijn met de hoogste kosten-effecriviteitsratio (dat wil zeggen de hoogste 
kosten per gewonnen levensjaar), tenvijl CAPD en niertransplantatie relatief lage kosten-
effecriviteitsratio's hadden. 1Iet behulp van het J\Iarkov-keten model werd onderzocht of 
beleid gericht op subsritutie van patiEnten van duurdere naar goedkopere behandelvormen 
invloed zou hebben op de kosten-effectiviteit en kosten-utiliteit van het totale ~ederlandse 
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ruervervangmgsprogramma. Deze studie wees uit dat dergelijk beleid waarschijnlijk "\Veinig 
zal verbeteren aan de totale kosten-effectiviteit van nierfunctievervangende behandelingen, 
omdat in Nederland reeds een relatief groot deel van de patienten behandeld wordt met de 
meer kosten-effectieve behandelvormen zoals CAPD. Slechts een drastische verhoging van 
het aantal transplantaties zal de doelmatigheid van het Nederlandse niervervangingspro-
gramma verbeteren. Er zijn echter veel landen waar haemodialyse de enige of verreweg 
belangrijkste behandelvorm voor nierfalen is. In deze landen zou dergelijk substitutiebeleid 
wellicht de kosten-effectiviteit van het totale behandelprogramma kunnen doen toenemen. 
In Hoofdstuk 8 keren we weer terug naar het thema kwaliteit van leven. In dit hoofdstuk 
gaat het om de vraag wat de gevolgen zijn van bet gebruik van patienrwaarderingen (zoge-
naamde patientutiliteiten) in evaluatieonderzoek. Het idee voor dit hoofdstuk werd geboren 
uit de observatie dat patienten uit alle dialysegroepen ongeveer dezelfde Time Trade Off en 
Standard Gamble scores hadden, tenvijl de waarderingen van buitenstaanders (groepen uit 
de algemene populatie) voor de gezondheidstoestand van die verschillende patienten-
groepen wei degelijk heel verschillend waren. Allereerst wordt in dit hoofdstuk een samen-
vatt:ing gegeven van de bestaande literatuur op het terrein van waarderingsverschillen voor 
de eigen dan wel een hypothetische gezondheidstoestand, zowel tussen groepen patiCnten 
onderling als tussen pat:iCnten en buitenstaanders. Een buitenstaander kan zowel een 
volledig gezond persoon zijn als een patient die een andere dan zijn eigen gezondheidstoe-
stand waardeert. Voorts worden nvee empirische studies gepresenteerd waarbij patient-
waarderingen vergeleken worden met waarderingen van buitenstaanders. In de eerste studie 
werd aan dialysepatienten en gezonde studenten gevraagd om hypothet:ische gezondheid-
stoestanden te waarderen met behulp van Standard Gamble en Time Trade Off. PatiCnten 
gaven hogere waarderingen aan deze hypothetische toestanden dan studenten. In de tweede 
studie werd aan vier groepen dialysepatiCnten, die allen met een andere vorm van dialyse 
behandeld werden, gevraagd om hun eigen gezondheidstoestand van dat moment te 
waarderen met Time Trade Off, Standard Gamble en een Visueel Analoge Schaal CEQvAs)· 
Tevens werd gevraagd om de eigen gezondheidstoestand te beschrijven met behulp van het 
EQ-5Dpwfilo· Gebaseerd op die door de patient zelf beschreven gezondheidstoestand wer-
den voor de vier dialysegroepen EQ-SDindex waarden berekend. EQ-SDindex waarden weer-
spiegelen de waarderingen van de algemene populatie voor bepaalde gezondheidstoes-
tanden die beschreven worden met het EQ-SDprofile· Er werden verschillende beschikbare 
EQ-5Dindex '\Vaarden gebruikt, afkomstig van populatiestudies uit verschillende Europese 
landen en gebaseerd op verschillende meetmethoden, zoals Time Trade Off en Visueel 
Analoge Schaal. Op basis van de EQ-SDindex Time Trade Off waarderingen kon een ran-
gorde in de vier dialysegroepen aangebracht worden die overeen kwam met klinische obser-
vaties. Op basis van de directe patientwaarderingen ( ook Time Trade Off) was echter geen 
onde:rscheid tussen de vier behandelgroepen te maken. \Xlaar buitenstaanders (i.e. de 
algemene populatie) vrijwel de hele beschikbare schaal gebruiken voor de waardering van 
de verschillende gezondheidstoestanden, worden de waarderingen van patienten gecom-
primeerd in het bovenste gedeelte van de schaal, het gedeelte waarin de betere gezondhei-
dstoestanden zich bevinden. Dit zou het gevolg kunnen zijn van succesvol coping gedrag 
van patiemen. Deze resultaten suggereren dat buitenstaanders beter in staat zijn om 
gezondheidstoestanden te onderscheiden in termen van bvaliteit van leven dan de patien-
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ten zelf. Het gebrek aan sensitiviteit van patiCntwaarderingen voor hvaliteit van leven 
beperkt de toepassing van patiCntv.raarderingen. Gebruik hiervan als primaire uitkomstmaat 
bij economisch evaluatieonderzoek moet dan ook worden ontraden. 
In Hoofdstuk 9 worden de belangrijkste bevindingen van de verschillende studies uit dit 
proefschrift samengevat en bediscussieerd. Ook worden aanbevelingen voor verder onder-
zoek gedaan. De resultaten van dit onderzoek laten weinig verschillen in h"Waliteit van leven 
zien tussen haemodialyse en peritoneale dialyse patiCnten. De hvaliteit van leven van dialy-
sepatiCnten, zoals gemeten met gezondheidsprofielen, is aanmerkelijk lager dan de kwaliteit 
van leven van leeftijdgenoten uit de algemene populatie. Ondanks de problemen op het 
gebied van kwaliteit van leven werden voor alle patiCntgroepen hoge waarderingen voor de 
kwaliteit van het leven gevonden. 
Hoe\vel dat forrneel niet de bedoeling is, rneten de waarderingsmethoden meer dan de 
waardering voor de gezondheidsgerelateerde kwaliteit van leven aileen. Dit zou de kloof 
tussen de uitkornsten van de gezondheidstoestandrneting en de waarderingsrnethoden kun-
nen verklaren. Persoonlijke omstandigheden en karakteristieken, waaronder coping gedrag, 
familieornstandigheden en religie, hebben invloed op Time Trade Off en Standard Gamble 
scores. Dit bemoeilijkt de interpretatie van patiCntwaarderingen en mede daarom zou het 
gebruik van patiCntwaarderingen in (economisch) evaluatieonderzoek moeten worden 
afgeraden. Een studie naar de maatschappelijke kosten van nierziekten liet zien dat nierbe-
handelingen in Nederland leiden tot hoge maatschappelijke kosten en een flinke ziektelast. 
Uit een scenariostudie bleek dater weinig ruimte is voor verdere verbetering van de kosten-
effectiviteit van het totale nierbehandelprogramrna in Nederland. Aileen een drastische ver-
hoging van het aantal niertransplantaties kan de doelmatigheid van nierfunctievervangende 
behandelingen in Nederland verder verbeteren. Nader onderzoek is nodig om op te 
helderen waarorn de Standard Gamble en Time Trade Off scores van Nederlandse nier-
patienten hager zijn dan die van nierpatiCnten uit andere landen. Op het terrein van 
kostenonderzoek is er behoefte aan verbeterde kostenramingen, in het bijzonder op het nu 
nog onontgonnen gebied van directe kosten buiten de gezondheidszorg, zoals kosten van 
inforrnele zorg voor nierpatiCnten. Verder zouden toekomstige economische evaluaties zich 
moeten richten op de kosten-effectiviteit van niervervangende behandelingen voor speci-
fieke groepen patiCnten met vergelijkbare achtergrondkenmerken. 
188 
Abbreviations 

APD 
CAPD 
CBA 
CCPD 
CEA 
CMA 
CUi\ 
DALY 
EDTAERA 
EQ-SD 
EQ-SDvAS 
EQ-5Dprofile 
ESRD 
FCHD 
HD 
HHD 
HRQOL 
HYE 
ICD-9 
KVZ 
LCHD 
LMR 
MCS (SF-36) 
MTA 
NECOSAD-I 
NECOSAD-TAS 
NHP 
NLG 
PCS (SF-36) 
PD 
QALY 
QLI 
RENINE 
RRT 
SF-36 
SG 
SIP 
ITO 
TX 
Abbreviations 
Automated Peritoneal Dialysis 
Continuous Ambulatory Peritoneal Dialysis 
Cost Benefit Analysis 
Continuous Cycling Peritoneal Dialysis 
Cost Effectiveness Analysis 
Cost ~finimisation Analysis 
Cost Utility Analysis 
Disability Adjusted Life Year 
European Dialysis and Transplant Association - European Renal 
Association 
EuroQol-SD Instrument 
EQ-SD Visual Analogue Scale 
EQ-SD classification system 
End Stage Renal Disease 
Full Care Centre Haemodialysis 
Haemodialysis 
Home Haemodialysis 
Health Related Quality of Life 
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Nottingham Healcl1 Profile 
Dutch guilder 
Physical Component Summary score 
Peritoneal dialysis 
Quality Adjusted Life Year 
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Short-Form 36 
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Sickness Impact Profile 
Time Trade Off method 
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Dankwoord 

Dankwoord 
Degenen die mij goed kennen hebben mij vaak horen fulmineren tegen de cliche dankwo-
orden waarmee de meeste proefschriften worden besloten. Hoe kon ik vermoeden dat er 
aan het eind van zo'n promotietraject een oprecht verlangen bestaat om enkele mensen te 
bedanken voor de rol die zij hebben gespeeld? Het in dit proefschrift beschreven onderzoek 
is het derde onderzoek \vaaraan ik begon met de intentie daarop te promoveren. Over de 
risico's van technology assessments binnen klinisch patientgebonden onderzoek zou ik 
eventueel een vierde onderzoek kunnen wijden. Eventueel. .. , maar voorlopig toch maar 
even niet. 
Omdat mijn promotietraject (heel) wat meer jaren omvat dan de jaren waarin ik aan het 
in dit proefschrift beschreven onderzoek heb gewerkt, wil ik bier graag de mensen 
bedanken die in dat lange traject belangrijk voor me waren. 
Professor David Banta, jij begeleidde me bij mijn afstudeeronderzoek in 1Iaastricht en tij-
dens mijn eerste jaren in Rotterdam. Toen de onderzoeken niet liepen zoals gepland schei-
dden onze wegen zich in professionele zin, maar ik ben je altijd als mijn leermeester blijven 
beschouwen. \'\le zullen elkaar in Rugny en ·villiers-le-Bois blijven treffen in onze liefde voor 
lekker eten en goede wijn en onze vriendschap voor elkaar. Ik ben blij dat je op 17 oktober 
in de promotiecommissie zitting wilt nemen. 
Ook mijn promotor, prof.dr. Frans Rutten, en co-promotoren dr. Frank de Charro en dr. 
Hans Jager wil ik op deze plaats graag bedanken. Frank, dat ik bijna 9 jaar in jou"\v groep in 
Rotterdam heb gewerkt aan veel uiteenlopende en interessante onderzoeken is te danken 
aan jouw onuitputtelijke vermogen om altijd wel weer ergens een onderzoekssubsidie los te 
peuteren. Frans, jij raakte pas later bij dit onderzoek betrokken, maar je hebt altijd con-
structief meegedacht en snel je opbouwende commentaar op concepten gegeven. Hans, 
ook voor jou geldt dat je pas wat later, toen ik bij het RIVJ\T ging werken, bij dit onderzoek 
betrokken raakte. Juist daardoor kon je echter kritische vragen stellen en af en toe de vinger 
op de zere plek leggen. lk wil jullie alledrie heel hartelijk danken voor jullie bijdragen aan 
dit proefschrift. 
Baxter Nederland en de Nierstichting dank ik voor de financiering van delen van dit 
onderzoek. Ook al worden de leden van het NECOSAD-1 team in de acknowledgements 
van de verschillende hoofdstukken reeds genoemd, graag wil ik bier met name Roos \Visse, 
Barbara Nijman en Rita Niorren nog eens bedanken voor het interviewen van de patienten. 
Zoveel patienten had ik in mijn eentje nooit kunnen interviewen! De patienten hebben een 
zeer belangrijke bijdrage aan dit onderzoek geleverd door belangeloos met ons te willen 
praten over hun kwaliteit van leven en allerlei aanvenvante onderwerpen. De trekkers van 
her NECOSAD-I onderzoek, prof.dr. Ray Krediet en dr. Els Boesch oren, dank ik voor de 
bereidheid om bet onderzoek uit te breiden met een technology assessment component. 
Co-auteurs, hartelijk dank voor het meedenken, meelezen en bet opbouwend commentaar 
dat ik kreeg op de concept artikelen. 
Hans Linders en Jan van Busschbach, samen begonnen we als AIO's in Rotterdam. \Y/e 
vormden een hechte drieeenheid, samen stonden we sterk. Zo'n acht jaar nadat ik jullie 
paranimf mocht zijn, staan jullie mij nu bij. Eindelijk kan de rok weer uit de kast! Jullie bei-
den dank ik voor jarenlange steun en vriendschap. Jules van Horen heeft de vormgeving van 
mijn proefschrift verzorgd. En het is mooi geworden! Bedankt! Rianne de \\7it, aan het eind 
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van het lange promotietraject was jij als "proefschrift pitbull" werkelijk belangrijk, ja, onmis-
baar. Je hebt me continue gestimuleerd om door te gaan en het af te maken. Onze vele geza-
menlijke schrijfweken, jij aan jouw proefschrift en ik aan het mijne, waren altijd productief 
en bovendien zeer genoeglijk. Als jij me niet zo vaak had "gedwongen" om tijd vrij te maken 
voor het proefschrift dan was het werk echt in de la blijven liggen. Rianne, ook al sta jij op 
17 oktober niet aan mijn zijde, weet dat ik je als paranimf voor het leven beschouwl Zullen 
we onze schrijfweken zo nu en dan gewoon maar voortzetten en champagne aan de door 
jou beschreven gouden formule toevoegen? 
Familie, vrienden en collega's, wat heerlijk dat het "p-woord" voortaan volmondig uitge-
sproken mag worden. Dank voor jullie continue interesse en steun! Lucas, al vijftien jaar 
mijn lief, wat is het leven leuk met jou! 
\Xlaarmee dit toch nog een cliche dankwoord werd ..... Het zij zo! 
Utrecht, augustus 2002 
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